Life Science Success: Recent Episodes
Don Davis PhD, MBA
On this podcast, you'll find interviews with high-performing successful individuals in Life Sciences. On a weekly basis, we cover their proven methods, principles, strategies, and mindsets to implement new technologies that scale to meet the needs of people in our world.
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Stella Vnook. Stella is the CEO, Co-Founder, and Executive Board Chair at Kaida BioPharma, where she is advancing precision oncology therapies and bringing her experience as a serial biotech entrepreneur, investor, and life sciences leader to the future of cancer treatment.
00:00 Welcome to the Podcast
00:38 Meet Stella Vnook
01:23 From Big Pharma to Startups
04:58 Thriving as Startup CEO
08:08 Mission Driven by Family
10:27 Hard Lessons in Translation
15:08 Building Kaida BioPharma
18:12 Fundraising in a Tough Market
22:33 De Risking and Milestones
25:03 Faster to Clinic with Rigor
29:12 Women Leading in Biotech
35:47 Precision Medicine Outlook
38:17 Inspiration and Concerns
45:46 How to Connect and Wrap Up
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Dr. Seth Toback. Dr. Toback is the Chief Medical Officer at ARMR and a board-certified physician-scientist with over 20 years of experience leading clinical development and medical affairs across biotech, pharmaceuticals, vaccines, infectious diseases, and respiratory medicine.
00:00 Show Introduction
00:29 Meet Dr Seth Toback
01:28 From Pediatrics to Vaccines
03:11 Pandemic Vaccine Milestones
04:51 Speeding COVID Development
07:04 Leading in Crisis
08:59 ARMR Mission and Opioid Waves
11:00 How the Fentanyl Vaccine Works
12:45 Who Benefits Most
14:12 Human Challenge Trial Design
16:02 Endpoints and Real World Evidence
17:57 Clearing Up Misconceptions
21:21 Risk Disinhibition Concerns
22:27 Defining Success and Impact
24:14 Rapid Fire Fun Questions
26:44 How to Learn More
28:01 Closing and Subscribe
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Simran Padam, MD, APMMC, Executive Director of Medical Affairs at Worldwide Clinical Trials. A physician with 17+ years guiding global studies, she shares insights on medical monitoring, complex oncology and hematology programs, and the clinical judgment behind drug development highlighted in her newsletter, The Medical Monitor’s Desk.
00:00 Show Intro and Guest
01:49 Simran Career Journey
04:22 Why CRO Variety Matters
05:48 What Medical Monitors Do
08:04 Protocol vs Reality
09:43 Physicians Role Evolving
11:14 Better Trial Decisions
13:31 Newsletter Behind Scenes
16:09 LinkedIn Newsletter Reach
17:07 From Science to Execution
19:18 Therapeutic Specialization
21:20 Collaboration Across Teams
23:05 Capabilities for Future
25:16 Rapid Fire Inspiration
32:44 Where to Connect
34:09 Podcast Outro
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Megha Sinha. The founder and CEO of Kamet Consulting Group LLC, she brings 17+ years of experience advising global pharma and life sciences on regulatory operations, quality, and large-scale transformation, including senior leadership at PwC solving complex regulatory, supply chain, and lifecycle management challenges.
00:00 Show Introduction
00:30 Meet Megha Sinha
01:18 Engineering Into Life Sciences
03:29 First FDA Audit Lessons
04:29 PwC Shaping Consulting
07:27 Three Career Pivots
12:22 Why Found Kamet
17:24 Mission And Programs
19:27 Global Regulatory Depth
24:57 Transformation In Practice
30:24 Scaling Team And Tech
35:14 Leadership Inspiration Concerns
40:48 AI Beyond Automation
44:27 Closing And Next Steps
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Ian Crone. He is the VP Regulatory strategy and growth at ArisGlobal and a global life sciences leader known for RIM, UDI, IDMP, and data migration expertise, inspiring teams to deliver compliant, client-centric solutions.
00:00 Show Intro
00:30 Meet Ian Crone
01:12 From Lab Bench Up
03:07 Regulatory Deja Vu
05:15 IDMP Explained
07:39 Single Source Truth
10:38 Why Migrations Fail
14:40 Interpretive Drift Risk
15:56 Best of Breed Debate
21:27 Compliance Clock Ticking
23:59 AI Needs Humans
26:00 Why ArisGlobal
27:33 Sportify Overlay Approach
28:49 Data Cortex XDI
31:10 IDMP Data For AI
32:31 AI As Experimentation
33:54 Leading Under Pressure
36:20 Mentorship Lessons
37:05 Personal Motivation Story
39:23 AI Hype Versus Readiness
42:15 Human In The Loop
44:42 Breaking Silos Wins
47:02 Closing And Next Steps
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Jennifer Vavala, Founder & Principal at AlignPoint Partners. With more than 27 years in pharma, medical device, and diagnostics leading QA/QC in complex regulated organizations, she focuses on quality systems, inspection readiness, and operational delivery, and developed the Operational Stability Recalibration framework to help leaders rebalance escalating mandates with operating capacity before compliance or delivery risks surface.
00:00 Intro
00:30 Meet Jennifer Vavala
01:39 Microbiology Origins
04:13 Capacity Not Capability
08:43 Across Regulated Sectors
12:25 AlignPoint Partners Mission
13:15 Operational Stability Framework
18:02 Early Warning Signals
19:52 Inspection Readiness Reality
23:55 Executives And Regulators
32:37 Quality Leadership Future
36:15 Inspiration Concerns Excitement
39:39 Wrap Up And Where To Connect
40:19 Outro
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Dean Erhardt, President and CEO at D2 Solutions. He brings more than 20 years of experience across pharmaceuticals and consumer products, with expertise in support program development, distribution, and specialty product management, and has worked with over 100 pharmaceutical, biotech, and medical device manufacturers as well as many small and midsized organizations on commercial operations, strategy, and national accounts.
00:00 Intro
00:34 Dean's career: HMO, Cardinal Health, Express Scripts
03:00 Founding D2 Solutions in 2008
04:00 Pricing strategy and middlemen taking 50–70% of revenue
08:00 What separates successful commercialization from failure
10:00 D2's three pillars: distribution, reimbursement, patient services
15:00 Pharmaceutical support programs for specialty medications
16:00 D2's digital patient engagement platform in action
21:00 Resource challenges for small and mid-sized pharma
22:00 Retail deserts and the rise of direct-to-consumer models
24:00 National accounts strategy and long-term payer relationships
26:00 When to engage D2 and cleaning up commercialization missteps
28:00 The prior authorization crisis
31:00 Leadership advice: one vision, said a million times
32:00 AI, remote surgery, and the future of care
34:00 Looming shortage of 3.9 million healthcare workers
36:00 Concerns: aging population, lost patients, NIH funding
37:00 Technology accelerating drug approvals
38:00 Outro
Send us Fan Mail
Jesse Mendelsohn and Michael Grosberg from Model N discuss why U.S. pricing complexity is spreading globally, the collapse of the PBM rebate model, what's really driving the pharmaceutical manufacturing boom, and why direct-to-consumer discount programs won't solve America's drug access problem.
00:00 Introduction to Life Science Success Podcast
00:34 Pressing Issues in Pharmaceutical Manufacturing
00:51 Introducing the Experts from Model N
03:08 Understanding International Reference Pricing
04:14 Impact of US Pricing on Global Drug Launches
09:26 Challenges with Pharmacy Benefit Managers
16:29 Domestic Manufacturing Boom in Pharmaceuticals
23:08 AI in Drug Discovery and Personalized Medicine
29:03 Access and Policy Discussion
30:01 Direct to Consumer Pricing
31:32 TrumpRx Overview
33:11 Compliance Challenges
38:30 Pharmaceutical Revenue Management
41:38 AI in Life Sciences
48:35 Future of Life Sciences
50:45 Concerns and Challenges
53:52 Excitement in Current Work
55:54 Conclusion and Final Thoughts
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Troy Fugate. The CCO of Compliance Insight, Inc., Troy brings 30+ years of FDA readiness, GMP, and quality leadership—turning complex requirements into practical, culture-shaping solutions and championing the Align–Apply–Adapt framework used across pharma, cell and gene therapy, and medical devices.
00:00 Introduction to Life Science Success Podcast
00:37 Meet Troy Fugate: CCO of Compliance Insight
01:09 Troy's Career Journey and FDA Focus
04:10 The Align, Apply, Adapt Framework
04:47 Differentiating Compliance Insight
08:03 The Importance of Clarity in Compliance
17:10 Challenges and Solutions in Compliance
25:38 Human Behavior and Continuous Improvement
34:39 Troy's Inspirations and Concerns
39:07 Final Thoughts and Closing Remarks
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Byron Purse, co-founder of AlidaBio and professor of chemistry at San Diego State University who is pioneering innovative approaches to studying RNA modifications. Byron brings a wealth of expertise in synthetic and natural nucleic acid modifications, with a passion for advancing biotechnology and human health through his groundbreaking research and entrepreneurial endeavors.
00:00 Introduction to Life Science Success Podcast
00:29 Meet Byron Purse: Professor and Co-Founder of AlidaBio
01:05 Byron's Journey into Life Sciences
03:10 From Academia to Entrepreneurship
06:49 Founding AlidaBio: Vision and Mission
08:59 Innovations in RNA Modifications
23:09 Challenges and Successes in Developing the EpiPlex™ Platform
28:44 Leadership and Inspiration
35:00 Concerns and Future Outlook in Life Sciences
43:02 Conclusion and Final Thoughts
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is James Piacentino, CEO of Thrive Genetics, Inc., a pioneering digital health startup focused on transforming addiction risk assessment through genetic and behavioral science. James brings a unique blend of entrepreneurial experience, technical expertise, and personal mission to develop innovative solutions that help healthcare providers manage dependency risk with unprecedented precision.
00:00 Introduction to Life Science Success Podcast
00:46 Upcoming Podcast Announcement
01:08 Introducing James Piacentino
01:49 James Piacentino's Background in Digital Health
03:29 Corporate Experience and Startup Journey
06:53 Founding Thrive Genetics
08:35 The Impact of Addiction on Families
09:19 Thrive Genetics' Approach to Addiction Risk
18:43 Partnerships and Technological Advancements
21:29 Combining Genetics, Behavior, and AI
25:06 The Conservative Approach to AI in Customer Journeys
26:12 Balancing Scientific Rigor with Business Models
27:09 Adoption and Value Creation in Technology
30:54 The Importance of Customer Feedback
40:05 Leadership Lessons and Values-Based Leadership
43:18 Inspiration and Overcoming Limiting Beliefs
45:29 Concerns and Complexities in Today's World
46:47 Excitement for the Future
47:35 Conclusion and Farewell
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Josh Yelen, a CPA, MBA, and the Founder & CEO of Function, a strategic financial leadership and bookkeeping services company that supports businesses across various industries, including life sciences. With over two decades of experience in operations, accounting, finance, and sales, Josh is also a co-founder of Venture Forward Capital, where he supports early-stage entrepreneurs in building disruptive companies.
00:00 Introduction to Life Science Success Podcast
00:40 Join Our Free School Community
01:41 Introducing Our Guest: Josh Yelen
02:10 Josh Yelen's Professional Journey
04:30 The Birth of Venture Forward Capital and Function
09:05 Function's Unique Approach to Financial Services
14:55 Challenges in Biotech and Pharma
20:40 Trends Shaping the Future of Biotech
29:19 Firing the Biggest Client and Growing the Business
29:46 Innovative Use of AI in Business
30:53 Aligning Company Goals with OKRs
32:45 The Importance of Focus and Avoiding Distractions
36:46 Leadership Advice and Entrepreneurial Challenges
39:31 Motivational Videos and Personal Drive
45:37 Concerns About AI and the Future of Work
50:48 Excitement for the Future and Final Thoughts
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Nissan Cohen, a worldwide expert with over 45 years of experience in high purity water systems, pharmaceutical engineering, and water technology innovation. Nissan is the Owner of Biopharmaceutical Water Doc company and has made significant contributions to the field through his extensive publications, technical expertise, and leadership in international professional societies like ISPE.
00:00 Introduction to Life Science Success Podcast
00:29 Meet Dr. Nissan Cohen: Water Technology Expert
01:24 The Importance of Potable Water
01:52 Journey into High Purity Water Systems
03:32 Transition to Pharmaceutical Industry
06:12 Milestones in Pharmaceutical Water Technology
09:54 Current Consultancy and Industry Challenges
14:32 Advancements in Pharmaceutical Water Technologies
20:51 Sustainability and Zero Liquid Discharge
29:22 Agricultural Water Innovations
35:43 Leadership and Professional Insights
41:23 Concerns and Future Outlook
44:42 Conclusion and Final Thoughts
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Victoria Donovan. Victoria is the Founder and CEO of Clinically Media, an award-winning agency that is transforming patient recruitment and retention strategies in clinical research.
00:00 Introduction to Life Science Success Podcast
00:38 Meet Victoria Donovan: Founder and CEO of Clinically Media
01:34 Victoria's Journey into Life Sciences
03:12 The Birth and Growth of Clinically Media
05:03 Clinically Media's Mission and Vision
08:46 Innovative Approaches in Patient Recruitment
11:59 Challenges and Future of Patient Recruitment
23:45 Leadership and Personal Insights from Victoria Donovan
32:34 Conclusion and Final Thoughts
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Mark Stead, Head of Business Development at Atomic AI, a pioneering biotech company using artificial intelligence and structural biology to develop innovative RNA-targeted therapeutics. Mark brings over 12 years of experience in biotechnology, with a proven track record of negotiating high-value partnerships and driving strategic collaborations in drug discovery.
00:00 Introduction to the Life Science Success Podcast
00:30 Meet Mark Stead: Journey into Life Sciences
03:26 Career Insights: From Amgen to Atomic AI
11:20 Innovations at Atomic AI: Leveraging AI and Structural Biology
19:37 The Future of AI in Drug Discovery
31:03 Leadership and Personal Insights
39:38 Conclusion and Farewell
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Kristien Van Vlasselaer, a Vice President of Operations at Gordian Biotechnology who is a passionate generalist and strategic operations leader dedicated to helping biotech teams execute with excellence. With her unique ability to bridge technical expertise and practical problem-solving, Kristien brings a holistic approach to optimizing organizational performance and driving innovative solutions in the biotech industry.
00:00 Introduction to Life Science Success Podcast
00:40 Meet Kristien Van Vlasselaer: A Passionate Generalist
01:05 Kristien's Journey into Life Sciences
02:26 The Generalist Powerhouse in Biotech
04:23 Career Evolution and Key Milestones
09:03 Challenges and Trends in Biotech
11:58 Kristien's Role and Initiatives at Gordian Biotechnology
27:43 Innovative Approaches in Osteoarthritis Research
28:21 Challenges and Limitations of Animal Models
29:23 Complex Problem Solving in Biotech
35:12 Leadership Advice and Insights
42:31 Inspiration and Concerns in the Industry
50:26 The Value of Generalists and Future Outlook
52:53 Conclusion and Final Thoughts
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is John Schmitt, a military veteran, entrepreneur, and Co-Founder & CEO of iXpressGenes who is leveraging innovative RNA biomarker technologies to revolutionize trauma screening in healthcare. With over 20 years of leadership experience in the U.S. Army and a Master's degree in Microbiology and Immunology, John is dedicated to developing data-driven solutions for early detection and prevention of trauma-related diseases.
00:00 Introduction and Podcast Overview
01:02 Welcoming the Guest: John Schmitt
02:00 John Schmitt's Journey to Biotechnology
05:58 Military Experience and Leadership Insights
13:09 Founding iXpressGenes: The Origin Story
17:31 Mission and Objectives of iXpressGenes
23:08 Challenges and Innovations in Biomarker Technologies
27:42 Personal Leadership and Inspirations
35:00 Conclusion and Podcast Wrap-Up
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Lyle Small, a seasoned innovator with 35 years of experience in interactive inks and coatings who is now the Founder and CEO of Lahjavida, Inc., a promising cancer research company developing targeted chemotherapy technologies. Lyle has an impressive track record of technological innovation, having previously founded Chromatic Technologies and developed groundbreaking color-changing technologies for brands like Coors Light, and is now focused on creating potentially transformative cancer treatments.
00:00 Introduction to Life Science Success Podcast
00:40 Celebrating Podcast Achievements
01:27 Interview with Lyle Small: Background and Journey
02:43 Lyle's Early Career and Innovations
07:13 Founding Chromatic Technologies Inc. (CTI)
09:00 CTI's Impact and Innovations
15:13 Transition to Lahjavida: New Ventures in Cancer Research
20:16 Challenges and Insights in Cancer Research
25:03 Understanding Success Rates in Business
27:40 The Importance of Failure Mode and Effects Analysis (FMEA)
28:58 Building Effective Teams: Lessons Learned
38:27 Leadership Qualities and Challenges
40:39 Current Endeavors and Fundraising Efforts
43:45 Inspiration, Concerns, and Excitement
48:05 Conclusion and Final Thoughts
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Lauri Befus, Vice President of Clinical Operations at M3 Wake Research, a leading integrated site network in the United States. With over 13 years of experience in clinical research and healthcare operations, Lauri brings a unique perspective to clinical trials, focusing on patient-centric strategies and operational excellence.
00:00 Introduction to Life Science Success Podcast
00:37 Meet Lauri Befus: Vice President of Clinical Operations at M3 Wake Research
00:59 Lauri's Journey into Clinical Research
01:53 Educational Background and Early Career
02:36 Career Progression and Key Milestones
04:25 Challenges in the Life Sciences Industry
05:18 Diversity and Inclusion in Clinical Trials
06:16 Overview of M3 Wake Research
07:37 Lauri's Role and Responsibilities
13:59 Innovative Projects and Initiatives
16:28 Future Goals and Industry Innovations
17:31 Leadership Insights and Advice
24:19 Conclusion and Final Thoughts
Send us Fan Mail
In this episode of the Life Science Success Podcast, my guest is Ashley Scholz, the Vice President of Marketing at Vector Laboratories, who brings over 16 years of experience in medical devices, diagnostics, and strategic marketing. With a proven track record of driving growth, building high-performing teams, and optimizing commercial strategies, Ashley shares her insights on innovation in the life sciences industry.
00:00 Introduction to Life Science Success Podcast
00:47 Meet Ashley Scholz: VP of Marketing at Vector Laboratories
01:21 Ashley's Career Journey and Experience
04:52 Transition to Vector Laboratories
06:16 Challenges and Learnings at WL Gore
13:10 Building High Performing Teams
16:08 Why Vector Labs?
21:36 Vector Labs' Mission and Future Focus
22:49 Marketing's Role in B2B Transition
25:24 Supporting Scientists and Researchers
26:35 Innovative Projects and AI Integration
29:31 Impact of Recent Acquisitions
31:12 Balancing Commercial Growth and Customer-Centricity
35:14 Leadership and Organizational Insights
38:56 Inspiration and Concerns
40:47 Excitement for Future Strategies
43:52 Conclusion and Final Thoughts
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Brad Doerschuk, a visionary leader in clinical research with over 20 years of experience in pharmaceutical and biotech development. As the founder of PharmaMed Research and current President and CEO of InFocus Clinical Research, Brad has a proven track record of leading successful clinical development programs across multiple therapeutic areas and is a PharmaVoice 100 recipient.
00:00 Introduction to Life Science Success Podcast
00:34 Meet Brad Doerschuk: Visionary Leader in Clinical Research
01:22 Brad's Journey into Life Sciences
02:57 Founding a Research Organization
06:00 Challenges and Pivotal Moments in Drug Development
09:43 Specialization in Retina Diseases
18:54 Building and Leading High-Performing Teams
21:11 Merging Best Practices for Efficiency
22:48 The Role of Innovation in Clinical Trials
25:38 Leadership Advice and Personal Insights
31:11 Conclusion and Final Thoughts
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Oliver Loson, a Vice President of Business Operations at Holoclara, Inc. who brings a wealth of experience in translating scientific discoveries from academia to commercial applications, with a background in neurosciences and a passion for developing innovative therapies that can improve human health.
00:00 Introduction to Life Science Success Podcast
00:37 Meet Oliver Loson: From Academia to Business Operations
01:36 Oliver's Early Interest in Neuroscience
03:26 From Pre-Med to Research Enthusiast
06:20 Transitioning to Caltech and Technology Transfer
09:59 Startup Journey: Developing Next-Gen Cancer Therapies
13:31 Business Operations and Intellectual Property
20:56 Holoclara: Harnessing Host-Parasite Relationships
25:39 Current Projects and Future Goals
29:19 Switching Gears: From Analogies to Soccer
30:23 Innovative Approaches in Human Health
34:49 Challenges in the Biotech Industry
35:56 Leadership Insights and Advice
42:08 Inspiration and Concerns in Science
47:05 Excitement for the Future of Biotech
50:54 Conclusion and Final Thoughts
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Frank Jäger, a Commercial Director at CCL Clinical and Managing Director of CCL Faubel, who brings extensive expertise in pharmaceutical labeling, sales, and innovative IoT applications. With a background in economics and a leadership role in multiple companies within the pharmaceutical packaging sector, Frank has been a prominent figure in the industry, serving on the ISPE Steering Committee and delivering insightful presentations on pharmaceutical packaging challenges.
00:00 Introduction to Life Science Success Podcast
00:34 Meet Frank Jäger: Career Journey and Insights
04:48 Transition from Economics to Life Sciences
07:36 Role and Responsibilities at CCL Clinical
15:38 Innovations and Future Projects
31:43 Leadership and Personal Insights
36:28 Conclusion and Podcast Wrap-Up
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Christopher Duma, a board-certified neurosurgeon who is pioneering innovative treatments for neurodegenerative diseases at Regeneration Biomedical, Inc.
00:00 Introduction to Life Science Success Podcast
00:34 Meet Dr. Christopher Duma: A Pioneer in Neurosurgery
00:59 Dr. Duma's Journey to Neurosurgery
03:13 Challenges in Treating Neurodegenerative Diseases
05:59 The Potential of Stem Cells in Neurosurgery
10:06 Technological Advances in Neurosurgery
13:34 Innovations in Deep Brain Stimulation
15:57 Exploring Immunotherapy and Gene Therapy
18:14 The Mission of Regeneration Biomedical
20:15 Understanding Stem Cell Therapy for Brain Diseases
27:28 FDA Trials and Initial Research
28:07 Innovative Stem Cell Injection Method
30:20 Phase One Trial and Results
34:20 Future of Stem Cell Treatments
40:30 Challenges and Advancements in Movement Disorders
45:14 Leadership and Personal Insights
52:50 Conclusion and Final Thoughts
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Sameer Lal, a highly respected pharma veteran and business leader with three decades of experience in advancing the life sciences industry through technological innovation. With his strategic vision and people-first approach, Sameer has been instrumental in helping pharma CXOs navigate digital transformation and is currently serving as the SVP-Enterprise Medical Solutions at Indegene, where he has played a pivotal role in the company's remarkable growth and leadership in generative AI.
00:00 Introduction to Life Science Success Podcast
00:29 Meet Sameer Lal: Pharma Veteran and Business Leader
01:21 Sameer's Journey in Life Sciences
04:01 Technological Evolution in Pharma
05:53 Generative AI in Pharma: The Third Wave
08:23 Indegene's Role and Sameer's Leadership
20:54 Challenges and Opportunities with Generative AI
24:44 Leadership Insights and Personal Reflections
35:12 Conclusion and Final Thoughts
Send us Fan Mail
In this episode of the Life Science Success Podcast my guest is Janet Kwiatkowski, a proven executive leader with extensive experience in medical devices and in vitro diagnostic technologies.
00:00 Introduction to Life Science Success Podcast
00:35 Meet Janet Kwiatkowski: Executive Leader in Life Sciences
01:10 Janet's Journey into Life Sciences
03:49 Educational Background and Career Path
04:46 Significant Career Milestones
06:23 Challenges in Leadership Roles
08:13 May Enterprises: Mission and Innovations
09:06 Thermal Brachytherapy Technology
13:04 Product and Innovation Strategy
16:43 Successful Partnerships and Market Expansion
18:47 Regulatory Environment and Future Trends
20:12 Integrating AI and Precision Medicine
21:30 Leadership Advice and Inspirations
22:38 Concerns and Hopes for the Future
23:58 Conclusion and Final Thoughts
Send us a text
In this episode of the Life Science Success Podcast my guest is Holley Miller, a category designer and commercial growth expert who helps life sciences companies drive reliable revenue and build market dominance through her innovative strategies at Grey Matter Marketing. With 30 years of experience in global marketing and product management, Holley transforms companies by changing market behaviors and creating category leadership.
00:00 Introduction to Life Science Success Podcast
00:35 Meet Holley Miller: Category Designer and Commercial Growth Expert
01:35 Holley's Journey into Life Sciences
02:41 Transition from Tobacco to Medical Devices
05:15 Understanding Category Design
08:58 Examples of Successful Category Design
12:05 Founding Grey Matter Marketing
18:04 Challenges in Life Sciences Marketing
23:14 Strategies for Effective Market Adoption
26:46 The Importance of Problem Marketing
29:12 Innovative Solutions in Spinal Surgery
31:33 Frameworks for Understanding Company Vision
35:17 Challenges and Overcoming Obstacles
37:53 Evolution and Lessons from Grey Matter
40:35 Focus Areas and Client Selection
43:27 Success Stories and Impact
47:29 Leadership Advice and Inspirations
48:44 Concerns and Future of Healthcare Technology
50:12 Generative AI and Future Prospects
54:25 Conclusion and Contact Information
Send us a text
Daniel Tabb brings over 15 years of experience in the insurance industry, specializing in working with Life Science companies ranging from pre-seed startups to publicly traded corporations. As a leader of the Life Science Practice at Houchens Insurance Group, Daniel possesses a deep understanding of the unique risks and challenges faced by life science companies in today's dynamic environment.
00:00 Introduction to Life Science Success Podcast
00:29 Meet Daniel Tabb: Life Sciences Insurance Expert
01:26 Daniel's Journey into the Insurance Industry
03:32 Specializing in Life Sciences
05:09 Key Career Transition Points
12:06 Understanding Life Sciences Insurance
15:49 Unique Risks and Challenges in Life Sciences
18:23 Innovative Projects and Future of Insurance
24:17 Leadership and Personal Insights
33:49 Conclusion and Final Thoughts
Send us a text
In this episode of the Life Science Success Podcast my guest is Jim Pollock, an experienced technology entrepreneur with a background in electrical engineering from MIT and a track record of successfully launching and exiting multiple startup companies. Jim is currently the CEO and Co-founder of LumenAstra, a pioneering medical technology company developing a non-invasive, wearable sensor that can measure core body temperature with potential life-saving applications in surgical procedures like aortic dissection.
00:00 Introduction to Life Science Success Podcast
00:34 Meet Jim Pollock: From MIT to Serial Entrepreneur
01:17 Jim's Early Influences and Career Path
03:28 The Passion for Innovation and Technology
06:22 LumenAstra: Revolutionizing Temperature Sensors
15:42 Challenges and Breakthroughs in Sensor Development
19:52 Future of Medical Technology
20:16 Revolutionizing Health Monitoring
21:16 Continuous Wearable Sensors
22:40 AI in Healthcare
27:10 Leadership Lessons
28:19 Building a Smart Team
33:45 Challenges in Science Funding
38:55 Excitement and Inspiration
40:00 Conclusion and Farewell
Send us a text
In this episode of the Life Science Success Podcast my guest is Jonathan Usuka, a seasoned pharmaceutical industry executive with over 25 years of experience in both scientific and business leadership roles. Dr. Usuka brings a wealth of knowledge from his diverse background, including senior positions at top pharmaceutical companies, strategic roles at McKinsey & Company, and his current role as CEO at Sapient.
00:00 Introduction to Life Science Success Podcast
00:34 Guest Introduction: Jonathan Usuka
00:52 Jonathan's Journey into Pharmaceuticals
03:23 Advancements in Genomics and Personalized Medicine
05:29 Key Milestones in Jonathan's Career
09:07 Challenges and Team Management
11:37 Current Role and Mission at Sapient
16:21 Innovative Projects and AI Integration
29:02 Leadership Insights and Career Advice
34:30 Concerns and Future of AI
41:37 Closing Thoughts and Podcast Wrap-Up
Send us a text
SonarMD CEO Beth Houck has more than 25 years of experience in the healthcare industry. Before joining SonarMD, she led customer experience for SA Ignite, a cloud-based healthcare technology company helping provider organizations manage performance and compliance with their MACRA initiatives.
00:00 Introduction to Life Science Success Podcast
00:35 Meet Beth Houck: CEO of SonarMD
01:01 Beth's Journey to Life Sciences
02:55 Becoming the CEO of SonarMD
04:59 Leadership Insights and Strategy
10:04 The Value of an MBA in Health Services
15:56 Introduction to SonarMD
21:04 How SonarMD Improves Healthcare Outcomes
24:29 The Future of Healthcare Technology
27:56 Predictive Analytics in Healthcare
28:17 Leveraging Claims Data for Predictive Analytics
30:05 The Role of Data and Analytics in Healthcare
32:30 Challenges in Actuarial Science and Team Management
37:39 Future Goals and Expansion Plans for SonarMD
41:02 Leadership Insights and Personal Inspirations
50:53 Conclusion and Final Thoughts
Send us a text
In this episode of the Life Science Success Podcast my guest is Elizabeth Chabe, the founder of High Touch Group (HTG) and an expert in science marketing with a distinguished background spanning research universities, national labs, and technology transfer offices. Elizabeth brings a wealth of experience in guiding researchers through technology commercialization and providing data-driven marketing strategies for life sciences and diagnostics companies, and is also the author of "The Giant's Ladder: The Science Professional's Blueprint for Marketing Success."
00:00 Introduction to Life Science Success Podcast
00:29 Meet Elizabeth Chabe: Entrepreneurial Journey
01:12 Early Business Ventures and Education
03:59 Transition to Life Sciences and Marketing
06:41 Challenges and Insights from Academia
11:39 Founding High Touch Group
14:55 High Touch Group Services and Success Metrics
19:34 The Giants Ladder: A Book for Founders
23:10 Commercializing Innovations: Strategies and Pitfalls
23:56 Challenges in Creating Market Demand
25:26 Common Pitfalls in Product Development
25:56 Importance of Audience Research
27:05 Y Combinator's Critique on Entrepreneurial Approaches
27:47 The Role of Multi-Skilled Teams in Marketing
29:55 Successful Marketing Campaigns
34:32 Innovative Trends in Life Sciences Marketing
38:00 Leadership Advice and Team Collaboration
42:54 Concerns About Federal Funding Cuts
46:33 Excitement for Future Diagnostic Products
Send us a text
In this episode of the Life Science Success Podcast my guest is Thomas Ruggia, the President and CEO of Samsara Vision, a specialty medical device company focused on developing innovative implantable ophthalmic technologies to improve vision for individuals with untreatable retinal disorders. With extensive experience in ophthalmology from his previous roles at Johnson & Johnson and Alcon, Thomas brings a wealth of knowledge and passion to Samsara Vision's mission of rejuvenating eyesight and helping people reconnect with the world around them.
00:00 Introduction to Life Science Success Podcast
00:34 Meet Thomas Ruggia: CEO of Samsara Vision
01:38 Thomas Ruggia's Journey into the Medical Device Industry
03:14 Career Highlights: Alcon and Johnson & Johnson
11:49 Samsara Vision's Flagship Product: SING IMT
17:31 Future of Ophthalmic Devices and Treatments
27:26 Personal Insights and Leadership Advice
31:08 Global Perspective and Concerns
34:46 Excitement for Future Technologies
40:19 Conclusion and Farewell
Send us a text
In this episode of the Life Science Success Podcast my guest is David Yourgrau, a seasoned technology and workforce development professional with 15 years of experience. David is the Cofounder and COO of Stack Education, bringing his extensive expertise to help shape innovative solutions in the education and technology sectors.
00:00 Introduction to Life Science Success Podcast
00:34 Meet David, Co-Founder and COO of Stack Education
01:02 David's Journey into Technology and Education
03:33 The Birth of Stack Education
06:05 Challenges and Pivots in Stack Education's Journey
08:21 Innovations in Clinical Research Training
11:45 Future Directions and Personal Reflections
21:38 Current Challenges and Workforce Planning
23:31 Workforce Development and AI Tools
25:49 AI in Digital Marketing
31:20 Leadership and Accountability
33:51 Inspiration and Values
36:56 Concerns About AI and Fraud
45:57 Excitement for the Future of AI
47:32 Conclusion and Farewell
Send us a text
In this episode of the Life Science Success Podcast my guest is Justin Goodarz, Chief Commercial Officer at Verified Clinical Trials. With extensive experience in strategic partnerships and eClinical technology across leading industry companies, Justin brings a wealth of expertise in enhancing patient recruitment and site centricity to our conversation.
00:00 Introduction to Life Science Success Podcast
00:45 Meet Justin Goodarz: Chief Commercial Officer at Verified Clinical Trials
01:07 Justin's Journey into Life Sciences
03:23 Career Highlights and Experiences
06:55 Challenges and Innovations at Verified Clinical Trials
11:50 Mission and Objectives of Verified Clinical Trials
19:56 Leadership Advice and Personal Insights
28:22 Conclusion and Final Thoughts
Send us a text
In this episode of the Life Science Success Podcast my guest is Amy Pooler, Senior Vice President of Research and Development at Life Edit Therapeutics. With over 20 years of scientific leadership experience in genetic medicine, neuroscience, and drug development, Dr. Pooler brings a wealth of expertise from her impressive career spanning roles at Sangamo Therapeutics, the University of Oxford, and Harvard Medical School.
00:00 Introduction to Life Science Success Podcast
00:34 Guest Introduction: Amy Pooler
01:06 Amy's Journey into Life Sciences
02:10 Early Career and Influences
04:49 Leadership Roles and Challenges
09:44 Joining Life Edit Therapeutics
11:30 The Future of Genomic Medicine
13:15 Role and Responsibilities at Life Edit Therapeutics
19:10 Partnerships and Collaborations
26:27 Leadership Insights and Advice
33:27 Conclusion and Final Thoughts
Send us a text
In this episode of the Life Science Success Podcast my guest is Divya Vijay Pratheek, a seasoned biotechnology leader with over a decade of experience in product and commercial strategy. With a remarkable background spanning roles at QIAGEN, Automata, and Congenica, Divya brings a wealth of expertise in managing global product portfolios and driving innovation at the intersection of biotechnology and product development.
00:00 Introduction to Life Science Success Podcast
00:43 Meet Divya Vijay Pratheek: Biotechnology Leader
01:18 Divya's Journey into Life Sciences
01:54 Early Career and Transition to Marketing
03:29 Experience at Accenture and Moving to Germany
05:32 Joining QIAGEN and Career Growth
09:00 Challenges and Overcoming Imposter Syndrome
13:39 Transition to Startups and Learning Adaptability
19:47 Significant Projects and Accomplishments
22:29 Communicating Complex Biotechnology Concepts
29:44 Current Focus and Understanding Product Management
30:22 A Funny Story About Product Management
30:51 Defining Product Management
31:24 Product Development and Market Fit
32:42 Challenges in Product Management
35:29 Balancing Tech and Sales
41:51 The Future of Biotechnology
48:46 Advice for Aspiring Biotech Professionals
53:58 Inspiration and Concerns
58:02 Closing Thoughts and Farewell
Send us a text
In this episode of the Life Science Success Podcast my guest is Matt Veatch, President & COO and Co-Founder of Navidence, Inc., a SaaS company advancing the use of Computable Operational Definitions for real-world data in clinical trials and evidence generation. With over 30 years of experience in biopharmaceutical and medical device development, Matt brings extensive leadership expertise from roles at Syneos Health, Quintiles, and his own consulting practice.
00:00 Introduction to Life Science Success Podcast
00:30 Meet Matt Veatch: President and COO of Navidence
01:22 Matt's Journey in the Life Science Industry
05:49 Entrepreneurial Ventures and Consulting
06:54 The Birth of Navidence
17:26 Navidence's Mission and Impact
27:25 Innovative Projects and Partnerships
30:58 Matt's Podcast and Personal Insights
35:13 Leadership Advice and Inspirations
38:55 Concerns and Future Excitements
46:33 Conclusion and Farewell
Send us a text
In this episode of the Life Science Success Podcast my guest is Hari Kiran Chereddi, a Managing Director at HRV Global Life Sciences and CEO of New Horizon Global Pharma, who has been recognized on the Forbes Global CEO list and has transformed multiple industries through innovative business strategies. With a remarkable background in energy, pharmaceuticals, and entrepreneurship, Hari brings a wealth of experience in market expansion, technology transfer, and creating value in complex global markets.
00:00 Introduction to Life Science Success Podcast
00:42 Meet Hari Kiran Chereddi: A Transformative Leader
01:26 Hari's Journey from Corporate to Entrepreneurship
04:34 Scaling and Operational Efficiency Insights
07:11 Strategic Business Questions and Insights
13:30 Career Shifts and Challenges
17:06 Role and Mission of HRV Global and New Horizon
21:38 Innovation in Life Sciences
26:10 Global Market Expansion Strategies
29:25 Angel Investing and Mentorship
33:40 Personal Insights and Leadership Advice
40:34 Conclusion and Farewell
Send us a text
In this episode of the Life Science Success Podcast my guest is Karen Tkaczyk, a seasoned professional with a robust academic background in chemistry and a proven track record in translation and business development within the life sciences sector. With a PhD from the University of Cambridge and extensive experience leading translation and sales efforts, Karen currently serves as the Director of Sales – Life Sciences at Vistatec, where she helps global clients navigate complex localization challenges.
00:00 Introduction to Life Science Success Podcast
00:35 Meet Karen Tkaczyk: From Chemistry to Sales
01:43 Karen's Early Passion for Science and Languages
02:57 From Academia to Big Pharma
04:22 Transition to the US and Formulation Chemistry
07:38 Freelance Translation Career
12:50 Joining Vistatec
17:26 The Importance of Networking
21:39 Vistatec's Unique Approach
25:05 Common Scenarios in Clinical Trials
25:52 Complexities of Global Clinical Trials
26:03 Translation Challenges in Regulatory Affairs
27:24 Localization in SaaS for Life Sciences
29:10 The Role of AI in Translation
35:17 Balancing Innovation with Regulation
39:37 Favorite Meals and Cultural Insights
41:55 Inspiration, Concerns, and Excitement
47:06 Conclusion and Farewell
Send us a text
In this episode of the Life Science Success Podcast my guest is John Phillips, a seasoned global leader with over 30 years of experience in biotechnology, pharmaceuticals, and healthcare. As President at InnovaPath Consulting, LLC, John has a proven track record of guiding organizations through complex growth stages, transforming businesses, and delivering strategic results across diverse corporate landscapes.
00:00 Introduction to the Life Science Success Podcast
00:43 Sponsor Message: Bio on the Bayou 2025
02:20 Guest Introduction: John Phillips
02:56 John Phillips' Career Journey
05:09 Challenges and Opportunities in Life Sciences
10:20 Leadership and Organizational Growth
14:33 Differences Between Small and Large Organizations
20:11 Supporting Life Sciences Companies at InnovaPath
23:04 Outsourcing Strategies for Startups
25:46 Ensuring Seamless Collaboration
31:18 Innovative Projects and Initiatives
32:02 Streamlining Alliance Management
33:08 AI-Driven Drug Development
34:50 Continuous Improvement in CDMOs
37:34 Integrating Complex Vendor Networks
41:18 Adapting to Digital Transformation
44:07 Leadership Insights and Advice
50:39 Personal Inspirations and Concerns
56:58 Closing Remarks and Podcast Information
Send us a text
In this episode of the Life Science Success Podcast my guest is Michael Edwards, the founder and CEO of Bioinfo Solutions LLC, a data analytics company specializing in extracting insights from complex biological information. Dr. Edwards brings over two decades of experience in genomics, spanning from laboratory research to teaching data science and bioinformatics, with a passion for deciphering the genetic language of cells.
00:00 Introduction to Life Science Success Podcast
00:38 Sponsor Message: Bio on the Bayou 2025
02:12 Guest Introduction: Michael Edwards
02:36 Michael's Journey into Genomics and Bioinformatics
05:07 Key Milestones in Michael's Career
08:18 Founding Bioinfo Solutions
09:31 Diverse Projects and Client Engagements
15:38 The Role of Bioinformatics in Modern Research
22:28 Challenges and Insights in Data Analysis
27:00 Exploring Methodologies and Exciting Projects
28:05 Gene Expression as a Language
30:22 Future of AI in Bioinformatics
31:17 Networking and Data Visualization
32:20 AI and Automation in Various Fields
38:12 Importance of Statistics and Data Visualization
41:09 Broadening Skills and Tools in Bioinformatics
44:07 Inspiration and Concerns in Science
48:52 Concluding Thoughts and Reflections
Send us a text
In this episode of the Life Science Success Podcast my guest is Jesse Mendelsohn, a Senior Vice President at Model N with nearly two decades of experience in pharmaceutical pricing, revenue, and payer management. Jesse brings deep expertise in government regulation, including Medicaid and state pricing laws, making him a recognized leader in revenue optimization and compliance for life sciences and high-tech manufacturers.
00:00 Introduction to Life Science Success Podcast
00:40 Sponsor Message: Bio on the Bayou 2025
02:15 Guest Introduction: Jesse Mendelsohn
02:35 Jesse's Background and Career Journey
04:22 Complexities of Pharmaceutical Pricing
07:38 Career Milestones and Industry Changes
13:28 Current Role and Responsibilities at Model N
23:45 Innovative Projects at Model N
32:29 Leadership and Personal Insights
42:03 Conclusion and Podcast Wrap-Up
Send us a text
In this episode of the Life Science Success Podcast my guest is Ernesto Villarini, a Managing Director at the Community Development Venture Capital Alliance with extensive experience in development finance and economic development. Dr. Villarini brings over 25 years of executive management expertise, including leading key initiatives like the Puerto Rico Fund for Growth and the Unlock Capital business accelerator, and holds advanced degrees in biology and business administration.
00:00 Introduction to Life Science Success Podcast
00:41 Sponsor Message: Bio on the Bayou 2025
02:18 Guest Introduction: Ernesto Villarini
02:41 Ernesto's Career Journey
06:34 Key Inflection Points in Ernesto's Career
14:43 Mission and Goals of CDVCA
19:36 Puerto Rico's Biotechnology Landscape
23:29 Balancing Financial and Social Returns
30:44 Sourcing Investment Opportunities
36:42 Leadership Advice and Personal Insights
43:09 Conclusion and Contact Information
Send us a text
In this episode of the Life Science Success Podcast my guest is Brian Lortie, the Chief Executive Officer of Uniquity Bio, who brings over 25 years of pharmaceutical leadership experience ranging from startup ventures to large corporate operations. Brian has an impressive track record of leading successful teams and driving strategic development in the biopharmaceutical industry, including his previous roles as CEO of Onspira Therapeutics and President of the pharmaceutical business at Endo Pharmaceuticals.
00:00 Introduction to the Podcast
00:43 Sponsor Message: Bio on the Bayou 2025
02:20 Guest Introduction: Brian Lortie
02:57Brian Lortie's Career Journey
04:02 Key Challenges and Successes in Pharmaceuticals
06:42 Leadership Lessons and Career Highlights
11:29 Founding Onspira Therapeutics
18:15 Transition to Uniquity Bio
23:25 Uniquity Bio's Mission and Vision
27:29 Partnership with Blackstone
29:07 Current Projects and Innovation in R&D
33:12 Leadership Advice and Inspiration
38:31 Concerns and Hopes for the Future
42:19 Conclusion and Farewell
Bio on the Bayou
BIO on the BAYOU premier Gulf South biotech conference
Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.
Send us a text
In this episode of the Life Science Success Podcast my guest is Paul Fabre, a Vice President of Client Services for the Greater Boston Region at BioBridges LLC, A PharmaAlliance Company. With a diverse professional background spanning entertainment, restaurant work, corporate sales, and recruiting, Paul has found his calling as a facilitator, connecting great minds to drive meaningful progress in the life sciences industry.
00:00 Introduction to Life Science Success Podcast
00:43 Sponsor Message: Bio on the Bayou 2025
02:20 Guest Introduction: Paul Fabre
03:32 Paul's Diverse Career Journey
05:00 Transition to Corporate Sales and Recruiting
09:10 The Role of Emotional Intelligence in Sales
16:09 Understanding BioBridges and Its Unique Offerings
24:08 Real-World Examples of BioBridges' Impact
27:13 Client Success Stories
27:35 Navigating Large-Scale Projects
28:48 Adapting to Client Needs
29:50 Impact of Trends in Life Sciences
32:05 Innovative Projects and Future Impact
35:13 Automating Reference Checks
38:00 The Importance of Relationships
46:41 Leadership and Personal Insights
50:52 Conclusion and Final Thoughts
Send us a text
In this episode of Life Science Success, host Don Davis PhD, MBA interviews Yaky Yanay, the CEO of Pluri, an innovative Israeli biotech company. Dr. Davis explores Pluri's groundbreaking work in regenerative medicine using placenta-derived cells. Yanay explains their unique allogeneic approach, which allows for the use of cells from healthy donors to treat various conditions without the need for genetic matching.
00:00 Introduction to Life Science Success Podcast 00:38 Sponsor Message from D3 Digital Media Marketing 01:15 Interview with Yaky, CEO of Pluri 01:55 Yaky's Journey in Biotech and Leadership 07:50 Pluri's Mission and Innovations 17:30 Exciting Projects and Future Initiatives 26:20 Challenges and Perspectives in Life Sciences 29:41 Leadership Advice and Inspirations 37:14 Conclusion and Final Thoughts
Send us a text
Dr. Prakash Narayan is a distinguished biotech executive with over 20 years of experience in leading IND- and BLA-enabling programs from concept through clinical trials for heart, lung, kidney, and liver indications. As a founding member of a startup biotech that became a publicly traded company, Dr. Narayan has demonstrated exceptional leadership skills and a proven track record in nonclinical and translational R&D, attracting approximately $30 million in non-dilutive funding as a Principal Investigator from various organizations including NIH, NSF, DoD, and BARDA
00:00 Introduction to the Life Science Success Podcast
00:37 Sponsor Message: D3 Digital Media Marketing
01:10 Guest Introduction: Dr. Prakash Narayan
01:51 Journey from Academia to Biotech Executive
04:34 Growing a Startup into a Publicly Traded Company
06:49 Drug Development Process: From Discovery to FDA Filings
12:53 Challenges and Future of Cell-Based Therapies
16:10 Predictive Analytics in Biomedical Science
19:10 Adapting Approaches Across Disease Areas
22:56 Precision Medicine in Clinical Trials
24:40 Understanding Fatty Liver Disease
25:00 Precision Medicine: A Tailored Approach
25:25 Repurposing Drugs for Kidney Disease
27:10 The Role of Biobanks and Electronic Health Records
28:26 Non-Dilutive Funding: Pros and Cons
32:56 Exploring Transcriptomics and Functionomics
36:55 The Impact of Technology and AI in Medicine
40:53 Inspiration and Concerns for the Future
47:42 Final Thoughts and Advice for Entrepreneurs
Send us a text
In this episode of the Life Science Success Podcast, I am interviewing Dr. Stavros Papadopoulos, the founder and CEO of TileDB, Inc. We delve into Dr. Papadopoulos's journey from academia to entrepreneurship, exploring how his experiences at Intel, MIT CSAIL, and in Hong Kong shaped his innovative approach to data management. Dr. Papadopoulos shares insights on TileDB's mission to revolutionize data analytics in life sciences, discussing the unique features of their data management system and how it's addressing critical challenges in genomics and other scientific fields. We also explore the future of big data in life sciences, leadership in tech startups, and Dr. Papadopoulos's personal inspirations and concerns about the industry.
00:00 Introduction to Life Science Success Podcast
00:43 Sponsor Message from D3 Digital Media Marketing
01:19 Interview with Dr. Stavros Papadopoulos Begins
01:51 Dr. Papadopoulos' Background and Journey
02:33 The Birth of TileDB
03:16 Technical Innovations of TileDB
05:27 TileDB's Impact on Life Sciences
09:07 Influence of MIT and Intel on TileDB
10:40 Entrepreneurial Journey and Challenges
14:36 TileDB's Mission and Vision
15:58 Real-World Applications and Collaborations
25:45 Leadership and Business Insights
34:44 Final Thoughts and Reflections
41:37 Conclusion and Podcast Wrap-Up
Send us a text
In this episode, we dive deep into the world of healthtech with Jim St. Clair, the CEO of MyLigo, a startup revolutionizing patient-centric data solutions. With over 25 years of experience across public and private sectors, Jim shares insights on secure identity verification, AI-driven data exchange in healthcare, and the critical importance of protecting patient identities in an era of increasing cybersecurity threats.
00:00 Introduction to Life Science Success Podcast 00:47 Sponsor Message from D3 Digital Media Marketing 01:25 Interview with Jim St. Clair: Revolutionizing Healthcare Data 02:04 Jim St. Clair's Journey from Naval Officer to Health Tech CEO 06:33 Challenges and Innovations in Patient-Centric Data Solutions 13:27 Global Trends and Technology in Healthcare 25:05 Leadership and Personal Insights from Jim St. Clair 30:15 Conclusion and Future Outlook 30:40 Podcast Closing Remarks
Send us a text
In this episode of the Life Science Success Podcast, I am joined by Jimmy Bechtel, the Vice President of Site Engagement at the Society for Clinical Research Sites, or SCRS. With a diverse background spanning data specialization, patient recruitment, and operations management, Jimmy brings a unique perspective to the clinical research industry.
00:00 Introduction to Life Science Success Podcast 00:29 Meet Your Host: Don Davis 00:37 Sponsor Message: D3 Digital Media Marketing 01:45 Interview with Jimmy Bechtel Begins 02:52 Jimmy's Journey into Clinical Research 05:13 Role and Responsibilities at SCRS 07:16 Key Initiatives and Programs at SCRS 16:35 Challenges Facing Clinical Research Sites 19:42 Global Site Solutions Summit 22:37 Future of Clinical Research Sites 24:17 Leadership and Inspiration 33:01 Conclusion and Farewell
Send us a text
In this episode of Life Science Success, my guest is John McDonough, the Executive Chairman and CEO of Sunbird Bio. John is a seasoned life sciences executive with over 30 years of experience, known for his impressive track record of raising capital and creating substantial market value. He currently leads Sunbird Bio, a company at the forefront of developing innovative blood-based diagnostic tests for neurological disorders, particularly Alzheimer's disease. John's expertise extends beyond Sunbird Bio, as he also serves as chairman at Cytrellis Biosystems and BioPorto Diagnostics, and is the founder and president of the Crush Colon Cancer Foundation. With a history of successful IPOs, acquisitions, and mergers, John brings a wealth of knowledge and experience to our conversation about the future of neurological diagnostics and the life sciences industry.
00:00 Introduction to Life Science Success Podcast 01:20 Interview with John McDonough Begins 01:44 John McDonough's Career Journey 03:33 Challenges and Opportunities in Diagnostics 05:24 Significant Changes in Life Sciences 08:10 Sunbird Bio's Vision and Innovations 10:27 Development and Impact of Blood-Based Diagnostics 12:23 Future of Diagnostics and Neurological Disease 27:01 Philanthropy and Leadership Insights 28:36 Securing Funding and Company Growth 35:40 Leadership Advice and Personal Inspirations 42:31 Conclusion and Final Thoughts
Send us a text
Join us on the Life Science Success podcast as we dive into the world of clinical trial innovation with Richie McCann, Head of Global Sales for Site Payments at Greenphire. Discover how this pioneering company is transforming financial management and patient support in global clinical trials.
In this episode, we explore:
• Greenphire’s mission and impact on the clinical trial industry
• Innovative solutions for streamlining trial processes
• Balancing technology with participant experience
• The future of financial management in clinical research.
Don’t miss this insightful conversation on the cutting edge of life sciences.
00:00 Introduction to Life Science Success Podcast 00:43 Sponsor Message: Bullpen 01:18 Guest Introduction: Richie McCann 01:51 Richie McCann's Journey to Greenfire 03:37 Greenphire's Role in Clinical Trials 04:16 Importance of People in Career Transitions 06:25 Greenphire's Financial Management Solutions 10:09 Challenges in Clinical Trial Payments 22:10 Future Innovations at Greenphire 31:01 Leadership and Personal Insights 41:08 Conclusion and Podcast Details
Send us a text
In this episode of Life Science Success, my guest is John Houston, Ph.D., the Chairperson, Chief Executive Officer, and President of Arvinas. With over three decades of experience in drug discovery and development, Dr. Houston brings valuable insights into pioneering protein degradation therapeutics and the challenges of leading a cutting-edge biotech company.
00:00 Introduction to Life Science Success Podcast 00:46 Sponsor Message from D3 Digital Media Marketing 01:25 Meet John Houston: CEO of Arvinas 03:07 Transition from Big Pharma to Biotech 04:40 Remote Work and Company Growth 06:46 Impact of BMS Experience on Arvinas 10:57 Innovations in Protein Degradation 17:39 Collaborations and Partnerships 30:26 Challenges and Future of Biotech 35:06 Personal Insights and Leadership Advice 42:57 Conclusion and Final Thought
Send us a text
In this episode of the Life Science Success Podcast, we dive deep into the world of health communication with Michelle Bridenbaker, COO of Unbiased Science at Vital Statistics Consulting. Michelle shares her journey from nursing to leadership in health communications, offering insights into the challenges of conveying accurate scientific information in today's media-saturated landscape. She discusses innovative strategies for pharmaceutical companies to effectively reach healthcare professionals and combat misinformation. Michelle also explores the role of digital transformation in health communication and provides a glimpse into the future of scientific engagement. With her unique perspective on balancing regulatory compliance and dynamic audience engagement, this episode offers valuable insights for anyone interested in the intersection of healthcare, communication, and technology.
00:00 Introduction to the Podcast 00:42 Message from the Sponsor 01:16 Guest Introduction: Michelle Burdenbacker 01:39 Michelle's Diverse Career Journey 06:55 Joining Unbiased Science 13:13 Mission and Impact of Unbiased Science 17:09 Challenges in Pharma Communication 21:42 Social Media Strategies for Pharma 25:42 Enhancing Healthcare Communication through Digital Transformation 28:54 Strategies to Combat Health Misinformation on Social Media 35:28 Empowering Healthcare Professionals with Up-to-Date Information 38:55 The Future of Health Communication and AI's Role 45:04 Personal Reflections and Inspirations 48:24 Conclusion and Where to Find More Information
Send us a text
Broderick Jones is a seasoned executive with 25 years of experience in Healthcare, Life Sciences, and Financial Services, known for driving growth and operational excellence across key business functions. Currently serving as a senior leader at Verista, he brings his expertise in compliance and validation services to the pharmaceutical, medical device, and biotechnology industries.
00:00 Introduction to the Podcast 00:42 Sponsor Message: Bullpen 01:19 Interview with Broderick Jones Begins 02:08 Broderick's Journey in Life Sciences 08:27 Verista: A Niche Leader in Compliance 18:23 Consulting and Digital Transformation 27:02 Technical Troubleshooting and Software Tools 27:24 Innovative Solutions and Generative AI 28:38 Leadership Style and Experience 33:36 Challenges in Life Sciences 38:35 Talent Development and Leadership Advice 42:57 Concerns and Future Directions in Healthcare 48:19 Excitement About Technological Advancements 50:42 Conclusion and Contact Information
In this episode, we dive deep into the world of pharma data science with Dr. Ben Sidders, Chief Science Officer at Biorelate. With two decades of experience in drug discovery, including roles at AstraZeneca and Pfizer, Dr. Sidders shares his journey, insights, and the cutting-edge advancements Biorelate is making in computational oncology and immuno-oncology.
Learn how bioinformatics is reshaping drug discovery and the biggest challenges and opportunities facing the industry today. Plus, Dr. Sidders reveals the greatest leadership advice he's received and what truly inspires, concerns, and excites him in this rapidly evolving field.
00:00 Introduction to Life Science Success Podcast 00:46 Sponsor Message: Bullpen 01:20 Guest Introduction: Dr. Ben Sitters 01:46 Ben Sitters' Journey into Life Sciences 05:16 Career Highlights and Key Experiences 10:22 The Role of Data Science in Pharma 15:39 BioRelate: Mission and Innovations 27:42 Challenges and Opportunities in Data Science 32:34 Personal Insights and Leadership Advice 38:21 Conclusion and Farewell
In this episode of Life Science Success, we sit down with Katrina Rogers, a change expert with over 25 years in life sciences, dedicated to transforming the way therapies are brought to market. Katrina, an ASQ-certified Manager of Quality/Organizational Excellence and Pharmaceutical GMP Professional, shares insights on her mission to reduce costs and accelerate timelines in drug development.
She walks us through her journey, her company’s impactful work, and the innovative strategies she employs to streamline operations in life sciences. Join us as Katrina reveals the leadership lessons that inspire her and the exciting future of pharmaceutical advancements.
00:00 Introduction to Life Science Success Podcast 00:34 Meet Katrina Rogers 00:47 Sponsor Message: Bullpen 01:22 Katrina's Journey in Life Sciences 01:42 Joining Bullpen and Its Impact 03:08 Katrina's Background and Career Highlights 05:22 Key Career Moments and Transitions 10:32 Current Role and Responsibilities 21:36 Leadership Advice and Inspirations 27:33 Closing Remarks and Podcast Information
In this episode of the Life Science Success Podcast, host Don Davis, PhD, MBA, sits down with Dr. Patrick Hurley, VP of Marketing at EndoSound, to explore the cutting-edge world of endoscopic ultrasound technology. Dr. Hurley brings a wealth of experience to the conversation, with 13 years in product and market management in the medical device industry and a Ph.D. in biology specializing in neuroscience.
Listeners will gain insights into Dr. Hurley's journey from academia to the medical device industry, and how his background in neuroscience has influenced his career in marketing. The discussion delves into EndoSound's innovative approach to endoscopic ultrasound technology and its potential impact on patient care and the field of gastroenterology.
Dr. Hurley shares his expertise on building successful marketing strategies in the medical device sector, particularly in the GI space. He discusses the challenges and opportunities in launching new GI products and building strong relationships with key opinion leaders in the gastroenterology community
00:00 Introduction to the Podcast 00:40 Sponsor Message: D3 Digital Media Marketing 01:20 Guest Introduction: Dr. Patrick Hurley 01:51 Dr. Hurley's Career Journey 05:31 The Role of a PhD in Marketing 09:05 Transition from Consulting to Marketing 14:32 Pivotal Career Moments 17:04 Introduction to Endosound 17:13 Endosound's Technology and Mission 20:39 Role and Responsibilities of a VP of Marketing 24:35 Traditional Systems and Their Challenges 25:12 Endosound's Innovative Solution 25:28 Space Efficiency in GI Suites 28:13 EGD and EUS Procedures 30:42 Marketing Medical Devices 34:35 The Future of Endoscopic Ultrasound Technology 36:44 Building Brand Identity 39:20 Leadership and Personal Insights 46:15 Conclusion and Final Thoughts
In this episode of Life Science Success, we welcome Ani Sinha, the Vice President of Commercial Operations at Shionogi Inc. Ani brings nearly 15 years of deep commercial expertise in the pharmaceutical and biotech industries. She shares her inspiring journey from studying microbiology and biochemistry at Yale and Columbia to holding strategic leadership roles at companies like Pfizer, Bayer, and Celgene. We delve into her current role at Shionogi, exploring how she leads functions like Analytics and Insights, Market Research, and Field Operations. Ani discusses the innovative projects she's excited about and how they're contributing to Shionogi's mission. She also shares the greatest piece of leadership advice she's ever received and opens up about what inspires, concerns, and excites her in the world of life sciences. Tune in to gain valuable career insights and explore the dynamic future of pharmaceutical advancements.
00:00 Introduction to Life Science Success Podcast 00:42 Sponsor Message: D3 Digital Media Marketing 01:25 Interview with Ani Sinha Begins 02:08 Ani Sinha's Career Journey 05:18 Transition from Lab to Consulting 07:58 Skills Gained from Management Consulting 11:25 Joining Shinogi and Role in Commercial Operations 20:13 Future of Commercial Operations 22:21 Building a Team: The Land of Misfit Toys 23:02 Navigating Different Companies and Roles 24:05 The Evolving Role of Analytics and Insights 25:41 Challenges in Market Research and Operations 29:32 Addressing Trends in Biotech and Pharma 32:13 Greatest Leadership Advice Received 34:44 Inspiration and Concerns in the Pharma Industry 40:52 Final Thoughts and Farewell
In this episode of Life Science Success, we dive deep with Dr. John L. LaMattina, former president of Pfizer Global R&D and current biotech industry leader. From groundbreaking drug discoveries to shaping the future of pharmaceuticals, Dr. LaMattina shares his journey from the lab to the boardroom. Gain unique insights into innovation, challenges, and opportunities in life sciences as we explore the ever-evolving world of drug development. Whether you're an industry professional or simply curious about the future of healthcare, this conversation promises to inform and inspire.
The episode also ventures into his post-Pfizer endeavors in biotech, where Dr. LaMattina supports innovative ventures in areas like the microbiome and schizophrenia treatment through PureTech Health. He addresses current industry challenges, including drug pricing pressures and the significance of ongoing innovation, emphasizing the critical role of biotechnology and pharma in advancing healthcare. The conversation covers key factors in fostering innovation, the impact of venture capital on drug development, and the pressing need for public understanding and appreciation of the biopharmaceutical industry's contributions. 00:00 Introduction to Life Science Success Podcast 00:39 Sponsor Message: D3 Digital Media Marketing 01:20 Guest Introduction: Dr. John LaMottina 01:48 Dr. LaMottina's Journey from Chemist to Pfizer President 03:57 Challenges and Learnings at Pfizer 05:56 Impact of Torcetrapid and Industry Insights 08:48 Transition to Biotech and PureTech Health 11:50 PureTech Health's Innovative Approach 15:45 Authorship and Industry Advocacy 20:14 Drug Pricing and Industry Challenges 26:37 Future Trends and Innovations in Life Sciences 33:20 Reflections on Career and Contributions 35:08 Fostering Innovation and Overcoming Challenges 37:40 Inspiration, Concerns, and Excitement 41:56 Conclusion and Farewell
Nishtha Jain is a strategic thought leader with over 14 years of experience in global information technology, specializing in digital technology transformations and innovation strategies within the life sciences sector. As the Head of Innovation and Digital Technology at Takeda Pharmaceuticals, she drives digital and data initiatives to enhance global R&D quality and is actively involved in diversity, equity, and inclusion efforts.
Nishtha shares her journey from India, discussing the challenges she faced in the competitive field of medicine, leading her to pursue a career in biotechnology. She explores the impact of generative AI in the audit space, emphasizing problem-first approaches and the importance of mental health and diversity in clinical trials. She also reflects on leadership advice, her inspirations, and her passion for travel. This episode offers valuable insights into the intersection of technology and life sciences, urging listeners to consider both the benefits and challenges of innovation. 00:00 Introduction to Life Science Success Podcast 00:35 Sponsor Message from D3 Digital Media Marketing 01:20 Guest Introduction: Nisha Jain 01:47 Nisha's Journey into Life Sciences and Technology 05:08 Achievements and Recognitions 08:22 Career Highlights and Pivotal Moments 13:57 Role at Takeda: Innovation and Digital Technology 17:52 Challenges and Emerging Technologies in Biopharma 26:40 Leadership Advice and Inspirations 31:51 Concerns and Future Challenges 42:23 Excitements and Passions Outside Work 44:12 Conclusion and Farewell
In this episode of the Life Science Success Podcast, my guest is Dr. Zachary S. Brooks, a serial entrepreneur, #1 Best Selling Author, and founder of UGenome AI. Dr. Brooks brings a wealth of experience from his diverse background in technology startups, financial services, and digital authentication. As the founder of UGenome AI, he's at the forefront of developing innovative SaaS tools for genomic medicine. We'll explore his journey from studying bilingual decision-making to becoming a leader in the life sciences field, and discuss how his experiences as an international athlete and multilingual individual have shaped his approach to business and innovation. Dr. Brooks will share insights on the future of personalized medicine, the intersection of genomics and organ transplantation, and the challenges of bringing cutting-edge technology to market. We'll also delve into his work with World Transplant Athletes and his vision for improving healthcare outcomes for organ transplant recipients. This episode promises to be an inspiring and informative conversation about the exciting developments in genomic medicine and the power of entrepreneurship in the life sciences.
00:00 Introduction to Life Science Success Podcast 00:41 Sponsor Message from D3 Digital Media Marketing 01:23 Introducing Dr. Zachary S. Brooks 02:35 Dr. Zachary Brooks' Background and Journey 03:20 The Concept of Anticipated Regret 04:19 Academic and Professional Achievements 07:34 Life Sciences and Personal Health Journey 11:03 Founding Ugenome and Its Mission 13:22 Innovative Tools at UGenome 16:12 The How to Algorithm Series 19:34 World Transplant Athletes and Genomic Medicine 21:51 The Role of Athletics in Entrepreneurship 24:22 Reflecting on Athletic Lessons 27:18 Insights from Previous Startups 31:05 Innovative Projects at UGenome 34:34 Future Aspirations for UGenome 37:51 The Role of Multicultural Experience 41:53 Inspiration and Concerns 45:50 Excitement and Final Thoughts
In this episode of the Life Science Success Podcast, my guest is Dr. Vlad Vitoc, Chairman of the Board, CEO, and President of MAIA Biotechnology. Dr. Vitoc shares his journey from practicing medicine in Romania to leading a cutting-edge biotech company in the United States. We explore MAIA Biotechnology's innovative approach to cancer treatment, focusing on telomere-targeting therapeutics and their lead compound, THIO. Dr. Vitoc offers insights into the challenges of developing new cancer therapies, the future of targeted treatments, and how his international background influences his leadership style.
He also discusses the balance between scientific innovation and commercial viability in the biotech industry. This episode provides a fascinating look into the intersection of medical expertise, business acumen, and scientific innovation in the fight against cancer.
00:00 Introduction to Life Science Success Podcast 00:43 Sponsor Message from D3 Digital Media Marketing 01:24 Introducing Dr. Vlad Vitoc 02:00 Dr. Vitoc's Journey in Oncology 10:08 Innovations in Cancer Treatment 17:20 Challenges and Future Plans 26:35 Global Clinical Development Strategy 28:11 Closing Remarks and Reflections 40:16 Podcast Conclusion and Call to Action
In this episode of the Life Science Success Podcast, my guest is Dr. Russ Lebovitz. Dr. Lebovitz is a seasoned expert in the life sciences, with over 15 years of experience as a senior scientist and research physician. He has served on the faculties of Baylor College of Medicine and The Fox Chase Cancer Center. Transitioning from academia to industry, he has led biotech companies in the diagnostics field, focusing on early detection of neurodegenerative diseases. As the CEO of Amprion, Dr. Lebovitz is pioneering innovative technologies to revolutionize brain health. He collaborates with organizations like the Alzheimer's Drug Discovery Foundation and the Michael J. Fox Foundation to advance research and awareness. Join us as we delve into his remarkable journey and the groundbreaking work he's doing to transform the future of diagnostics.
Dr. Lebovitz shares his extensive experience in life sciences, discussing the journey and development of Amprion from its early days to the present. He explains the science behind prion-like particles, misfolded proteins, and how they relate to neurodegenerative diseases such as Alzheimer's and Parkinson's. He also talks about the company's groundbreaking technology, its FDA recognition, and the critical role of collaborations with organizations like the Michael J. Fox Foundation and the Alzheimer's Drug Discovery Foundation. Tune in to learn about the innovations in diagnostics and the impactful strides being made in the field. 00:00 Introduction to Life Science Success Podcast 00:36 Sponsor Message: D3 Digital Media Marketing 01:27 Meet Dr. Russ Lebovitz 01:53 Dr. Lebovitz's Journey in Life Sciences 02:33 Founding Amprion: The Early Days 04:22 Breakthroughs in Neurodegenerative Disease Research 14:27 The Science Behind Amprion's Technology 19:41 Collaborations and FDA Support 24:52 Amprion's Unique Approach and Availability 32:05 Personal Insights and Reflections 37:20 Conclusion and Farewell
Join us for an insightful conversation with Sanj Singh, CEO of Temple Therapeutics, as we dive into the world of life sciences innovation. With over 18 years of leadership experience in biotech and pharma, Sanj shares his journey from academia to entrepreneurship, and how he's revolutionizing female-centric precision medicine.
In this episode, we explore: • Temple Therapeutics' mission and groundbreaking approach to gynecological health • The challenges and opportunities in developing therapies for underserved populations • Sanj's experience with successful biotech startups and high-value asset transactions • The future of precision medicine and early diagnostics • Valuable insights on leadership in the fast-paced world of biotech
Discover how Sanj's unique background as a professor of entrepreneurship and his involvement with industry organizations like BIOTECanada are shaping the future of healthcare. Whether you're a biotech enthusiast, aspiring entrepreneur, or simply curious about the latest advancements in medical science, this episode offers something for everyone.
Don't miss Sanj's perspective on what inspires, concerns, and excites him about the future of life sciences. Subscribe now and join the conversation on innovation, leadership, and the future of healthcare!
00:00 Introduction to Life Science Success Podcast 00:42 Sponsor Message: D3 Digital Media Marketing 01:24 Guest Introduction: Sanj Singh, CEO of Temple Therapeutics 02:28 Sanj Singh's Background and Journey 05:15 Leadership and Entrepreneurship Insights 08:22 Temple Therapeutics: Mission and Vision 15:00 Challenges in Women's Health Innovation 25:29 Temple Therapeutics' Unique Approach 30:32 Accomplishments and Future Vision 38:02 Personal Reflections and Inspirations 45:59 Conclusion and Farewell
In this episode of Life Science Success, my guest is Michelle Briscoe, the Chief Operating Officer and Chief Financial Officer of Talus Bio. We dive into Michelle's extensive 26-year career in leading scientific organizations and her current role at Talus Bio. Michelle shares insights on the company's innovative MARMOT platform for drug discovery, targeting "undruggable" transcription factors. We explore her strategies for creating exceptional workplaces, her experience with M&A, and her co-founding of OUTbio Seattle. Michelle also discusses balancing financial and operational demands in biotech, industry trends, and her leadership philosophy.
In this episode of Life Science Success, host Don engages in an insightful conversation with Michelle Briscoe, the COO and CFO of Talus Bio. Michelle shares her fascinating career journey from growing up in Oregon, falling in love with science, to leading scientific organizations in Seattle. She discusses her transition from bench science to leadership roles, the importance of creating a positive workplace culture, and her experiences with mergers and acquisitions. Michelle also talks about Talus Bio’s mission to drug the undruggable, leveraging AI for rapid drug discovery, and her excitement about building the largest proteomics dataset. Tune in to learn more about Michelle's inspiring story and the innovative work happening at Talus Bio. 00:00 Introduction to Life Science Success Podcast 00:42 Sponsor Message from D3 Digital Media Marketing 01:23 Guest Introduction: Michelle Briscoe, COO and CFO of Talus Bio 01:53 Michelle's Career Journey and Leadership Roles 07:21 Talus Bio: Mission and Innovations 18:42 Creating a Positive Workplace Culture 23:13 Mergers, Acquisitions, and Leadership Insights 27:18 Future of Life Sciences and Personal Reflections 34:34 Conclusion and Farewell
Dive into the cutting-edge world of cancer research and precision medicine with Dr. Wahid Awad, CEO and Founder of Rosetta Omics. In this episode, we explore how spatial multiomics and AI are revolutionizing cancer treatment. Dr. Awad shares his journey from Egypt to founding a biotech startup in France, and discusses the challenges and opportunities in the field of personalized medicine. Learn about the latest advancements in cancer diagnostics, the role of AI in biotechnology, and how global perspectives are shaping the future of healthcare. Whether you're a science enthusiast, healthcare professional, or simply curious about the future of medicine, this episode offers valuable insights into the forefront of cancer research and biotechnology innovation.
In this episode of Life Science Success, host Don interviews Waheed Awad, CEO and founder of Rosetta Omics. Waheed shares his inspiring journey from Egypt to founding his deep-tech biotech startup in France, focusing on precision medicine and cancer research. Listen in to discover Waheed's innovative use of spatial multiomics and AI, his personal motivation stemming from his father's battle with cancer, and his global experiences shaping his entrepreneurial path. Sponsored by D3 Digital Media Marketing, tune in for an engaging conversation about the future of cancer treatment and personalized medicine. 00:00 Introduction to Life Science Success Podcast 00:40 Sponsor Message: D3 Digital Media Marketing 01:22 Guest Introduction: Waheed Awad 03:06 Waheed's Journey from Egypt to France 08:30 Founding Rosetta Omics 10:10 Personal Connection to Cancer Research 15:25 Global Experiences Shaping Biotechnology 24:06 Rosetta Omics: Precision Medicine and AI 31:16 Balancing Roles and Responsibilities 39:50 Challenges and Inspirations 49:09 Conclusion and Final Thoughts
Join host Don Davis as he sits down with Tarun Mathur CTO at Indegene, a visionary leader in digital transformation for the life sciences industry. With over two decades of experience, Tarun shares his insights on leveraging AI, machine learning, and cutting-edge technologies to solve complex challenges across the pharmaceutical lifecycle. In this episode, you'll discover: • How AI is reshaping drug development, clinical research, and patient care • Strategies for blending domain expertise with technological innovation • The importance of customer-centric approaches in life sciences • Tarun's philosophy on continuous learning and staying ahead of the curve Whether you're a life sciences professional, tech enthusiast, or curious about the future of healthcare, this conversation offers a fascinating glimpse into the intersection of technology and medicine. Tune in to explore how Tarun and his team at Indegene are paving the way for a more efficient, effective, and patient-focused future in life sciences.
Join us for an insightful episode of the Life Science Success Podcast as we dive into the world of AI and digital transformation with Tarun Mathur, a visionary leader in the life sciences industry. Discover Tarun's journey from his early fascination with coding to his role in revolutionizing pharmaceutical life cycles with AI and machine learning at Indigene. In this episode, we explore the intersection of domain expertise and technology, the challenges and opportunities in the industry, and the exciting potential of emerging technologies like multimodal models and the metaverse. Whether you're in the life sciences field or just interested in the future of AI, this episode is packed with valuable insights and inspiration. 00:00 Introduction to Life Science Success Podcast 00:31 Sponsor Message: D3 Digital Media Marketing 01:23 Guest Introduction: Tarun Mathur 01:58 Tarun's Early Journey in Technology 04:09 First Foray into Healthcare 04:31 Startup Success and Challenges 06:14 Acquisition by Indigene 08:24 Operational Challenges and Remote Work 13:20 AI in Healthcare: Early Beginnings 21:24 AI and Knowledge Engineering 28:53 The Importance of Trust and Accuracy in Pharma Communication 30:56 Balancing Data Privacy and Effective Marketing 32:40 The Future of AI in Digital Marketing 34:54 Challenges Facing Life Sciences in the Next Decade 40:33 Indigene's Approach to Integrating Domain Knowledge and Technology 48:12 Emerging Technologies and Their Impact 50:49 Personal Inspirations and Ethical Concerns 53:52 Conclusion and Final Thoughts
In this episode of Life Science Success, we sit down with Paul Jaminet, Ph.D., founder and CEO of Angiex, Inc., to explore his groundbreaking work in developing Nuclear-Delivered Antibody-Drug Conjugates™ for cancer therapy. Paul shares his unique career journey from astrophysics to biotech, insights into leading innovative projects, and the challenges and triumphs of pushing the boundaries in cancer treatment. Don't miss this inspiring conversation with a visionary leader in the life sciences.
🔗 Learn more about Angiex, Inc.: https://angiex.com/ 📚 Discover Paul's book, "Perfect Health Diet": https://www.amazon.com/Perfect-Health... 🎙️ Subscribe for more insights from top industry leaders!
In this episode of Life Science Success, host Don interviews Paul Jaminet, founder and CEO of Angenex. Paul shares his unique journey from astrophysics to life sciences, detailing his groundbreaking work in developing nuclear delivered antibody drug conjugates targeting angiogenic tumor vasculature. Learn about the challenges, motivations, and scientific discoveries driving Angenex's success. Sponsored by D3 Digital Media Marketing. 00:00 Introduction to Life Science Success Podcast 00:41 Sponsor Message from D3 Digital Media Marketing 01:23 Interview with Paul Jaminet: Founder and CEO of Angenex 01:45 Paul Jaminet's Journey from Astrophysics to Life Sciences 04:35 The Birth of Angenex and Its Groundbreaking Work 06:34 Challenges and Innovations in Developing Antibody Drug Conjugates 13:07 Phase One Clinical Trials and Progress 25:59 Leadership and Strategic Decisions in Biotech 37:10 Inspiration and Motivation Behind the Work 41:10 Concerns and Future Outlook 46:00 Conclusion and Final Thoughts
In this episode of Life Science Success, host Don interviews Artug Akar, Chief Operating Officer at Mercury, about his journey from mechanical engineering in Turkey to leading logistics transformation in the life sciences and healthcare sectors. Artug shares insights on the complexities and challenges of logistics, particularly cold chain management, during the pandemic. They also discuss Mercury's innovative digital transformation initiatives in logistics, such as AI and blockchain. Artug emphasizes the importance of trust, empathy, and leading by example in leadership, along with the benefits of growing and supporting team members. This episode is brought to you by D3 Digital Media Marketing. 00:00 Introduction to Life Science Success Podcast 00:33 Sponsor Message: D3 Digital Media Marketing 01:21 Interview with Artug Akar: Transforming Logistics in Life Sciences 01:53 Artug Akar's Background and Journey 03:30 Impact of the Pandemic on Mercury 06:08 Mercury's Role in Healthcare and Life Sciences 08:58 Challenges and Innovations in Cold Chain Logistics 12:16 Digital Transformation and Future Projects at Mercury 14:58 Leadership and Personal Insights from Artug Akar 25:50 Conclusion and Final Thoughts
Scaling Innovations in Life Sciences: An Interview with Tim Glennon | Life Science Success In this episode of Life Science Success, host Don interviews Tim Glennon, the principal owner of Illumination Strategy Group. With more than 26 years of experience in the pharmaceutical industry, Tim shares his journey, starting from his early career at Bayer to leadership roles at Teva and other companies. The discussion covers the importance of strategic commercial planning for pre-IPO biopharma companies, the role of commercial involvement from the pre-IND stage, and how smaller companies can effectively scale their innovations. Tim also touches on his motivations for founding Illumination Strategy Group, the impactful trends in the pharmaceutical industry, and the significance of AI in drug development. Additionally, leadership advice, ongoing learning, and the excitement of new challenges are explored in this insightful conversation. 00:00 Introduction to Life Science Success Podcast 00:42 Sponsor Message from D3 Digital Media Marketing 01:24 Guest Introduction: Tim Glennon 01:55 Tim Glennon's Career Journey 04:08 Insights on Working in Big Pharma vs. Small Pharma 09:07 Founding Illumination Strategy Group 14:34 The Importance of Commercial Strategy 16:55 Challenges and Opportunities in Biopharma 35:42 Leadership and Personal Growth 43:00 Conclusion and Final Thoughts
In this episode of Life Science Success, host Don Davis PhD, MBA interviews Alba Panatti Johnson, the Assistant Director of Economic Development for Sugar Land, Texas. Alba shares her journey from finance to economic development and discusses her role in fostering business retention, expansion, and attraction within Sugar Land. The conversation delves into the city's strategic initiatives, including the development of a life science campus and innovative projects like a new power plant. Alba also highlights the importance of customer service, community engagement, and future visions for the life sciences industry in the region. Additionally, the episode includes a sponsorship message from D3 Digital Media Marketing. 00:00 Introduction to Life Science Success Podcast 00:43 Sponsor Message: D3 Digital Media Marketing 01:24 Meet Alba Panatti Johnson 01:54 Alba's Journey in Economic Development 04:30 Geographical Insights: Sugarland, Texas 05:18 International Business and Economic Development 13:45 Life Sciences in Sugarland 18:10 Supporting and Nurturing Local Businesses 20:46 Advantages of Sugarland for Life Sciences 27:18 Innovative Initiatives and Future Vision 35:27 Leadership and Personal Insights 42:32 Conclusion and Final Thoughts
In this episode of Lifescience Success, host Don Davis interviews Bill Bullock, a key member of the senior executive team at NC Biotech. Bullock shares his extensive experience in life science economic development, biotechnology consulting, and research. He discusses the incredible growth of North Carolina's life sciences ecosystem, particularly in biomanufacturing, and the unparalleled collaboration among educational institutions, community colleges, and industry. They explore major recent partnerships and initiatives to enhance workforce development, attract investment, and bolster North Carolina's position as a global life sciences leader. Reflecting on the ambitious history and visionary leadership behind NC Biotech, Bullock emphasizes the ongoing challenge of preparing for the future by continuously innovating and expanding infrastructure to maintain the state's competitive edge. 00:00 Introduction to Lifescience Success Podcast 00:42 Sponsor Message from D3 Digital Media Marketing 01:23 Introducing Bill Bullock 02:33 Bill Bullock's Career Journey 08:56 The Role and Mission of NC Biotech 18:22 Innovative Projects and Initiatives at NC Biotech 25:52 Business Climate in North Carolina 27:13 Impact of COVID-19 on Manufacturing 29:26 North Carolina's Biotech Success 30:23 Founding and Vision of the Biotech Center 35:14 Future of Life Sciences in North Carolina 39:53 Leadership and Personal Insights 47:41 Conclusion and Final Thoughts
In this episode of Life Science Success, Don interviews Dr. Geoffrey Stephens, the CEO of AICella, who brings over 20 years of experience in biotechnology. Dr. Stephens delves into his impressive background in immunology and CAR T cell therapies, sharing invaluable insights into the impact of artificial intelligence on the efficiency and affordability of manufacturing cell therapies. This discussion, which D3 Digital Media Marketing is sponsoring, covers Dr. Stephens' contribution to the FDA's approval of Fasenra for asthma, the difficulties and myths surrounding AI in healthcare, and the future of personalized medicine. Tune in to learn how AICella is poised to revolutionize the field of cell therapy with innovative AI-driven solutions. 00:00 Introduction to Life Science Success Podcast 00:40 Sponsor Message: D3 Digital Media Marketing 01:18 Meet Dr. Jeffrey Stevens, CEO of AICella 01:47 Dr. Stevens' Journey in Biotechnology 03:56 The Impact of CAR T Cell Therapies 06:29 Challenges and Innovations in Cell Therapy 18:47 AI's Role in Revolutionizing Cell Therapy 31:11 Future of Personalized Medicine and Cell Therapies 34:07 Collaborations and Data Sharing in Life Sciences 40:30 Leadership Insights and Inspirations 49:44 Closing Remarks and Podcast Information
In this episode of Life Science Success, host Don Davis interviews Bill Enright, a seasoned biotech executive with over 30 years of experience. They discuss Bill's career journey from pre-med student to CEO roles, his experiences with companies like Barinthus Bio, Altimmune, GenVec, and Life Technologies, and his strategic insights on leading biotech firms. Bill shares valuable leadership lessons, the importance of corporate culture, and the role of innovation in advancing precision immunotherapies. He also highlights his board position at Bullfrog AI and how AI is transforming the life sciences landscape. Tune in to learn about Bill's inspiring path and the future of biotech. 00:00 Introduction to Life Science Success Podcast 00:41 Sponsor Message: D3 Digital Media Marketing 01:28 Guest Introduction: Bill Enright 01:49 Bill Enright's Career Journey 09:38 Challenges and Resilience in Biotech 14:38 Board Membership and AI in Life Sciences 18:04 Barinthus Bio: Mission and Projects 25:54 Leadership and Corporate Culture 34:28 Closing Remarks and Podcast Information
- Introduction of InvivoSciences: Ayla Annac, co-founder and CEO of InvivoSciences, discusses the company's focus on developing therapies for cardiovascular and cardiometabolic diseases through innovative precision medicine technology.
- Personal Motivation: Ayla’s passion for addressing cardiovascular diseases stems from the personal loss of her father to heart disease at a young age, which motivated her to pursue solutions in this medical field.
- Technological Innovation: InvivoSciences utilizes a proprietary platform named Cordia for drug discovery and to identify subpopulations that match specific drugs, enhancing the effectiveness and safety of medications.
- Challenges and Perseverance: Ayla highlights the financial and industry challenges in drug development, emphasizing the need for increased investment and collaboration within the sector to bring innovative treatments to market.
- Vision and Future Goals: Ayla's mission extends beyond her company to push for a broader adoption of precision medicine in cardiovascular treatment, aiming to develop effective drugs that can significantly reduce the impact of heart diseases globally.
00:00 Introduction to Life Science Success Podcast 00:48 Sponsor Message: D3 Digital Media Marketing 01:30 Guest Introduction: Ayla Anak, CEO of InvivoSciences 02:10 Ayla's Personal Journey and Motivation 07:43 Challenges and Innovations in Cardiovascular Drug Development 08:59 The Journey of InvivoSciences 14:06 The Importance of Precision Medicine 24:54 Overcoming Challenges and Building a Team 34:39 Leadership Advice and Personal Inspirations 42:25 Conclusion and Final Thoughts
In this episode of the Life Science Success Podcast episode featuring Markus Gershater, co-founder of Synthace, listeners can learn about the intersection of synthetic biology, AI, and automation in revolutionizing life sciences research and development. Here are the key points:
- Role of Synthetic Biology and AI in Life Sciences: Markus discusses how Synthace leverages synthetic biology and AI to automate and enhance laboratory experiments, focusing on improving the efficiency and effectiveness of research processes.
- Design of Experiments (DOE): The conversation highlights the application of DOE, a statistical method that allows simultaneous examination of multiple input factors to determine their effect on a desired output, which is critical in managing the complexity of biological systems.
- Impact of Automation in Research: Markus explains how automation integrated through Synthace can significantly speed up and increase the precision of biological experiments, reducing the time and cost associated with traditional methods.
- Challenges and Opportunities with New Technologies: The discussion also covers the challenges of adopting new technologies in traditional research settings, the potential of AI to transform discovery processes, and the importance of aligning innovations with actual lab workflows.
- Vision and Aspirations for the Future: Markus shares his optimistic view on the potential of advanced technologies to make substantial impacts on life sciences, expressing hope and excitement about future possibilities to understand and control biological complexity more effectively.
This episode provides insights into how cutting-edge technologies are shaping the future of biotechnological research and emphasizes the importance of integrating new tools with current scientific practices to maximize their benefits.
In this episode of Life Science Success, my guest is William Hind. William, the founder of Alpharmaxim, is transforming how pharma companies communicate their value to healthcare providers.
In this episode of Life Science Success, host Don interviews William Hind, founder of Alpharmaxim, about the importance of effective communication in the life sciences industry. William shares his journey from working at MSD (Merck) to founding Alpharmaxim, emphasizing the need for storytelling and behavioral science in pharmaceutical communications. They discuss overcoming barriers in healthcare communication, the role of behavioral science, and the potential and challenges of AI in the pharmaceutical industry. Brought to you by D3 Digital Media Marketing, this episode delves deep into transforming pharma communication through scientific, validated methods. 00:00 Introduction to Life Science Success Podcast 00:39 Sponsor Message: D3 Digital Media Marketing 01:22 Guest Introduction: William Hind of Alpharmaxim 01:51 William Hind's Career Journey 05:47 Founding Alpharmaxim 07:12 The Importance of Storytelling in Pharma 12:27 Behavioral Science in Healthcare Communication 18:55 Challenges in Pharma Communication 24:14 Staying Updated in the Industry 34:25 Leadership and Personal Insights 42:50 Conclusion and Farewell
Tushar Pandey is a distinguished expert in the Life Sciences industry, currently making significant strides at SimBioSys with his innovative approach to healthcare technology. His contributions have been pivotal in advancing medical solutions and improving patient outcomes. In this episode of the Life Science Success Podcast, host Don interviews Tushar Pandey, CEO and Co-founder of SymBioSys, an innovative company reshaping precision cancer care. Tushar shares his intriguing journey from Uganda to the United States, his transition from engineering to healthcare, and the personal experiences that sparked his passion for precision medicine. The discussion highlights SymBioSys’ groundbreaking work in creating digital, cost-effective diagnostics to reduce uncertainty in cancer treatment. They explore the importance of addressing diversity in medical models, harnessing the power of AI, and solving challenges in drug development and patient care. Agendas like the company's comprehensive platform for early-stage breast cancer get a deep dive, showcasing how they bridge imaging, genomics, and patient-centered care for improved outcomes. This conversation is a rich mix of personal narrative, professional insights, and forward-thinking solutions in life sciences. 00:00 Introduction to Life Science Success Podcast 00:34 Sponsor Message from D3 Digital Media Marketing 01:25 Guest Introduction: Tushar Pandey 02:27 Tushar's Background and Journey 04:30 Early Career and Transition to Healthcare 06:01 Strata Decision Technology and Cost Optimization 07:57 Personal Impact of Cancer and Shift to Precision Medicine 08:54 Founding Symbiosis and Mission 11:04 Challenges and Innovations in Cancer Treatment 12:21 Symbiosis' Approach to Precision Medicine 14:04 Scientific and Emotional Theses 15:34 Digital Solutions and Global Scale 15:58 Breast Cancer Treatment and FDA Approval 18:05 Supporting Drug Developers and Dosing Regimens 19:30 Digital Orientation and Multi-Omics Data 20:24 Identifying Critical Data in Precision Medicine 20:50 Incorporating Diversity in Medical Models 23:49 Innovative Projects in Digital Health 25:07 The Role of Imaging in Precision Medicine 31:08 Challenges in Life Sciences and Overcoming Them 33:31 Leadership and Inspiration in Precision Medicine 37:28 Concerns and Future Directions in Healthcare 42:02 Conclusion and Final Thoughts
In this episode of the Life Science Success Podcast we are joined by Stephanie Oestreich, Managing Director of the Myeloma Investment Fund, who has an extensive background in life sciences, leadership, and a unique perspective as a semi-professional violinist.
Stephanie shares her extensive background in life sciences and leadership, and discusses her passion for finding cures and treatments for devastating diseases like multiple myeloma. She provides insight into the innovative work of the Myeloma Investment Fund, their mission, and the process of fostering and investing in breakthrough therapies. Stephanie also touches on her teaching role at MIT and her unique perspective as a semi-professional violinist, drawing parallels between her musical and professional experiences. 00:00 Introduction to the Podcast 00:32 Sponsor Message: D3 Digital Media Marketing 01:21 Meet Stephanie Asterik 01:54 Stephanie's Journey in Life Sciences 03:48 The Complexity of Multiple Myeloma 04:51 Investing in Innovation 08:42 The Role of the Myeloma Investment Fund 11:03 Stephanie's Background and Leadership Lessons 15:02 The Art of Playing the Violin 18:33 Leadership Insights from Music 22:07 Final Thoughts and Reflections 27:55 Conclusion and Farewell
In this episode of Life Science Success, host Don interviews Dr. Sam Clark, founder and CEO of Terran Biosciences. They talk about Dr. Clark's innovative approach to creating new neuropsychiatric therapeutics and how his personal experiences with mental illness inspired him to enter the biotech industry. The episode also explores various breakthroughs at Terran, including their innovative work with prodrugs, anti-psychotics, and psychedelics, along with their unique, efficient team structure modeled after Silicon Valley tech companies. Additionally, they delve into the inspiration, challenges, and methodologies that drive Terran's mission to provide affordable and modern treatments for patients in need. 00:00 Introduction to Life Science Success Podcast 00:40 Sponsor Message from D3 Digital Media Marketing 01:21 Guest Introduction: Dr. Sam Clark 02:12 Dr. Clark's Journey into Biotech 04:15 Founding Terran Biosciences 07:13 Innovative Projects at Terran 13:00 Psychedelic Compounds and Patient Use 20:00 Overcoming Barriers in Drug Development 23:57 Leadership and Inspiration 31:09 Conclusion and Final Thoughts
In this episode of Life Science Success, host Don interviews Vance Lyon, an accomplished chemist with a four-decade career in the life sciences industry. Vance discusses his educational background, career journey, and key experiences. The conversation also delves into the vital role of Davos Pharma in providing comprehensive services for biotech companies, including API production, formulation, and IND filings. Vance shares insights on leadership, his inspirations, and concerns, while reflecting on his contributions to significant pharmaceutical projects. Join us for an engaging discussion on life sciences, chemistry, and the intricacies of pharmaceutical development. 00:00 Introduction to Life Science Success Podcast 00:39 Sponsor Message: D3 Digital Media Marketing 01:22 Meet Vance Lyon: A Journey in Chemistry 02:27 Early Life and Education 07:22 Career Beginnings at Parish Chemical 11:08 Transition to Kemmerer Polytech 12:57 Joining Davos and Key Projects 16:06 Services Provided by Davos 27:34 Leadership and Personal Insights 35:52 Conclusion and Farewell
In this episode of the Life Science Success Podcast, host Don Davis, PhD, MBA, interviews Dr. William Chou of Passage Bio. Dr. Chou discusses his transition from a practicing physician to a leader in biotechnology, reflects on the profound patient relationships he misses, and shares insights into Passage Bio's work on gene therapy for neurodegenerative diseases like Frontotemporal Dementia (FTD). They delve into the progress of their Phase 1/2 clinical study, the urgency of developing treatments for genetic mutations, and the potential impact on patients and their families. Learn about the most recent developments and how Passage Bio is working to give those suffering from these life-threatening conditions hope. 00:00 Welcome and Introduction 00:25 William's Journey into Life Sciences 01:30 The Emotional Impact of Leaving Clinical Practice 02:31 Overview of Passage Bio 02:52 Understanding Frontotemporal Dementia (FTD) 06:38 Current Progress and Future Prospects 10:04 The Urgency and Hope for FTD Treatments 11:37 Goals and Closing Remarks
In this episode of the Life Science Success Podcast, Don Davis PhD, MBA interviews Igor Fisch, founder of NewBiologix. Igor shares his journey from academia to entrepreneurship, highlighting his success with Selexis, a company he sold in 2017 that specialized in monoclonal antibodies. He discusses the challenges of gene therapy, specifically the high costs, and NewBiologix's innovative approach to making gene therapy more affordable. Igor also provides insights into the industry's future, emphasizing the significance of stable production platforms for viral particles.
00:00 Introduction and Welcome
00:15 Igor's Journey into Life Sciences
00:37 The Success of Selexis
00:56 Transition to Gene Therapy
03:32 Challenges in Gene Therapy
03:50 The Importance of Stable Platforms
05:11 The Role of Biotech Startups
05:57 Balancing Science and Business
06:51 Networking at BIO Conference
08:14 Future Vision for New Biologics
09:21 Conclusion and Farewell
In this episode of the Life Science Success Podcast, Dean Petkanas, co-founder of Kannalife Sciences, is interviewed at the Bio International Convention in San Diego. Dean shares his journey from investment banking in the 80s to founding Kannalife Sciences in 2009. He discusses the company's focus on developing cannabinoid-based drugs, specifically targeting chemotherapy-induced peripheral neuropathy. The conversation covers the challenges and opportunities in cannabinoid drug development, the importance of targeting specific types of pain, and the current state and future prospects of Kannalife Sciences. Dean also highlights the significance of partnering and collaboration in advancing novel therapeutics. 00:00 Welcome to the Life Science Success Podcast 00:20 Dean's Journey into Life Sciences 01:04 The Evolution of Kannalife Sciences 02:18 Challenges and Opportunities in Cannabinoid-Based Drugs 03:06 Understanding Pain and Neuropathy 06:08 Investment Insights and Market Trends 07:40 Kannalife Sciences's Current Focus and Future Prospects 10:02 The Importance of Partnering at Bio 11:02 Closing Remarks and Future Meetings
In this episode of the Life Science Success Podcast, host Don interviews Sean Rothwell, CEO of Evoke Nano, about the company's groundbreaking work in developing EBQ218, a revolutionary nanoparticle-based pulmonary therapeutic. They discuss the efficacy of EBQ218 in treating cystic fibrosis and its potential as a broad-spectrum antibiotic against drug-resistant superbugs. Sean shares insights into the company's journey, their upcoming clinical trials, and the broader impact of their work on patient outcomes in the healthcare landscape. Tune in to learn how Evoke Bio is poised to make a significant difference in combating infectious diseases and improving lives. 00:00 Welcome and Introduction 00:09 First Impressions of BIO Conference 00:37 Sean's Background and Journey into Life Sciences 01:42 The Science Behind Evoke Nano 02:28 EBQ218: A Revolutionary Pulmonary Therapeutic 04:16 Challenges and Future Pathways 05:24 Investment and Partnership Opportunities 06:42 Broader Applications and Future Vision 08:16 Addressing Drug Resistance and Regulatory Pathways 18:48 Conclusion and Final Thoughts
This is the second part of the interview where, with Maruiano, we will discuss more of the technology and development for Elem Biotech.
In this episode of the Life Science Success Podcast, Don Davis discusses the BIO conference and the future of biomedical research with Mauriano Vázquez. They delve into the significance of networking events, the evolution of computing capabilities, advanced simulation codes, and the potential applications of AI and quantum computing in life sciences. Mauriano shares his unique journey from Argentina to becoming a physicist specializing in computational mechanics, and how his work in cardiac electrophysiology can significantly impact patient care. The conversation wraps up with insights into the future use of virtual and augmented reality in medical applications. 00:00 Introduction and Conference Impressions 02:37 Mariano's Background and Journey into Life Sciences 06:22 Applications of Simulation Technology 10:48 Evolution of Computing Capabilities 13:37 Future of AI and Quantum Computing 14:41 Virtual Reality in Medical Applications 19:40 Conclusion and Final Thoughts
There are two parts of this interview, in the first session, I dive into Elem and what the company is doing with Christopher Morton.
In this exciting episode of Life Science Discussed Podcast, host Don Davis welcomes Christopher Morton, CEO of Elem Biotech, to talk about the groundbreaking work of virtual human twins in drug and medical device testing. Morton, an aeronautical engineer turned biotech innovator, discusses Elem's platform that allows pharmaceutical companies, medtechs, and CROs to test new therapeutics using virtual human models instead of animal models. They delve into how this approach, distinct from AI-based methods, focuses on mechanistic modeling using MRIs and CT scans to replicate human physiological functions. Morton explains how Elem Biotech's solutions help in precision medicine, clinical trial design, and reducing animal trials, supported by supercomputing power and cloud technology. Tune in to discover how virtual human models are poised to transform life sciences and medical testing. 00:00 Introduction and Welcome 00:43 Christopher Morton's Background 01:57 Introduction to Elem Biotech 02:45 Mechanistic Approach vs. AI Models 03:47 Precision Medicine and Virtual Human Twins 08:58 Supercomputing and Technological Infrastructure 13:07 Applications in Pharma and Medical Devices 21:07 Challenges and Future Directions 25:59 Conclusion and Final Thoughts
In this episode of the Lifescience Success Podcast, host Don Davis interviews James Hackworth, who shares insights about his background in physics and his journey into the life science industry. James discusses his experiences from McKinsey up to his current role at Tris Pharma, focusing on their innovative drug development and formulation technologies. He dives into the company's advancements in ADHD medications and an exciting new pain management drugs. Additionally, the conversation highlights the importance of partnerships, technology in drug development, and future industry trends. James provides a fascinating glimpse into the complexities and future of pharmaceuticals.
00:00 Welcome and Introduction 00:08 Impressions of the Bio Conference 00:42 James' Background and Journey into Pharma 03:17 Formation and Growth of Park Therapeutics 04:20 Overview of Tris Pharma 04:41 Tris Pharma's Focus and Innovations 08:00 Challenges and Opportunities in Partnering 10:58 Future of Tris Pharma and the Industry 15:41 In-depth Look at Drugs that are progressing 19:21 Conclusion and Final Thoughts
In this episode of the Life Science Success Podcast, Don interviews Himanshu Gadgil from Enzine during Bio International. Himanshu explains Enzine’s dual focus on developing biosimilars and their role as a CDMO with a game-changing platform, Enzine X. They discuss how Enzine's continuous manufacturing technology significantly cuts costs and speeds up market access for clients. Himanshu also talks about Enzine’s global presence, clientele, and their future plans for expansion in the U.S. and India. Tune in to learn about the innovative approaches Enzine is bringing to the biotech industry. 00:00 Welcome and Introduction 00:07 Overview of Enzine Biotech 00:26 Enzine's Unique Manufacturing Platform 01:08 Clientele and Market Reach 01:41 Timelines and Efficiency 02:08 Future of Continuous Manufacturing 04:22 Geographical Expansion and Workforce 05:02 Enzine's Differentiators 06:10 Conclusion and Final Thoughts
Join us on the Life Science Success Podcast as we delve into the fascinating journey of Andy Mehrotra, a pharmacist turned entrepreneur, who pioneered Unipr, an AI and machine learning platform aimed at addressing inefficiencies in drug development. Learn about his transition from sales and marketing to leading an innovative company, the significance of integrating and unifying data, and how Unipr is reshaping the pharmaceutical industry. Discover how Unipr is not just a solution for the life sciences but a model for other complex industries. Listen in for insights on the future of collaborative technology and its potential to accelerate health innovations. 00:00 Introduction and Guest Welcome 00:06 Guest Background and Career Journey 01:19 Transition to Leadership 02:29 Pharmaceutical Industry Insights 06:00 Introduction to Unipr 06:08 Uniper's Technology and Solutions 08:56 Client Use Cases and Success Stories 12:37 Integration vs. Unification 17:23 Conference Goals and Future Vision 21:41 Conclusion and Final Thoughts
Welcome to the Life Science Success Podcast! In this episode, host Don interviews Catherine from Jellox Biotech at Bio Interntional June of 2024. Catherine shares insights into her journey from financial engineering to the life sciences field, her experience in investment banking, and her current role in business development at Jellox Biotech. She discusses Jellox Biotech's groundbreaking 3D imaging technology for digital pathology, its benefits for early cancer diagnosis, and the company's expansion plans. Catherine also sheds light on the challenges and hopes for the future, especially regarding raising venture capital and global outreach. 00:00 Introduction and Guest Welcome 00:07 Catherine's Background and Career Journey 00:43 Introduction to Jellox Biotech 01:11 Innovations in 3D Imaging and Digital Pathology 02:22 Product Development and Market Expansion 03:56 Challenges and Goals at Bio Conference 08:06 Global Expansion Plans 09:37 Future Aspirations and Technological Impact 15:39 Conclusion and Farewell
In this episode of the Life Science Success podcast, we have Dr. David E. Martin, the President and CEO of TrippBio, Inc., a distinguished translational scientist with over 30 years of experience in drug development. Dr. Martin has led numerous groundbreaking projects and is here to share his insights on the future of therapeutic advancements.
🚀 Book a FREE Digital Marketing strategy Session 👉 https://link.cxnector.com/widget/book...
- Introduction of Dr. David E. Martin: Dr. David E. Martin, with over 30 years in drug development, joins Don on the "Life Science Success" podcast to discuss his career and insights into therapeutic advancements.
- Dr. Martin's Background: Dr. Martin, trained as a pharmacist during the AIDS epidemic, developed a passion for infectious diseases and clinical research, which led him into life sciences. His career is marked by his role as a translational scientist focusing on groundbreaking projects.
- Professional Achievements: He highlights his work with HIV RNA as a surrogate marker in drug development, detailing his involvement in pioneering studies that validated PCR technology in clinical trials. This work significantly contributed to how drug efficacy is evaluated, particularly concerning HIV treatments.
- Role at TrippBio: As the CEO of TrippBio, Dr. Martin discusses the company's focus on developing drugs targeting host factors rather than the pathogens themselves, reducing the likelihood of resistance. TrippBio is exploring treatments for major respiratory viruses using this novel approach.
- Vision and Challenges: Dr. Martin shares his vision for TrippBio to develop a universal treatment for major respiratory infections and discusses the challenges small biotechs face, especially in securing funding and managing innovative research within tight budgets.
In this episode of Life Science Success, host Don Davis PhD, MBA, a digital marketer in life sciences, interviews Sabrina Johnson, CEO, and founder of DARE Bioscience. With a passion for advancing women's healthcare, Sabrina shares her career path from biochemical engineering to founding DARE Bioscience. She discusses the inception of the company, its innovative pipeline, including non-hormonal contraceptives and treatments for female arousal disorder, and the unique challenges they faced, like funding and public awareness. Sabrina emphasizes the importance of addressing unmet needs in women’s health, the strategic decisions behind their reverse merger, and her optimistic vision for the future of women's health treatments.
Key Takeaways 1. Purpose-Driven Innovation: Daré Bioscience was founded to address significant gaps in women's healthcare, driven by Sabrina Johnson's commitment to making a difference in areas with unmet needs. 2. Strategic Funding: Opting for a public company model allowed Daré Bioscience to secure necessary funding for its extensive product pipeline. 3. Collaborative Development: Partnering with established companies like Bayer helps in the commercialization and broader reach of innovative products. 4. Focus on Unmet Needs: The company's approach starts with identifying specific unmet needs in women's health, ensuring their products address significant issues. 5. Leadership and Authenticity: Sabrina Johnson highlights the importance of authentic leadership, problem-solving, and not shying away from challenges to drive innovation and success in healthcare.
In this episode of the Life Science Success Podcast, host Don Davis interviews Christian Engstrom, CEO of Bullpen, an elite club focused on fostering collaborative success in the life sciences industry. They discuss Christian's background, his motivation for creating Bullpen, the club's mission to help entrepreneurs and investors connect and support each other, and the various success stories stemming from Bullpen's initiatives. They also delve into upcoming events at the BIO International Convention and the club's future direction. Christian emphasizes the power of authentic networking and resource sharing among life sciences professionals.
Key Takeaways:
- Collaborative Environment: Bullpen Ventures fosters a collaborative environment where members can network and support each other, addressing gaps in the life sciences sector.
- Event Organization: Bullpen organizes unique, engaging events at major conferences to facilitate networking and partnerships among life science professionals.
- Philosophical Approach: The club operates on mutual support, humility, and leveraging each member's strengths to create a supportive and effective community.
- Non-Profit Focus: Bullpen emphasizes non-profit collaboration and relies on sponsor partners to cover costs, ensuring that resources are directed towards helping entrepreneurs and small businesses.
- Future Vision: Bullpen aims to be a hub for DEI initiatives and a power center for collaboration, with a focus on aligning with partners who share their values and contribute to the community's success.
In this episode, we sit down with Aron Knickerbocker, President and CEO of Aulos Bioscience. Aron shares his extensive experience in the Life Sciences industry, highlighting his pivotal roles at RayzeBio, Five Prime Therapeutics, and Genentech. He discusses Aulos’ innovative approaches to cancer treatment, particularly in radiopharmaceuticals and targeted therapies. Aron also reflects on the key leadership advice that has shaped his career and shares his insights on the future of oncology. Tune in to learn about the groundbreaking work at Aulos and Aron’s vision for advancing cancer treatment.
- Personal Motivation: Aron’s dedication to cancer treatment is deeply personal, influenced by his mother’s death from cancer.
- Innovative Approaches: Aulos Biosciences uses immune system engagement instead of traditional radiotherapy, showing promise in early trials.
- Diverse Experience: Aron’s career spans research, business development, and leadership roles, providing a comprehensive understanding of the biotech industry.
- Leadership Values: Effective decision-making, scientific rigor, and a strong team are central to Aron’s leadership style.
- Future Vision: Aron envisions AU-007 making a significant impact on cancer treatment, with aspirations of achieving groundbreaking results in clinical trials.
https://www.lifesciencesuccess.com/pauledwards/
Paul Edwards is the President and CEO of DoseMeRx. He has been a Senior Executive with Merck and GSK, and start-ups including ILUM Health Solutions, Infectious Disease Connect, and TrackMy Solutions. He has an extensive history in infectious disease, antimicrobial stewardship, and precision medicine.
- Guest Introduction: Paul Edwards, the President and CEO of DoseMeRx, shares his extensive background in the pharmaceutical industry, including roles at Merck, GSK, and various startups, focusing on antibiotics and infectious diseases.
- Pharmaceutical Journey: Paul discusses his career progression from selling macrolides to leading infectious disease units and moving to the U.S. to transform commercial models at Merck, emphasizing the importance of real-world data over clinical trial data.
- DoseMeRx Focus: DoseMeRx specializes in precise dosing for critically ill patients using therapeutic drug monitoring, particularly for injectable antibiotics, aiming to provide accurate dosing information through web-based and integrated models within hospital systems.
- Challenges and Future of Medicine: Paul highlights the importance of antimicrobial stewardship, pharmacogenomics, and personalized medicine in improving patient care and expresses concerns about the current insurance and payment systems based on actuarial science.
In this episode of the Life Science Success Podcast, I am joined by Dr. Rafael G. Amado, an esteemed leader in oncology research and development, currently serving as the President and Head of Global Oncology at Zai Lab. With a distinguished career spanning multiple leading biotech firms, Dr. Amado brings a wealth of experience in gene-engineered cell therapies and innovative cancer treatments.
- Professional Background: Dr. Rafael G. Amado is currently the president and head of global oncology at Zai Lab. He has a rich background in medicine, starting with his education in Spain, followed by a move to the U.S. where he specialized in Internal Medicine and later Hematology Oncology at the University of California, Los Angeles.
- Passion for Oncology: Dr. Amado's interest in oncology stems from its complex nature and the multifaceted approach it requires, combining diagnostics, therapeutics, and a detective-like inquiry into patient cases. His career shift towards oncology was influenced by its holistic approach to patient care and his personal drive to solve complex medical puzzles.
- Research and Development Focus: At Zai Lab, Dr. Amado oversees oncology research and development, focusing on gene-engineered cell therapies among other innovative treatments. He has been involved in significant breakthroughs, such as determining drug inefficacies in patients with certain genetic mutations, which has influenced global regulatory changes in cancer treatment.
- Corporate and Global Strategy: Under Dr. Amado’s leadership, Zai Lab has approved six drugs in China, with a strong emphasis on addressing grievous illnesses through open innovation. He is instrumental in expanding the company's global reach, aiming to impact a broad patient base internationally by aligning clinical trials and regulatory strategies across diverse geographic locations.
- Vision and Future Goals: Dr. Amado is committed to advancing drug development that significantly outweighs potential risks with therapeutic benefits. He is driven by a mission to impact oncology treatment on a global scale, with ambitious goals to reach approximately a million patients by 2030 through continuous innovation and strategic drug development.
This week on the Life Science Success Podcast my guest is Dan Lunz. Dan Lunz is the CEO and Co-founder of Previse, a pioneering company based in Baltimore, Maryland, that specializes in offering tests for the prediction and earlier detection of upper-GI cancers.
- Background of Dan Lunz: Dan Lunz, CEO and co-founder of Previse, shares his journey from growing up in Baltimore, serving in the Marine Corps, experiencing healthcare firsthand as a patient in the VA system, to studying at Johns Hopkins and working in clinical research. His career path was significantly influenced by his desire to serve others, leading him to the life sciences sector.
- Formation of Previse: Lunz's collaboration with Dr. Steven Meltzer, a professor at Johns Hopkins, sparked the founding of Previse. They focused on developing diagnostic tools for early detection of upper GI cancers based on Meltzer's research on biomarkers. Their shared mission was to improve patient outcomes through innovative medical technologies.
- Previse's Diagnostic Innovations: Previse specializes in detecting and predicting upper gastrointestinal (GI) cancers. The company offers a commercial test called ESO Predict, which assesses the risk of esophageal cancer in patients with conditions like Barrett's esophagus, helping physicians strategize patient management and surveillance intervals.
- Challenges and Leadership Insights: Throughout the interview, Lunz discusses the entrepreneurial challenges of securing funding and navigating regulatory landscapes. He emphasizes the importance of perseverance and humility in leadership, learning from rejections, and the critical role of assembling a talented team to overcome complex challenges.
- Future Goals and Impact: Looking forward, Previse aims to expand access to its existing diagnostics across the U.S. and continue developing non-endoscopic tools and medical devices to enhance GI cancer detection. Lunz is driven by the potential impact of their technology in preventing cancer and improving patient care, underscoring his dedication to service and innovation in life sciences.
In this episode of the Life Science Success Podcast our guest is Leonard Mazur, CEO and Co-Founder of Citius Pharmaceuticals. With over 50 years of experience in the biopharma industry, Leonard has been at the forefront of developing groundbreaking therapies for patients with unmet medical needs.
- Background and Entry into Biopharmaceuticals: Leonard Mazur, CEO and co-founder of Citius Pharmaceuticals, began his career through an unexpected newspaper ad, leading him to pharmaceutical sales. His liberal arts background as a psychology major did not initially suggest a career in biopharma, highlighting the unpredictability of career paths.
- Early Career Development: Mazur's rapid career advancement occurred within Cooper Laboratories, an entrepreneurial company where he transitioned from sales to marketing and strategic planning. This period involved substantial growth through acquisitions, providing him with a broad range of experiences in the pharmaceutical sector.
- Entrepreneurial Ventures: Throughout his career, Leonard Mazur has initiated multiple entrepreneurial efforts, ultimately leading to the founding of Citius Pharmaceuticals. His story is marked by significant risk-taking, including personal financial stakes in business initiatives, reflecting his deep commitment to his entrepreneurial pursuits.
- Focus of Citius Pharmaceuticals: Citius Pharmaceuticals, which Mazur co-founded, is dedicated to developing innovative treatments for critical care. A key product from Citius is an antibiotic lock solution for treating infections in central venous catheters, illustrating the company's commitment to addressing complex medical needs.
- Views on Industry and Innovation: Mazur discusses the critical role of the biopharmaceutical industry in global drug development, emphasizing the potential risks to innovation from policy changes such as the implementation of socialized medicine. His insights reflect on the industry's dynamics and the importance of sustaining an environment conducive to pharmaceutical innovation.
In this episode of Life Science Success, we sit down with Marc, an entrepreneur, certified coach, and a beacon of leadership in the life sciences and business coaching sectors. Marc shares his journey from the entrepreneurial services group at EY to founding and leading companies in the life sciences field, and how he leverages his vast experience to mentor and inspire others towards professional excellence and personal growth. Tune in for a deep dive into the intersection of business acumen and scientific innovation, and discover Marc's unique approach to fostering success in the competitive world of life sciences.
- Marc Cote's background includes a transition from being a CPA at Ernst & Young to becoming an entrepreneur and certified coach, focusing on leadership within the life sciences. He credits his father, a second-generation business owner, for influencing his career path and emphasizing the importance of a strong business foundation.
- During his career, Cote identified a gap in leadership and soft skills training among highly technically trained professionals in the life sciences. He aims to help these individuals realize their potential not only as scientists but also as visionary leaders and effective managers.
- Cote discusses his journey from consulting at Ernst & Young to launching his own companies that supported biotech and small pharmaceutical companies. He emphasizes the value of leadership coaching to enhance emotional intelligence (EQ), crucial for effective leadership.
- The podcast conversation covers Cote's approach to coaching, focusing on understanding and leveraging one's strengths and appreciating different leadership styles. He highlights the importance of continuous personal development and adaptability in achieving career advancement within the life sciences.
In this episode of Life Science Success, my guest is Darwin Shurig, founder and CEO of Shurig Solutions. Darwin brings strategic value to medical device, life science, and pharma companies. Darwin is responsible for most, if not all, business processes, including project management, recruitment, sales, operations, quality, and regulatory affairs, to mention a few.
- Guest Introduction: Darwin Shurig, the guest, is introduced as the founder and president of a company involved in the recruitment industry, particularly within the life sciences sector. Darwin shares his journey of starting the business, highlighting his prior experience in clinical respiratory therapy and his transition to entrepreneurship nearly nine years ago.
- Business Challenges and Insights: Darwin discusses the challenges he faced as a newcomer to the business and recruitment industries. He emphasizes the importance of resilience, learning from failures, and the critical role of understanding market needs and analytics to sustain a business in a competitive environment.
- Recruitment Philosophy and Strategies: Throughout the interview, Darwin explains his approach to recruitment, focusing on the importance of specialization, understanding client needs, and delivering value without having to return fees. He stresses a high client acceptance rate and successful placement track record as indicators of his company's effectiveness.
- Industry Perspective and Future Outlook: Closing the conversation, Darwin reflects on the broader industry trends, including the impact of technology like AI on recruitment and other business processes. He is optimistic about the potential of new technologies to enhance business efficiency and expresses curiosity about future developments in life sciences and AI.
In this episode of Life Science Success, host Don Davis has a conversation with Dr. Mohit Jain, a physician scientist with extensive experience in physiology, biomedicine, and mass spectrometry. Dr. Jain shares his unique journey from clinical training to leading breakthroughs in mass spectrometry and computational biology.
He discusses the inception of Sapient Bio, a company that leverages mass spectrometry to unlock new horizons in drug discovery and patient diagnosis by analyzing thousands of molecules in the human body. They explore the future of medicine, emphasizing personalized therapy and the potential to diagnose diseases like diabetes and Alzheimer's years in advance.
Dr. Jain also sheds light on the challenges and opportunities in biotech, the impact of computational biology, and the pivotal role of Sapient Bio in pioneering the field of drug discovery. The conversation concludes with Dr. Jain's reflections on leadership, inspiration, concerns, and what excites him about his work, offering deep insights into the promising future of life sciences.
Key Highlights:
01:23 Introducing Dr. Mohit Jain: A Multifaceted Scientist 02:04 The Journey to Sapient Bio: Unraveling Dr. Jain's Career Path 03:39 The Evolution of Mass Spectrometry and Its Impact on Health 06:45 Sapient Bio: Democratizing Access to Advanced Technologies 13:33 Challenges and Opportunities in Leading a Biotech Company 16:54 The Future of Drug Discovery and Personalized Medicine 23:47 Sapient Bio's Differentiation and Future Prospects 29:24 Leadership Insights and Personal Reflections from Dr. Jain
Jennifer Hawks Bland is a distinguished leader in the life sciences sector, serving as the Chief Executive Officer of NewYorkBIO, an organization at the forefront of advancing New York's life sciences ecosystem. With a rich background spanning legal practice, government affairs, and executive leadership in companies like Merck and GlaxoSmithKline, she brings a wealth of experience and insight to her role in fostering innovation and growth within the industry.
- Jennifer Hawks Bland, CEO of New York Bio, discussed her unique path into life sciences, transitioning from a legal background where she initially engaged with the pharmaceutical industry through mass tort defense litigation, to advocacy and lobbying roles, eventually leading her to her current position.
- She detailed the mission and operations of New York Bio, highlighting its role in advancing New York’s life sciences ecosystem by collaborating with early-stage companies, academic medical centers, and leveraging the state’s rich resources in life sciences for regional and statewide economic development.
- Hawks Bland emphasized the importance of storytelling in advocacy, drawing on her legal and lobbying background to influence policy and support the life sciences industry, both at the state and federal levels, and how this skill has been crucial in her roles leading up to and including her leadership at New York Bio.
- The conversation also covered the challenges and opportunities facing the life sciences sector, particularly in New York, from fostering startup growth to navigating policy and funding landscapes. She stressed the significance of collaboration across various stakeholders, including government, academia, and the private sector, to drive innovation and support the ecosystem.
- Hawks Bland shared her excitement for the future of life sciences, reflecting on the potential for breakthroughs in health and medicine, and the critical role of advocacy and strategic partnerships in overcoming challenges and capitalizing on opportunities within the industry.
In this episode of Life Science Success, we're thrilled to welcome Britney Winterberger, the Senior Director of North America Project Management and Clinical Operations at Tigermed. Britney brings a wealth of experience in clinical trials across various therapeutic areas and a deep personal commitment to advancing patient treatments, particularly in the fight against cancer.
- Britney Winterberger is the Senior Director of North America Project Management and Clinical Operations at Tigermed, with a rich career history in life sciences, inspired by a personal loss to leukemia. She initially aspired to be a pediatric oncologist but shifted towards clinical research to contribute to cancer treatment advancements.
- Winterberger, who was born and raised in Cincinnati, Ohio, has a Marquette University undergraduate degree in biological sciences as well as study abroad experiences. She is also a family person, emphasizing the importance of travel, outdoor activities, and being sports enthusiasts with her husband and two children.
- Her journey into the field of life sciences was somewhat unintentional, transitioning from a goal in pediatric oncology to clinical research due to the emotional challenges of the former. She transitioned because of a special opportunity through a family connection, which led her to a career in clinical research organizations (CROs).
- Throughout her career, pivotal moments included receiving a 'B' on a performance review, which was a significant learning experience for her, highlighting the importance of adaptability, innovation, and the need to work in a more agile and innovative environment. Joining Tigermed represented a culminating point where she found a space to innovate and drive meaningful change in the clinical research landscape.
- Winterberger discusses the evolution of clinical trials, emphasizing the shift towards patient-centric approaches, the integration of digital health technologies, and the push for decentralized clinical trials to improve patient access and compliance. She also highlights Tigermed's role in advancing clinical research through innovative trial designs and efficient patient recruitment strategies, underlining her commitment to making a difference in cancer treatment and patient care.
In this episode of Life Science Success my guest is Dr Dr. Rahul Kakkar we will dive into the life and innovations of his tremendous career. From founding groundbreaking biotech companies to his vital role at Tome Biosciences and balancing life as a practicing physician, Rahul's journey is nothing short of inspirational. Discover the cutting-edge of genomic medicine and get a peek into the mind of a true life sciences pioneer.
- Dr. Rahul Kakkar's Journey: Dr. Kakkar, CEO of Tome Biosciences and a distinguished biotech executive and physician scientist, shares his journey from training in the Harvard Hospital System to his disillusionment with academia's limitations on drug development. This frustration led him towards a career in biotech, underscored by his entrepreneurial spirit and the significant influence of mentors who supported him at pivotal moments.
- Entrepreneurial Shift and Tome Biosciences: His experiences, particularly at AstraZeneca, highlighted the challenges of navigating entrenched corporate cultures, sparking his entrepreneurial journey. This journey includes the founding of Corvidia Therapeutics and ultimately leading to his current role at Tome Biosciences, where he emphasizes a flat, open company culture focused on innovative drug development.
- Balancing Medicine and Leadership: Kakkar balances his roles as a physician and a biotech leader, finding real-world clinical experiences vital for grounding his work in biotech. He maintains an active part in patient care, which he finds complements his leadership in biotech, keeping his work relevant and impactful.
- Advancements in Biotech and Tome's Focus: Kakkar discusses the evolution of biotechnology, from monoclonal antibodies and nucleotide-based therapeutics to the future of DNA editing. At Tome Biosciences, the focus is on programmable genomic integration, aiming to create differentiated, impactful drugs. This approach underscores the importance of technology in developing meaningful new therapies.
- Leadership Philosophy and Inspiration: Sharing insights on leadership, Dr. Kakkar emphasizes the importance of resilience, adaptability, and making the best of situations. He finds inspiration in the human spirit's perseverance, whether in family, healthcare, or scientific discovery, driving him to overcome challenges in healthcare and biotech innovation.
This week on Life Science Success, we are thrilled to welcome back Elizabeth Smalley as our guest. Elizabeth is the VP, Product Management, Data & Analytics at ArisGlobal, where she plays a pivotal role in steering the company’s strategic initiatives in the realms of artificial intelligence and machine learning within the life sciences sector. With an impressive background that bridges technology and life sciences, Elizabeth has been instrumental in the formation and launch of the GenAI Council, an innovative effort aimed at harnessing generative AI to revolutionize research and development in life sciences.
- Introduction of Guests and Focus: Don, a consultant in life sciences, introduces Elizabeth Smalley, VP of Product Management, Data, and Analytics at ArisGlobal. The discussion emphasizes the transformative power of generative AI (GenAI) in the life sciences sector, with a particular focus on Elizabeth's leadership in strategic AI initiatives at ArisGlobal.
- Elizabeth Smalley's Background and Journey: Elizabeth recounts her diverse experience in product management across e-commerce, manufacturing, and healthtech. Her story highlights the central role of AI in her career, including significant achievements in developing AI-driven clinical solutions at Teladoc Health and her progression to leading ArisGlobal's data, analytics, and AI strategies.
- ArisGlobal's Innovations and Role: The conversation explores ArisGlobal's impact on life sciences, especially its innovative use of AI in pharmacovigilance and regulatory processes. Elizabeth points out ArisGlobal's pioneering introduction of AI into case processing workflows and its leadership in adopting generative AI, aiming to enhance efficiency and patient safety in the sector.
- Generative AI: Challenges and Opportunities: Elizabeth discusses the economic potential of generative AI in life sciences, acknowledging regulatory challenges and the necessity of industry-wide collaboration to navigate these. She emphasizes the importance of creating a responsible AI adoption playbook, addressing transparency, and fostering innovation within a regulatory framework.
- Vision for the Future: The interview concludes with a forward-looking view on how generative AI could revolutionize patient care, streamline drug development, and optimize regulatory compliance. Elizabeth advocates for a collaborative approach to leverage AI responsibly, aiming to improve health outcomes, enhance operational efficiencies, and ensure patient safety in the evolving landscape of life sciences.
This week on the Life Science Success Podcast, my guest is Dr. Tiago Reis Marques Dr. Marques is a psychiatrist and currently the Chief Executive Officer of Pas i thea Therapeutics. Pasithea is developing new molecular entities for the treatment of CNS disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis, Neurofibromatosis type 1 and Noonan syndrome.
On this episode of Life Science Success, Don Davis interviews Dr. Tiago Reis Marques, the CEO of PACEA Therapeutics. They discuss Dr. Marques's journey in psychiatry, the company's focus on CNS disorders, their pipeline of drugs targeting neurological conditions like schizophrenia and ALS, and the impact of their research on rare disorders like neurofibromatosis type one. The conversation also touches on leadership advice, inspiration, concerns about global issues, and what excites them.
- Dr. Tiago Reis Marques, a psychiatrist, is the CEO of Pasithea Therapeutics, a company focused on central nervous system (CNS) disorders. His background in medical research and his transition from academia to biotech were driven by a desire to apply his knowledge to develop treatments that benefit patients.
- Pasithea Therapeutics, co-founded with Professor Steinman from Stanford, aims to create innovative therapies for unmet needs in CNS disorders. The company's approach balances new drugs targeting novel mechanisms of action with known drugs repurposed for new applications.
- One of the company's focuses is on neurofibromatosis type one, a disorder affecting around 100,000 patients in the US, highlighting the company's commitment to tackling rare and challenging diseases with significant unmet needs.
- Marques emphasizes the importance of precision psychiatry and targeting specific subtypes of disorders, drawing parallels to how cancer treatments have evolved to focus on specific biomarkers and subtypes, reflecting a broader trend towards personalized medicine.
- His experiences and work in brain imaging, specifically with positron emission tomography (PET) and psychopharmacology, underscore his multidisciplinary approach to understanding and treating CNS disorders, leveraging his academic background to inform his leadership and strategic direction at Pasithea Therapeutics.
In the interview, Don Davis PhD, MBA talks to Toban Zolman about his company, Kivo. Zolman takes us through his impressive journey of over 20 years in life sciences and the transformation he has witnessed in the industry. He further details the services of Kivo, stating that the company helps businesses involved in life sciences, specifically those developing clinical trials for pharmaceutical, medical device, and biotech companies, to streamline and optimize their processes.
He specifically speaks about the significant shift in the industry from large pharmaceutical companies running drug trials to now being dominated by smaller companies without a product in the market yet. Regarding emerging trends, Zolman anticipates artificial intelligence will have a transformational impact on the industry. He also highlights the importance of knowing when to say "no" and making definitive decisions based on customer's needs, aligning company focus to customer growth, and maintaining transparency in their operations.
5 Key Points:
- Toban Zolman is the CEO of Kivo, with over 20 years of leadership experience in developing, deploying, and validating computerized systems for clinical trials.
- Zolman's career began in the early 2000s at an electronic submission company, pioneering the transition from paper to electronic submissions for pharmaceutical companies globally, impacting 47 out of the top 50 Pharma companies in 16 countries.
- At Kivo, Zolman leverages his extensive background to innovate in life sciences by integrating technology and regulatory best practices to support emerging companies in developing and marketing new drugs efficiently.
- Kivo stands out in the life sciences space by blending deep clinical and regulatory experience with enterprise SaaS expertise, offering a unique approach to accelerating drug development and approval processes.
- Zolman emphasizes the importance of adaptability, saying no to maintain focus, and the potential transformative impact of AI on drug development, viewing it as both an intimidating and exciting challenge for the future.
Revolutionizing Patient and Physician Experiences through Digital First Strategies - In this week's episode of Life Science Success, we dive into the intersection of digital innovation and healthcare commercialization with leaders from Indegene, a company revolutionizing patient and physician experiences through digital-first strategies. We'll explore the journeys of Nancy Phelan, a biopharma commercial strategy expert; Jeff Rothstein, a marketing visionary who has significantly expanded Indegene's brand and capabilities; and Kevin Patterson, a strategic thinker in medical solutions, as they share insights on driving healthcare forward in today's complex landscape.
Key Takeaways:
- Interdisciplinary Innovation: The convergence of diverse backgrounds and expertise is driving innovation in healthcare, emphasizing the importance of storytelling and engagement in healthcare marketing.
- Digital Transformation: The shift towards digital and data-driven strategies is revolutionizing patient and physician experiences, making healthcare more personalized and accessible.
- AI's Growing Influence: Artificial intelligence is poised to transform healthcare delivery and treatment, with current applications representing just the tip of the iceberg.
- Navigating Market Access Challenges: Successfully bringing new treatments to market requires overcoming regulatory and accessibility hurdles, highlighting the need for strategic market access planning.
- Optimism for the Future: Despite challenges, there's a strong sense of optimism about the future of healthcare, driven by technological advancements and a commitment to improving patient care.
This week on Life Science Success, we're excited to welcome Donald Zinn, a seasoned professional with nearly three decades of experience in the biotech, pharmaceutical, and medical device industries. Beyond his executive roles, Don contributes to the National Institutes of Health (NIH) as a Commercialization Grant Reviewer and has played a pivotal role at Crossject, leading their needle-free auto-injector platform to global success since the onset of COVID.
- Donald Zinn's Background and Experience: Donald Zinn, the Vice President of US Business at Crossject, has nearly 30 years of experience in the life sciences industry. He started his career with an undergraduate degree from UMBC and went on to innovate in the field by inventing dry process microarray during his time at the Uniform Services University. His journey included roles such as lab manager at Georgetown University's HIV Center, and leadership positions in companies focused on oncology, infectious diseases, and more.
- Crossject's Needle-Free Auto Injector: Zinn is part of the Crossject team, working on a needle-free auto injector, which he finds to be an exciting and innovative technology. This device is designed to deliver medications quickly and without the need for needles, addressing needle phobia and improving patient compliance.
- Demonstration of the Injector's Ease of Use: During the podcast, a demonstration was discussed showing how the injector works, including its ability to administer medication through clothing. This feature is particularly advantageous in emergency situations where speed and ease of use are critical.
- Focus on Partnerships and Market Expansion: Zinn emphasizes the importance of finding the right partners worldwide to distribute Crossject's needle-free injector. The company aims to select partners based on their expertise and market presence to ensure the technology is accessible to a broad audience.
- Future Prospects and Industry Impact: The conversation highlighted the potential of Crossject's technology to revolutionize drug delivery, especially for emergency medications like epinephrine. The ease of use, coupled with the effectiveness of the needle-free injector, presents a significant advancement in patient care and medication administration.
In this episode of Life Science Success, my guest is Dr. Kate Broderick. Dr. Broderick has more than 15 years of experience in the life science industry. A recognized vaccine expert, Dr. Broderick has a broad background in device and product development in the DNA therapeutic and drug delivery fields. She also actively works with teams at TriLink BioTechnologies, a Maravai company, to advance its global reagents and manufacturing services.
- Dr. Kate Broderick's Background: Originally from Scotland, Kate Broderick's academic journey began with using animals as models for human diseases. Her passion lies at the intersection of science and clinical application, leading her to focus on DNA therapeutics and drug delivery fields in the United States, particularly after her postdoctoral work at UCSD.
- Focus on DNA and RNA Technologies: Dr. Broderick is motivated by the fundamental roles of DNA and RNA in medicine. She discusses the potential of these molecules to revolutionize treatments, vaccines, and therapies, foreseeing a future where new medical solutions are developed using these technologies.
- Career Development and Innovation: Throughout her career, Dr. Broderick has embraced various roles beyond her scientific training, including clinical development and finance, which have enriched her understanding of product development and corporate strategy within biotech startups.
- Role as Chief Innovation Officer at Maravai: In her current role, Dr. Broderick emphasizes the importance of innovation in staying ahead in the fast-paced field of life sciences. She discusses fostering collaborative environments for scientists, integrating client needs into R&D, and focusing on structured innovation to drive the company's mission forward.
- Concerns and Future Outlook: Dr. Broderick expresses concerns about vaccine hesitancy and misinformation, emphasizing the need for better communication in the scientific community. She is excited about the future of nucleic acid medicines, predicting significant advancements in treating various diseases and developing new vaccines within the next decade.
In this episode of Life Science Success, my guest is Dr. Thomas Rademacher. Professor Rademacher, MD, PhD, co-founded Emergex and has served as CEO since the Company’s formation. He is an Emeritus Professor of Molecular Medicine at University College London (UCL) and a serial entrepreneur.
- Dr. Thomas Rademacher, MD, PhD, is the co-founder and CEO of Emergex, with a background as an Emeritus Professor of Molecular Medicine at the University College of London and a serial entrepreneur. His career has oscillated between academic and entrepreneurial roles, adhering to the philosophy of not staying in the same job for more than ten years.
- Rademacher's academic foundation in hardcore biochemistry was established during his PhD at the University of Wisconsin Madison. This rigorous training in biochemistry has been a cornerstone throughout his career, enabling him to navigate and innovate in the complex field of molecular medicine.
- His work has significantly contributed to the field of monoclonal antibodies, starting with foundational research at Oxford and involving the use of Chinese hamster ovary (CHO) cells. This work was pivotal for the development of recombinant proteins and monoclonal antibodies, leading to advancements in medicine.
- Rademacher has been involved in groundbreaking research and entrepreneurial ventures, including the Glycobiology Institute, which attracted interest from major corporations like Monsanto. His work has led to significant scientific advancements and the formation of companies that have had substantial impacts on the medical and biotechnological landscapes.
- He is currently focused on challenges in vaccinology and immunology, particularly in developing vaccines that activate the cellular immune response to fight viral infections effectively. Rademacher's innovative approach involves utilizing quantum-confined gold clusters and micro-needle technology to enhance vaccine delivery and efficacy.
Ronan O’Hagan, President & CEO, Bectas Therapeutics Inc. Rónán is a founder and the President and Chief Executive Officer for Bectas Therapeutics Inc. He has over 20 years of experience in oncology R&D including bringing over 20 molecules through IND and into clinical development and helping to guide 4 drugs through clinical development to FDA approval.
- Ronan O'Hagan is the President and CEO of Bectas Therapeutics, a cancer drug discovery and development company with over 20 years of experience in oncology R&D. He has been instrumental in advancing over 20 molecules through IND (Investigational New Drug) to clinical development and guiding four drugs through clinical trials to FDA approval.
- His approach at Bectas Therapeutics focuses on utilizing insights from human patients' immune responses to develop precision therapies, aiming to find the right drug for the right patient. This approach stems from his belief that understanding cancer's complexity requires a deep understanding of patients themselves.
- O'Hagan's career includes significant roles in various organizations: Chief Scientific Officer at Apricity Health and Exilio Therapeutics, leader of the Oncology Discovery team at Merck Research Labs, and involvement in a biotech startup originating from Dana Farber Cancer Institute.
- He emphasizes the importance of values like focusing on patients, people, and proof of concept in drug development. He believes in balancing innovation with discipline and highlights the need for collaborative but strong leadership in the pharmaceutical industry.
- O'Hagan discusses the challenges and triumphs of drug development, stressing the importance of speed in bringing therapies to patients and the need for alignment around core values within a team. He also underlines the role of precision in enhancing the effectiveness of immune therapies and the necessity of inclusive research to benefit diverse patient populations.
In this episode of Life Science Success, my guest is Matt Hill, Ph.D. Matt is founder and CEO of Elegen Corp., a privately-held company based in the San Francisco Bay Area committed to revolutionizing synthetic biology workflows with innovative DNA writing technology.
- Background and Experience: Matt Hill has a Ph.D. in genetics from Stanford University and was initially attracted to the Bay Area for its vibrant startup ecosystem. After completing his Ph.D., he joined Nera, a leading molecular diagnostics company, where he contributed to product development and new capabilities, particularly in massively multiplex PCR technology.
- Journey to Founding Elegen: Hill's experience at Nera, especially in DNA synthesis and production challenges, led him to identify DNA production as a critical bottleneck in life sciences. His interest in solving complex problems and connecting technology areas motivated him to found Elegen to address these challenges in DNA synthesis and production.
- Elegen's Impact and Infinia DNA: Elegen's product, Infinia DNA, aims to streamline workflows in life sciences, providing researchers with faster, more accurate DNA synthesis. This technology impacts various fields, including therapeutics and synthetic biology, by enabling quicker and more efficient product development cycles.
- Leadership and Vision: As a leader, Hill emphasizes inspiration, encouragement, and problem-solving. He discusses the importance of Elegen's technology in advancing fields like personalized therapeutics and its potential in addressing major health challenges. Hill also highlights the need for more investment in foundational research and development to foster scientific progress.
In this episode of Life Science Success, Ross Jackson, the guy who wrote two books about patient recruitment, is returning to tell us about his new patient recruitment book. Ross is a specialist in patient recruitment for clinical trials, having helped deliver many thousands of patient registrations for clients in the UK, Europe, and the US.
The key highlights from the interview:
- Ross Jackson is a specialist in patient recruitment for clinical trials with experience in the UK, Europe, and the US. He has authored two books on the subject.
- His career journey began in digital marketing, where he initially recruited patients for a doctor's new treatment. Over time, he shifted his focus to healthcare and clinical trial recruitment.
- Patient recruitment faces challenges related to awareness and access. Many people are unaware of clinical trials, and misconceptions like being seen as "guinea pigs" persist. Lack of understanding about the importance of clinical research compounds the issue.
- Ross Jackson's first book focused on using Facebook ads for patient recruitment. It aimed to make it easier for research sites and others to access potential trial participants effectively.
- His new book takes a unique approach, featuring a fictional character named Josh Black, a puzzle solver who tackles patient recruitment challenges. The book explores various aspects of patient recruitment and aims to make the topic more accessible and engaging.
- Ross emphasizes the need for collaboration within the industry and the potential impact of AI, particularly natural language processing, in improving patient recruitment processes.
- He also mentions his excitement about attending a conference and watching his first Super Bowl in Orlando, highlighting his interest in sports and the upcoming event.
- The interview concludes with gratitude for sharing information about his new book and the hope that it will benefit those interested in patient recruitment. The book is available on Amazon.
In this episode of Life Science Success, my guest is Dr. Lishan Aklog. Dr. Aklog is the CEO of Lucid Diagnostics he also co-founded and has served as Chairman and Chief Executive Officer of Lucid’s parent company, PAVmed Inc (Nasdaq: PAVM) since its inception in 2014, and as Executive Chairman of PAVmed’s other major subsidiary, digital health company Veris Health Inc., since its inception.
- Dr. Lishan Aklog's Background: Dr. Aklog, CEO of Lucid Diagnostics and executive chairman of PAVmed’s subsidiary Varys Health, was a cardiothoracic surgeon with a strong interest in technological innovation in medicine. He has an extensive background in academic cardiac surgery and was actively involved in medical device innovation.
- Transition to Entrepreneurship: Transitioning from a successful career in cardiac surgery, Dr. Aklog co-founded Lucid Diagnostics and PAVmed. He ventured into medical device entrepreneurship, focusing on developing and commercializing innovative technologies. He was instrumental in creating and selling medical devices, notably a device for non-surgically removing clots.
- Lucid Diagnostics and Focus on Cancer Detection: Under Dr. Aklog’s leadership, Lucid Diagnostics specializes in early cancer detection, particularly esophageal cancer. Dr. Aklog emphasizes the importance of pre-cancer detection and prevention, highlighting the challenges in raising awareness and adherence to screening guidelines.
- Challenges and Achievements: A significant challenge in Dr. Aklog's journey has been raising capital to bring innovative technologies to market. Despite these challenges, Lucid Diagnostics has made substantial progress, especially in gaining payer coverage and launching large-scale screening programs.
- Leadership and Vision: Dr. Aklog's leadership philosophy centers on building a culture of success, teamwork, and innovation. He stresses the importance of surrounding oneself with talented individuals and working cohesively towards a shared mission, with a particular focus on impacting patient lives through advanced medical technologies.
In this episode of Life Science Success my guest is Roee Hevrony. Roee is the CFO of ImmunoBrain Checkpoint. Prior to joining IBC in 2015, Roee worked for Babcock Power, Inc. in its nuclear power generation unit as a business controller and started his career as an investment banker with Merrill Lynch.
- The podcast features an interview with Roee Hevrony, the CFO of ImmunoBrain Checkpoint.
- Roee Hevrony discusses his background, which includes growing up in Israel and working in investment banking before joining ImmunoBrain.
- ImmunoBrain is focused on a novel approach to treating neurodegenerative diseases by targeting the immune system rather than the brain itself.
- The company has been conducting research for nine years, expanding from basic research to clinical studies, with a unique therapy approach.
- Roee Hevrony emphasizes the importance of long-term vision and patience in the pharmaceutical industry, especially in the field of neurodegeneration.
In this episode of Life Science Success, my guest is Tom Hartman. Tom is the President and CEO of the International Society of Pharmaceutical Engineering (ISPE), Tom leads a global network of 20,000+ professionals spanning the complete pharmaceutical lifecycle.
In this edition of Life Science Success, Don Davis interviews Tom Hartman, the president and CEO of the International Society of Pharmaceutical Engineering (ISPE). They discuss Hartman's career journey and the role of the ISPE in the life sciences industry. Hartman discusses the critical role of the society's volunteer network and emphasizes the importance of speed, quality, and solid decision-making in the industry. Concerns about industry shortages, workforce challenges, and readiness for future potential pandemics also arise. Hartman highlights several exciting incursions, such as the 'Facility of the Year Award' and ISPE's workforce of the future initiative. The interview sheds light on the ISPE's strategic goals and the overall current industry landscape and trends.
In this episode of the Life Science Success Podcast my guests are James Foster, CEO of Virax Labs and Nigel McCracken COO of Virax Labs. Virax Labs is a global biotechnology company specializing in the development of innovative diagnostic solutions. They focus on T-cell testing and immune profiling, with a novel portfolio of FluoroSpot T-cell diagnostics aimed at indications associated with chronic inflammation and T-cell exhaustion.
- Podcast Overview: The first "Life Science Success" podcast episode in 2024 features James Foster, CEO, and Nigel McCracken, COO, of Virax Biolabs.
- James Foster's Background: James Foster, CEO of Virax Biolabs, co-founded the company about 10 years ago. Initially starting in finance, he shifted to biotech and diagnostics due to his entrepreneurial interests, particularly influenced by the 2008 financial crisis. His goal is to develop comprehensive immune profiling in-vitro diagnostics (IVDs), focusing on early diagnosis of post-viral syndromes, chronic inflammation, and T-cell exhaustion.
- Virax Biolabs' Mission and Technology: Virax is dedicated to creating innovative diagnostic solutions, particularly their T-cell testing platform. This platform aims to address significant health issues like long COVID, affecting millions in the US and Europe. Foster emphasizes the importance of early detection in disease progression and the role of the immune system in combating pathogens.
- Nigel McCracken's Role and Insights: As COO, Nigel McCracken plays a crucial role in scaling Virax from a small team to a larger organization. He discusses the importance of strategic focus, effective decision-making, and the development of companion diagnostics, which are essential for personalized medicine, especially in oncology.
- Future Outlook and Challenges: Both Foster and McCracken highlight the challenges in biotech, including the need for innovation, execution, and efficient leadership. They foresee an increasing burden on healthcare systems due to post-viral syndromes and chronic conditions. The podcast also touches on the potential of venture capital in fostering new ideas and innovations in the biotech sector.
In this episode of Life Science Success, we are welcoming back Dr. AJ Mellott. Dr. Mellott is the CEO and Co-Founder, Ronawk manufacturer of customized tissue-mimetic technology that is advancing science.
- Dr. AJ Mellott is the CEO and co-founder of Ronawk, a company that specializes in creating hydrogel substrates that mimic various tissues in the human or animal body.
- Ronawk's tissue mimetic technology is used in cell culture to produce high-quality, active cells that are valuable for medical and diagnostic applications.
- The company has recently expanded and moved to Overland Park, Kansas, and has experienced significant growth in its team and production practices.
- Ronawk's technology has facilitated collaborations between researchers in different fields and has lowered barriers to experimentation and innovation in the life sciences.
- Dr. Mellott is excited about the potential of AI and machine learning to streamline research processes and the personalized screening of therapies for patients, ultimately improving healthcare outcomes.
In this episode of Life Science Success, my guest is Dr Paul Song. Dr. Song has served as Chief Executive Officer and Vice Chairman of NKGen since December 2022.
- Dr. Paul Song, CEO and Vice Chairman of NKGen since December 2022, shares his background as a radiation oncologist and his journey into biotech.
- Dr. Song talks about the importance of natural killer cells in the body's defense against diseases and their potential in treating conditions like Alzheimer's.
- NKGen's phase one trial showed promising results, with 90% of patients either stabilizing or improving in Alzheimer's treatment.
- NKGen is also exploring the use of natural killer cells in combination with other cancer therapies to enhance their effectiveness while minimizing side effects.
In this episode of Life Science Success, we are talking about Securing America's Pharmaceutical Supply with David Sanders and Tony Paquin. We are going to discuss derisking the supply chain and building resilience.
Don, is joined by guests, David Sanders and Tony Paquin. They discuss the importance and challenges of securing America's medical supply chain. David introduces himself as the Vice President of Government Affairs at Coherence Biosciences and Executive Director at Securing America's Medicine and Supply, and Tony as the CEO and co-founder of iRemedy Healthcare, an AI-driven supply chain platform. They delve into the impacts of the COVID-19 pandemic on these supply chains, their effort in repatriating pharmaceutical supply and manufacturing back in America, and the role of innovation in overcoming the costs and barriers involved. Tony also mentioned his book, "The End of Us," which talks about this same issue.
My guest today on the Life Science Success Podcast is Andrea Henderson. Andrea is a Partner in the Life Sciences, Healthcare, Diversity, CEO & Board practices at DHR Global where she is an executive talent solutions strategist.
Andrea Henderson, an Executive Talent Solutions Strategist, and they delve into Andrea's career journey, which started with a passion for diplomacy and evolved into a focus on talent management and diversity in the corporate world.
Key Takeaways:
- Operational Excellence: Don emphasizes the significance of operational excellence in the life sciences industry, particularly the importance of value stream mapping.
- Career Evolution: Andrea's career journey highlights the unpredictable nature of career paths. Her transition from diplomacy to talent management and executive search underscores the importance of adaptability and problem-solving skills.
- Diversity and Inclusion: Andrea discusses the role of diversity and inclusion in executive-level roles, emphasizing the need to consider a wide range of perspectives to build the best teams.
- Impactful Leadership: Don and Andrea touch on leadership styles, with Andrea describing her leadership style as collaborative, visionary, and empowering. They also discuss the importance of authenticity, trust-building, and clear communication in leadership.
- Championing Change: Andrea expresses her excitement about the various avenues available to impact the future, particularly in promoting diversity and creating a more inclusive corporate environment.
In this episode of Life Science Success, my guest is Sucheshna Patil. She is the CEO and founder of MobilityZ Health. A health-focused biotech engineer, innovator, and researcher building health technology products.
- Mobility Z Health's Focus: The company specializes in orthopedic care, particularly addressing the problem of delays in orthopedic appointments. Their goal is to provide early care and diagnosis for musculoskeletal injuries, reducing backlogs in orthopedic care.
- Transition from Humans in Space: Although the company initially operated as "Humans in Space," it later transitioned to the name "Mobility Z Health" to better align with its focus on healthcare and orthopedic solutions.
- Multifaceted Background: Sucheshna Patil has a background as a biotech engineer and researcher, with a passion for healthcare innovation. She drew from her experiences in healthcare, research, and engineering to develop solutions for musculoskeletal injuries.
- User-Friendly Approach: Mobility Z Health places a strong emphasis on user experience and user-friendliness in its products to ensure that a wide range of people, including patients and older generations, can use them.
- Development Stage: The company is currently in the alpha testing phase, with private access for patients and doctors who want to use the product. A beta version for broader consumer use is expected to launch in January.
In this episode of Life Science Success, my guest is Mara Holinger. Mara is the SVP and co-founder of Quantum Regulatory Solutions. She has extensive experience in assisting pharmaceutical and biotech firms with preparing their regulatory pathway, providing regulatory input for clinical trial designs and clinical development plans, performing gap analyses for preclinical testing and writing regulatory applications.
Key points covered in this interview:
- Background and Expertise: Mara Holinger has a strong background in Regulatory Affairs, with a Ph.D. in a related field. She also highlighted her co-founders' scientific expertise, making their team unique in the regulatory consulting field.
- Client Base: Quantum Regulatory Solutions primarily serves small to midsize pharmaceutical companies, offering a range of services beyond just regulatory strategy, including pre-meeting support and long-term pathway planning.
- Team Collaboration: Mara emphasized the importance of collaboration within her team, combining their diverse skill sets to provide comprehensive solutions to clients. This collaborative approach sets them apart from others in the field.
- Leadership and Empowerment: She mentioned the value of strong leadership and role models who encouraged her to speak up and not apologize for her opinions. This empowerment has been crucial in her career.
- Passion for Problem-Solving: What excites Mara is the opportunity to solve complex puzzles in the regulatory space, working closely with various stakeholders to ensure that innovative therapies can navigate the regulatory process successfully.
In this episode of Life Science Success, my guest is Cristian Massacesi MD. Cristian is the Chief Medical Officer & Oncology Chief Development Officer at AstraZeneca. In the interview, we will discuss his start in oncology, his career path, and current trends in oncology.
- Guest Introduction: Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca. The discussion focuses on his career in oncology, his path in the medical field, and current trends in technology.
- Background and Career Path: Cristian Massacesi, originally from Italy, pursued a career in oncology due to its challenges and potential for impact. After training in Italy, the UK, and the USA, he transitioned from clinical practice to pharmaceutical research, realizing his passion for clinical research.
- Role at AstraZeneca: In his dual role at AstraZeneca, Massacesi focuses on prioritizing tasks and managing a busy schedule. He works in R&D, particularly in oncology, overseeing the development of safe and effective products, and engaging with various teams globally.
- Clinical Trials and Leadership: Massacesi emphasizes the importance of clinical trial diversity and the need for innovation in trial execution. He shares his perspective on leadership, highlighting the necessity of assembling strong teams and being accessible and human in management.
- Vision and Challenges: He is driven by the goal of defeating cancer and leading an organization towards this aim. Massacesi expresses concerns about the complexity of change management in drug development and the regulatory environment, while also finding excitement in the advancements and recognition in the field.
In this episode of Life Science Success, my guest is Bob Rochelle the Chief Commercial Officer at Cleveland Diagnostics. Bob is a proven expert in launch, strategy, and marketing for novel healthcare products. His more than 30 years of experience ranges from start-ups such as Exact Sciences and Good Start Genetics to established multinationals such as Abbott Laboratories.
- Introduction of Bob Rochelle: The episode of "Life Science Success" features Bob Rochelle, Chief Commercial Officer at Cleveland Diagnostics. Rochelle is recognized for his expertise in launch strategy and marketing for novel healthcare products.
- Bob Rochelle's Background: With 35 years in the healthcare industry, Rochelle has extensive experience, primarily in diagnostics, working with both pharmaceuticals and startups. His career includes roles in various therapeutic and diagnostic areas, from antibiotics and antihypertensive drugs to genetic disease diagnostics and cancer.
- Transition to Startups: Rochelle discusses his transition from large corporations like Abbott Laboratories to smaller startups. He emphasizes the appeal of being able to rapidly implement ideas and the challenges of limited resources compared to larger companies.
- Cleveland Diagnostics and Novel Technology: At Cleveland Diagnostics, Rochelle is involved with a novel platform technology for cancer diagnostics. He highlights the importance of innovative technology and a strong team in his career choices.
- Insights on Cancer Diagnostics and Career Lessons: Rochelle shares insights on the evolution of cancer diagnostics, emphasizing the importance of specificity and sensitivity in tests like isopsa for prostate cancer. He reflects on lessons learned throughout his career, including the significance of diverse perspectives in small companies and the challenges of navigating healthcare reimbursement systems.
In this episode of Life Science Success, my guest is Todd Druley PhD. Todd is the Chief Medical Officer at Mission Bio. His expertise lies in translational genomic and computational tools to improve clinical diagnostics and apply these tools to disease-specific questions in cancer.
Key Takeaways:
- Dr. Todd Druley is the Chief Medical Officer at Mission Bio, specializing in translational genomics and computational tools for clinical diagnostics, especially in cancer.
- Dr. Druley's career was influenced by a personal connection to pediatric leukemia, leading him to bridge medicine and genomics research.
- He transitioned from academia to industry, joining companies like Archer DX and Mission Bio to have a broader impact in diagnostics and treatment.
- Dr. Druley emphasizes the importance of single-cell multiomics in diagnostics and bridging the gap between technical advancements and clinical treatments in pediatric oncology.
In this episode of Life Science Success, my guest is Kalyan Obalampalli. Kalyan is a disruptor and technology innovator with over 20 years of experience in leadership positions in clinical operations and outsourcing at major pharma and biotechs. Kalyan is the founder and president of Clin.AI, a disruptive start-up that is revolutionizing the way vendor selection and management is conducted in the industry.
- Introduction of Kalyan Obalampalli (KO): KO is a disruptor and technology innovator with over 20 years of experience in leadership positions in clinical operations and outsourcing at major pharmaceutical and biotech companies. He is the founder and president of Clin.AI, a startup revolutionizing vendor selection and management in the industry.
- KO's Background: KO's academic background includes a degree in electrical engineering and a master's in biomedical engineering. He started his career in pre-clinical animal work and transitioned to clinical operations in the pharmaceutical industry.
- The Problem Clin.AI Addresses: Clin.AI focuses on solving the problem of vendor selection and management, particularly for organizations with budgets in the range of $40-50 million. Traditional methods using Excel files can be time-consuming and inefficient.
- How Clin.AI Helps: Clin.AI provides a platform that streamlines vendor selection by quickly analyzing vendor proposals, facilitating negotiation, and aiding in the selection of the best vendor based on both price and quality. This platform can save organizations significant time and effort.
- KO's Philosophy: KO emphasizes the importance of spending time with people to understand their problems and potential solutions. He also highlights the significance of being forward-looking and adding value to clients' experiences.
• Susan Stipa, with a diverse background in pharmaceuticals, biotechnology, and financial services, discusses the evolution of her career and her transition into marketing, emphasizing her passion for blending scientific understanding with creative communication.
• She highlights the rapid and transformative advancements in biopharmaceuticals, touching on the challenges and excitement surrounding emerging therapies like cell and gene therapy and expressing concern about ensuring access to these innovations.
• Susan mentions the importance of effective communication within the biotech industry, especially when engaging with journalists to accurately relay complex scientific concepts, showcasing CG Life’s role as a mediator to foster better understanding.
• She reflects on valuable leadership advice received from her father about making a strong initial impression and the importance of human connection, opposing a rigid corporate mentality, to foster creativity and meaningful relationships.
• Both Susan and the host, Don, share an appreciation for the relentless drive within the biotech industry and its potential to address global health challenges, emphasizing the fulfillment derived from their roles in this dynamic field.
Today on the Life Science Success Podcast, we have a very special guest with us—David Hibbard, the Vice President of Engineering at Sunrise Labs. With over 25 years of experience in medical device development, David has been at the forefront of innovation in areas ranging from Stress Echocardiography to Robotics.
- The interview features David Hibbard, VP of Engineering at Sunrise Labs, who has over 25 years of experience in medical device development. He holds a biomedical engineering degree from Boston University.
- Sunrise Labs specializes in Class II and Class III medical devices and focuses on end-to-end service, from software to hardware. The team size is just under 100 people, with approximately 70 to 80 engineers.
- David discusses the importance of strong project management, emphasizing the need to understand regulatory strategy and timelines, and advises that good client relationships are formed through transparency and integration, even in daily scrums.
- On the topic of leadership, David mentions the importance of good integrity and communication for long-term partnerships. He emphasizes that understanding the end user's needs is crucial for successful medical device development.
- Hibbard also talks about the use of AI to improve code robustness and mentions some of the challenges they are facing with remote work and maintaining a work-life balance in the current environment.
In this episode of the Life Science Success Podcast my guest is Dr. Vibhor Gupta. Dr. Gupta is the Director and Founder at PangaeaData.AI. He trained in oncology research and has a breadth of experience in life sciences through his work in industry and academia over the last two decades.
- Dr. Vibhor Gupta is the Director and Founder of PangaeaData.AI. He has a background in oncology research and a breadth of experience in life sciences.
- Dr. Gupta's journey in the Life Sciences industry began when he realized the importance of combining scientific knowledge with computer programming skills to make sense of medical data, especially in the context of improving patient outcomes and advancing scientific research.
- He emphasized the importance of motivation in pursuing a career in life sciences and how it helps individuals weather challenges and stay focused on their goals.
- Dr. Gupta discussed his experience working in Silicon Valley with Quantum Secure, where he gained valuable insights into product development, customer behavior, and innovation in the tech industry.
- Pangaea Data's focus is on leveraging artificial intelligence to connect undiagnosed patients with appropriate treatments and clinical trials, benefiting patients, clinicians, and pharmaceutical companies. They have demonstrated success in finding previously undiagnosed patients and reducing treatment costs.
In this episode of the Life Science Success Podcast, we're honored to have Dr. Alan Trounson, the CEO of Cartherics Pty Ltd, a company at the forefront of redefining cancer treatment through immunotherapy. Tune in as we discuss the future of cancer treatment, and much more!"
- Dr. Alan Trounson, CEO of Cartherics Pty Ltd, has a rich background in reproductive sciences and stem cell research. He has been instrumental in the development of human IVF and embryonic stem cells, and has also led the California Institute for Regenerative Medicine with a $3 billion budget.
- Cartherics aims to redefine cancer treatment through immunotherapy. The company is working on off-the-shelf CAR-T therapies that are designed to be low-cost and widely accessible, aiming to make cancer a manageable condition rather than a terminal one.
- The company differentiates itself by focusing on overcoming immune inhibitors in solid tumors and recruiting the patient's own immune system for a more effective treatment. They are also involved in gene editing to extend the life of CAR-T cells and make them more effective.
- Cartherics is in discussions with the FDA and plans to enter clinical trials by 2025. They are also collaborating with various international partners, including companies in Korea, China, Malaysia, and Australia, to bring in innovative ideas and technologies.
- Dr. Trounson is enthusiastic about the science and the potential impact of their work. He believes that getting the science right is crucial for achieving the expected outcomes and is excited about the broader scientific developments in the field.
In this episode of Life Science Success, my guest is Gaurav Kapoor. Gaurav is a co-founder of Indegene, a digital-first life sciences commercialization company with 19 of the world's top 20 biopharma companies as clients. Gaurav is an expert in life sciences commercialization, having pioneered the co-commercialization model at Indegene. He has close to 25 years of experience in the technology-led healthcare solutions space.
Part 1: Introduction and Background * Don Davis: Host of the Life Science Success Podcast, focuses on strategy, people, process, and technology in life sciences. He also has a weekly series on LinkedIn Live about scaling organizations. * Gaurav Kapoor: Co-founder of Indegene, a digital-first life sciences commercialization company. They work with 19 of the world's top 20 biopharma companies.
Part 2: Journey and Motivation * Gaurav Kapoor: Shares his 25-year journey with Indegene. Initially focused on bridging the knowledge gap between doctors and the pharma industry using data and technology. They digitized thousands of hours of content from medical conferences.
Part 3: Business Model and Shifts * Indegene initially focused on B2C but shifted to a B2B model. They also moved their focus to the U.S. market due to its innovation and concentration of pharma companies.
Part 4: Industry Changes and Adaptation * Significant industry changes around 2010 due to the patent cliff led to a focus on centralization and compliance. * Indegene started reimagining the sales and marketing model around 2015, predicting a shift towards an omni-channel approach.
Part 5: Co-Commercialization * Indegene pioneered co-commercialization, focusing on an omni-channel sales model and a "launch in a box" platform for mid-pharma and biotech companies. This allows for leaner, more efficient launches and operations.
Part 6: Future Outlook * Both Don and Gaurav discuss the need for the industry to continue evolving, especially in the wake of the COVID-19 pandemic. They express hope that the new efficiencies and approaches adopted during the pandemic will become the new normal.
In this episode of Life Science Success, my guest is Brian DeDecker. Brian is the CEO and co-founder of Seedling Biosystems in Boulder, Colorado. The planet’s ecosystems strain from current chemical and protein manufacturing methods and Brian co-founded Seedling to help solve this crisis.
🔑 Key Takeaways:
1️⃣ Empathy in Communication: Whether talking to students or venture capitalists, understanding your audience's mindset is crucial. Brian shares how teaching has honed his skills in this area.
2️⃣ Sustainable Biomanufacturing: Seedling Biosystems aims to revolutionize industries by shifting processes to farming, particularly focusing on soybeans as a sustainable alternative.
3️⃣ Innovative Products: From baby formula proteins to squalene for vaccines, Seedling is working on products that not only meet market needs but do so in an eco-friendly manner.
4️⃣ Leadership Philosophy: "Do what you can with what you got, where you are." This Teddy Roosevelt quote serves as Brian's guiding principle, emphasizing resourcefulness.
5️⃣ Climate Change: Both a concern and a motivator, Brian believes that the challenges posed by climate change will bring out the best in humanity, driving us toward innovative solutions.
Today on the Life Science Success podcast, my guest is Oksana Bovt. Oksana is the founder of Theoria Creative, an agency that develops unique fundraising materials that enable biotech and life sciences clients to clearly and succinctly articulate their unique message and value when raising funds, soliciting partnerships, pitching at roadshows, or presenting to prospective buyers. Oksana was a previous guest, and we covered her company and, more broadly, the things Theoria Creative is working on. Today we are going to spend some time on scientific mechanisms of action.
-
Theoria Creative's Role:
- Oksana explains that her agency helps companies build a compelling story to attract investment. They work closely with venture capitalists and investment bankers.
-
Challenges and Milestones:
-
Oksana shares her journey and the importance of pivoting and sensing industry needs. Feedback from clients helps them stay relevant.
-
Client Focus:
-
Theoria Creative mainly focuses on late preclinical and early clinical companies that are in constant need of fundraising.
-
Mechanisms of Action (MOA):
-
Oksana discusses the importance of clearly explaining the scientific mechanisms of action (MOA) to differentiate one company from another.
-
Communication Strategies:
-
Oksana outlines three steps for companies to clearly communicate their MOA:
- Outline the step-by-step process.
- Write a descriptive paragraph for each step.
- Compare the mechanism with the healthy and unhealthy state.
-
Materials and Outputs:
-
Theoria Creative produces pitch decks and animations, depending on the client's budget and stage.
-
Closing Remarks:
-
Both Don and Oksana emphasize the importance of clear communication in the life sciences sector for successful fundraising and partnerships.
This episode provides valuable insights into the importance of clear communication and storytelling in the life sciences sector, especially when it comes to explaining complex scientific mechanisms. Oksana's expertise in this area offers a roadmap for companies looking to articulate their value proposition effectively.
In this episode of Life Science Success, my guest is Dr. Jim Woody, CEO of 180 Life Sciences.Dr. Woody leads a pioneering team of scientific innovators at 180 Life Sciences, a clinical stage biotechnology company with three families of novel biologic drugs that address separate areas of inflammation, fibrosis and pain.
- Background and Career: Dr. Jim Woody is a pediatric immunologist with a diverse career, including military service and venture capital experience. He was instrumental in the development of anti-TNF drugs, a class of biologics with a market value of about $40 billion per year.
- Focus on Patient-Centricity: Dr. Woody emphasizes the importance of patient benefit in drug development. He served on the board of Stanford Children's Hospital and aims to develop therapies that significantly improve patients' lives.
- Current Work at 180 Life Sciences: The company is focused on finding new indications for anti-TNF drugs. They are working on conditions like Dupuytren's contracture, frozen shoulder, and post-operative dementia, aiming to prevent disability and improve quality of life.
- Challenges and Future Plans: Regulatory hurdles and clinical trials are the next steps for 180 Life Sciences. Dr. Woody estimates that drug approvals could take a couple of years, depending on feedback from agencies like the FDA.
- Personal Insights: Dr. Woody advises aspiring professionals to seize new opportunities and emphasizes the role of luck in biotechnology. He is excited about the next generation of anti-inflammatory agents that could offer more targeted treatments.
In this episode of Life Science Success, my guest is Mike Martin, the CEO of CAI. CAI is a global professional services firm focused on engineering and quality consulting, Mike Martin guides a team of 800 individuals across the U.S., Europe, and APAC.
- Mike Martin shares his journey from being an engineering student at Purdue University to becoming the CEO of CAI. He emphasizes that his career was shaped by a series of choices based on guiding principles rather than a predetermined path to leadership.
- CAI focuses on areas like operational readiness, regulatory plans, and human performance but deliberately avoids facility and system design. They leverage their expertise in testing to guide clients through the complexities of launching new products.
- CAI has a global presence, allowing them to tap into a diverse pool of expertise and offer more comprehensive solutions to their clients. Being globally connected also helps them understand regional nuances in the life sciences industry.
- The company operates on an "owner's mindset," emphasizing that the growth of an owner's value is directly tied to the growth of the client's value. This philosophy is central to CAI's company culture.
In this episode of Life Science Success, my guest is Ravi Samavedam, the Chief Innovation Officer of Azzur Group. With over two decades of experience in the biotech and pharma industries, Ravi is a seasoned Biochemical Engineer who has worn many hats throughout his career. Prior to his current role, he served as the President of Azzur Cleanrooms on Demand™ and was also the General Manager of Azzur Boston. He's an expert in areas such as phase-appropriate cGMP implementation, process validation, and supplier management.
- Ravi Samavedam is the Chief Innovation Officer at Azzur Group, with over two decades of experience in the biotech and pharma industries. He transitioned from a biochemical engineer to his current role, having worked at companies like Baxter, Shire, and Amgen.
- His role at Azzur Group involves exploring potential growth areas for the company, such as their "Clean Rooms on Demand" business. This service aims to provide a flexible, cost-effective solution for companies in the biopharma sector, bridging the gap between traditional manufacturing options.
- Samavedam emphasizes the importance of innovation and impact in the healthcare industry. He believes that smaller, agile companies like Azzur can make a more significant impact compared to larger organizations where individual contributions may get diluted.
- One of the challenges he faces is educating the industry about new, more efficient models of operation. Traditional methods are often deeply ingrained, making it difficult for companies to see the value in innovative solutions like Azzur's.
- His leadership philosophy is "Don't let perfect get in the way of good," emphasizing the importance of practicality and risk mitigation in the pursuit of excellence. He is excited about the future of personalized medicine and believes that technology will continue to reduce inherent risks in biopharma processes.
In this episode of Life Science Success, my guest is RJ Kedziora, the co-founder of Estenda Solutions. With a career spanning over 30 years, RJ is a leading expert in healthcare technology and data analytics. We'll dive into his journey, the transformative work Estenda Solutions is doing, and the future of digital health.
- The podcast "Life Science Success" hosted by Don, a consultant in life sciences, features RJ Kedziora, the co-founder of Estenda Solutions, a company specializing in healthcare technology and data analytics.
- RJ Kedziora has a career spanning over 30 years and started Estenda Solutions in 2003 with Drew Lewis. The company initially focused on diabetes but has since expanded into other chronic conditions, offering solutions for Fortune 50 companies, startups, and government agencies.
- Estenda Solutions is unique in that it focuses on innovative product development, particularly in data analytics. They work with clients who have an idea but are not entirely sure how to execute it, rather than those who know exactly what they want.
- The company is ISO 13485 certified, indicating a strong quality assurance program. They take on larger projects and are audited annually to ensure they maintain high-quality processes.
- RJ Kedziora emphasizes the importance of data in healthcare, noting that the industry has evolved from having minimal data to dealing with billions of records. He is excited about the potential of AI and machine learning but also cautious about the rapid pace of technological advancements.
In this episode of Life Science Success, my guest is Hanns-Christian Mahler. Dr. Mahler is Founder, CEO and Board Member at Ten23 health AG, the human-centric and sustainable pharmaceutical development partner.
- Hanns-Christian Mahler is the Founder, CEO, and Board Member of ten23 health AG, a company specializing in sustainable pharmaceutical development. He has a background in pharmacy and has worked in various pharmaceutical companies and CDMOs (Contract Development and Manufacturing Organizations).
- Mahler's leadership style focuses on building organizations from the ground up, emphasizing the importance of values, purpose, and motivation. He believes in creating a work environment that fosters joy and engagement among employees.
- ten23 health AG differentiates itself from other CDMOs by its customer-centric approach and specialized expertise in developing difficult-to-produce products, such as high-volume blockbuster injectable products and products for subcutaneous self-administration.
- Mahler is deeply concerned about climate change and is inspired by young activists like Greta Thunberg. His company is committed to sustainability, even registering for B Corp pending status and implementing various eco-friendly initiatives.
- The best leadership advice Mahler has received emphasizes trust in employees. He believes that if you have the right people, there's no need to micromanage, and that trust fosters a more productive and engaged workforce.
In this episode of the Life Science Success Podcast, my guest is Lisa Sellers, PhD. Dr. Sellers is the CEO of Vector Laboratories. She is an innovative and impactful leader with a truly unique approach to leading teams. She has deep expertise in running global life science tools businesses, developing new business strategies, and demonstrating excellent execution by leveraging her leadership style to harness the value of talent.
- The episode features Lisa V. Sellers, PhD, who is the CEO of Vector Laboratories. The discussion aims to explore Lisa's career journey, her role as CEO, and the future of life sciences.
- Lisa V. Sellers has been in the life sciences industry for over two decades. She has held various roles, from being a product manager in smaller businesses to being the CEO of Vector Laboratories. She is passionate about understanding the intricacies of the business she leads, as well as the needs of the customers they serve. She believes in leveraging innovation to meet these needs and enjoys developing multi-year growth strategies with her teams.
- Vector Laboratories is a company that specializes in bioconjugation, a technical capability that allows them to serve customers in various sectors like drug development, diagnostics, and life science tools. The company has been around for 45 years and is currently in a unique position where it combines the stability of a mature portfolio with the agility and growth potential of a startup.
- One of the key challenges Lisa faces as a CEO is managing people's ability to adapt to change, especially in a rapidly evolving industry. To tackle this, she has implemented comprehensive onboarding programs for new hires and emphasizes the importance of mentoring and community engagement. She also collaborates with local schools for community service, blending it with coaching and mentoring to broaden perspectives.
- Lisa is particularly excited about the future convergence of genomics and proteomics in life sciences. She sees this as a significant step toward a more integrated understanding of biology. She also believes that the key to navigating the future successfully is to be flexible and open to possibilities. She expresses concern about whether people and organizations will be able to adapt quickly enough to the changes that are bound to come in the field of life sciences.
In this episode of Life Science Success, my guest is Rajeev Sehgal. Rajeev is the Sr. Director of Informatics at Azenta Life Sciences. Rajeev is responsible for development and execution of Informatics strategy including product management, development, SQA, delivery, and support.
- Rajeev Sehgal discusses his experience with developing strategies that can be executed effectively. He highlights the importance of not only thinking about strategy but also having a clear understanding of how to execute it.
- Sehgal emphasizes the significance of focusing on the process rather than solely on the results. He notes that if the steps are right and repeatable, the results will show up eventually.
- Sehgal advises new leaders to be kind to themselves and not put too much pressure on themselves to deliver right away, especially in a new role or organization.
- He expresses concern about people hiding behind processes to stop progress and analysis paralysis, where people want more data than necessary before making a decision.
- Sehgal finds inspiration in doing something that will have a patient impact, working with colleagues who are doing amazing work, and seeing his children grow.
Key takeaways:
- Strategies must lead to good execution paths for their value to be realized.
- Focusing on the process and making it repeatable is key to achieving results.
- New leaders should be kind to themselves and not put too much pressure on themselves to deliver right away.
- People should not hide behind processes to stop progress, and analysis paralysis should be avoided.
- Doing something that will have a patient impact and working with colleagues who are doing amazing work can be inspiring.
In this episode of Life Science Success, my guest is Meredith Manuel. Ms. Manuel is a proven leader with drive and determination in the scientific industry, specializing in global drug development and project management.
Key Takeaways:
- Introduction to Meredith Manuel: Meredith Manuel is an accomplished leader with extensive experience in the scientific industry, particularly in global drug development and project management.
- Focus on Life Sciences: The podcast features a conversation between Meredith Manuel and the host, Don, who is a consultant specializing in helping companies within the life sciences sector enhance their strategies, processes, and technologies.
- Exploring Spatial Biology: Meredith discusses her role at "enable" where she manages the commercial division of a company focused on spatial biology. Spatial biology involves analyzing markers and molecules in the context of tissue, allowing for a deeper understanding of cell interactions and disease mechanisms.
- Impact on Drug Development: The application of spatial biology in drug development is highlighted, emphasizing the importance of moving beyond traditional single biomarker approaches. Integrating various data sets and understanding complex interactions within tissues is seen as crucial for advancing drug development.
- Leadership and Collaboration: Meredith also shares insights about leadership and collaboration, encouraging individuals to advocate for themselves and promote diversity of perspectives. She emphasizes the need for open communication within teams and across disciplines, especially in the dynamic field of life sciences.
Details:
Meredith Manuel is introduced as a guest on the "Life Science Success Podcast." The podcast is hosted by Don, a life sciences consultant focusing on improving companies' strategies, processes, and technology within the life sciences sector. Meredith has a strong background in the scientific industry, with a focus on global drug development and project management. She has a lifelong fascination with science, dating back to kindergarten when she first became interested in the field. Her career has spanned different areas of drug development, and she is particularly passionate about spatial biology, a cutting-edge technology that involves analyzing markers and molecules in tissue context.
Meredith's role at "enable" involves managing the commercial division of a company that specializes in spatial biology. She explains that spatial biology allows researchers to analyze cell interactions and disease mechanisms by studying markers in the context of tissue. This technology enables a more comprehensive understanding of disease processes and has applications in challenging areas like oncology and immunology. Meredith emphasizes that this approach goes beyond the traditional single biomarker paradigm, enabling a deeper understanding of complex biological processes.
Meredith discusses leadership and collaboration, drawing from her extensive experience. She encourages individuals, especially women, to advocate for themselves and share their ideas openly. She shares a story about a female boss who advised her to be her own advocate and speak up. She believes that diverse perspectives are crucial for innovation and problem-solving. Meredith underscores the importance of listening, collaboration, and communication in achieving successful outcomes within teams.
The conversation concludes with discussions about the challenges and potential future directions of spatial biology and drug development. Meredith expresses her desire to contribute to improving the healthcare industry and patient outcomes through her work. She also highlights the need for a patient-centered approach and collaboration between academia, industry, and regulatory bodies to drive progress in the field.
In this episode of Life Science Success, I am interviewing one of the world’s leading business thinkers, Dr. David Burkus’ forward-thinking ideas and bestselling books are helping leaders build their best team ever.
- Dr. David Burkus discusses the challenges of remote and hybrid work environments and the importance of deliberate leadership
- He emphasizes the need for fair feedback, giving feedback in proportion to how someone is doing
- Dr. Burkus also stresses the importance of micro praises and the need to be deliberate about recognizing employees' successes
- He believes that many organizations are approaching remote and hybrid work in the wrong way and need to have a broader conversation about the type of work that should happen in the office versus remotely
- Dr. Burkus is inspired to make work not suck and wants to help organizations tap into their employees' potential
- He also discusses his course, "Build Your Best Team Ever," which provides research-based actions for team leaders to improve their teams' dynamics and productivity
In this episode of Life Science Success, my guest is Ketan Mehta, the founder and CEO of Tris Pharma. Under his leadership, Tris Pharma has developed many innovative technologies, launched new products, and established itself as a leader among technology-driven pharmaceutical companies.
- Ketan Mehta discusses the importance of being open to change and feedback in building successful companies
- Patient feedback has directly influenced Tris Pharma's product development
- Ketan Mehta believes that the pharmaceutical industry will evolve significantly in the next decade, particularly with the rise of personalized medicine and digital health
- He offers advice for aspiring entrepreneurs in the life sciences, emphasizing the need for clear motivation, commitment, and a focus on making a positive impact
- Ketan Mehta is excited about the future possibilities and the potential for significant change in the next few decades
This week on the Life Science Success podcast, my guest is Thomas Farb-Horch. Thomas is the CEO of Thrive Bio. He has been involved in the founding of 18 pharmaceutical, biotech, medtech, software, and AI companies, 7 of which have been unicorns. Currently, he is CEO and Co-Founder of Boston-based Thrive Bioscience, which commercializes instruments and software for a critically important but neglected area of life sciences, which is imaging, analytics, and automation of cell culture, cell-based research, and cell therapeutics.
- Thomas Forest Farb-Horch has experience automating cytology labs and now seeks to improve cell culture labs through Thrive.
- Thrive aims to improve the low chances of therapeutics getting from bench to patient by transforming cell biology.
- Thrive's technology collects large, comparable data sets that make better cells, which is important for bringing cell therapeutics to the market.
- Thrive's data sets and images are valuable to researchers because they can see things that they never saw before and make faster decisions.
- Thrive is transforming viral plaque assay, which is the standard way of studying viruses, and can now track plaques from day 2 instead of waiting for weeks.
- Thomas is concerned about divisiveness, duality, and false dualities, and the lack of equality of opportunity, education, and health.
- Thomas is excited about solving big, ignored problems and changing the world.
In this episode of the Life Science Success Podcast, my guest is Artem Britchenko. Artem is the CEO of Platforce, which helps companies that interact with healthcare professionals and care about the efficiency and compliance of these interactions. He has been working in the B2C Pharma industry, helping companies improve their sales force effectiveness, customer engagement, and customer centricity.
- Don Davis, PhD, MBA interviews Artem Brytchenko, CEO of Platforce
- Platforce is a CRM solution tailored to the unique needs of the life sciences industry
- The solution includes closed loop marketing, remote capabilities, consent collection, distributor order optimization, and more
- The biggest challenges faced by Platforce include constant innovation and adaptation, scaling operations, and managing a global, distributed team
- The biggest opportunities include the rapid digital transformation of the life sciences industry, expanding to new geographies and markets, and serving adjacent sectors within healthcare
- Artem is inspired by his team, challenges, and family, concerned about the rapidly changing technological landscape and global complexities, and excited about fostering innovation and collaboration, technological advancements, and personal growth and happiness
In this episode of Life Science Success, my guest is Rohit Sood EVP, COMPLETE Commercialization at EVERSANA. He is a life sciences strategy and operations executive with a passion for developing teams and solving business challenges. Track record of driving topline business growth while identifying significant operational efficiencies in PE-backed, startup, and publicly-listed organizations.
- Rohit Sood and Don Davis discuss challenges faced by organizations during the commercialization phase
- Eversana helps smaller biotechs evaluate the process of commercialization and provides support through it
- Good leadership inspires Rohit, and he values transparency and clarity in decision-making
- Short-term thinking and not listening to advisors concerns Rohit
- Traveling and food excite Rohit
In this episode of Life Science Success, I am joined by Daniel Thadani the Head of Retail and Tenders for IPCA Laboratories Limited. Daniel is based in Kyiv, Ukraine 🇺🇦. He is responsible for business promotion and development, sales forecasting, distribution management, marketing coordination with head office, pricing, product registration through a third party, team hiring, and management.
- Daniel Thadani worked as a country head in Kazakhstan for five and a half years
- He describes the differences in medical affairs, regulatory, people management, distribution, and the overall landscape of pharma in Central Asia
- Thadani emphasizes the importance of trust and integrity in leadership
- He works for IPCA Laboratories, a top-notch pharma company that produces branded generic products with 350 formulations and 80 APIs in various therapeutic areas
- IPCA has a solid footprint in Africa, South America, and Southeast Asia and is a world leader in APIs
- Thadani discusses the resilience of the pharma business in Ukraine during the COVID-19 pandemic and war
- He is concerned about indecency and political approaches in people, as well as discrepancies in numbers
- Thadani is excited by complex situations with a positive impact on his immediate ecosystem
In this episode of Life Science Success, my guest is Nusqe Spanton. Nusqe is the founder and CEO of Provectus Algae. He is an aquaculture and algae expert with nearly two decades of experience working in international aquacultural production, marine biotechnology, and corporate management.
- Nusqe Spanton discusses the potential of marine microorganisms to produce commercially valuable compounds.
- The company, Provectus, is focused on developing products for food, agriculture, and cosmetics, as well as oral fertility treatments.
- The company is still in an early phase of development and has around 30 employees.
- Spanton emphasizes the importance of making quick and decisive decisions as a leader, especially in a startup environment.
- He also stresses the need to move quickly in addressing environmental concerns.
- Spanton is inspired by his children and the potential of the younger generation to effect change.
- He is excited about building a great business with like-minded individuals and being a problem solver.
In this episode of Life Science Success, my guest is John Alderete. Dr. Alderete has successfully applied his wide range of experience and formal training to the evaluation, financing, formation, and operation of diagnostics and medical device technology companies.
- Don Davis and John Alderete discuss pitching scientific research to investors
- Davis emphasizes tailoring pitches to the audience and understanding investors' perspective
- Alderete stresses the importance of having the right team and being honest about limitations
- Alderete expresses concern about lack of progress in biological surveillance and potential for future pandemics
- Alderete is excited about modern tools and technologies available to younger generation of scientists
- The conversation offers insights on challenges of pitching research, importance of team, and need for better pandemic preparation
- It highlights exciting possibilities in modern tools and technologies for younger scientists.
In this episode of Life Science Success, my guest is Dr. Helen Torley. Dr. Torley is the President and CEO of Halozyme. Halozyme's innovative and disruptive solutions provide new therapeutic options that could significantly improve the patient experience by changing how treatments are delivered.
- Dr. Helen Torley, CEO of Halozyme, discusses the company's dedication to improving patient experiences and outcomes through their research and development of monoclonal antibodies and small molecules.
- Halozyme places a strong emphasis on corporate culture, including cross-functional collaboration and community outreach.
- Dr. Torley shares how the book "The Five Dysfunctions of a Team" has influenced her leadership style.
- Dr. Torley is inspired by the innovative ideas and enthusiasm of her team members.
- She expresses concern about the impact of remote work on creativity, problem-solving, and personal development.
- The company is focused on putting patients at the center of their mission.
- They have a strong focus on community outreach, with 70% employee participation in volunteering events.
- She shares a personal story about a family member's experience with cancer treatment to underscore the importance of improving patient experiences.
- This episode of the Life Science Success podcast provides insight into the innovative solutions Halozyme is developing and their commitment to patient-centered care.
In this episode of Life Science Success my guest is Kristofer Mussar. Kristofer graduated from University of Georgia with a PhD in Molecular Genetics where he focused on Epigenetics and Evolution. He simultaneously obtained his MBA from the Terry College of Business. He is currently the Managing Director and COO of VectorBuilder Inc.
- Kristofer Mussar, PhD, discusses his company Vector Builder and their innovative gene delivery methods.
- Vector Builder's platform is free to use and includes a design team for gene delivery methods.
- They are working on several R&D projects, including a capsid evolution for novel capsids, a bacterial backbone-free plasmid, and antibody-conjugated lipo nanoparticles with mRNA.
- Vector Builder emphasizes collaboration and treating researchers as collaborators.
- Mussar believes in the importance of genetics and personalized medicine.
- Vector Builder has a new software-based platform called Vector B in development.
In this episode of Life Science Success my guests are Rahul Sharma, the co-founder and CSO of Scienetix, a company dedicated to enabling Molecular Diagnosis. Dr. Sharma is a board-certified laboratory director and technical lead for Next Generation Sequencing (NGS) and PCR-based assay development and clinical testing. He has developed multiple Molecular Diagnosis tests and translated them into clinical testing.
Additionally, We are joined by Rob Carpenter PhD, MBA the CEO of Scienetix. Rob is a healthcare executive and educator with over 25 years’ experience in developing, managing, and assimilating healthcare companies. He is distinctly skilled in business development and various business growth strategies. He is founder and current CEO of Advanta Genetics, a highly complex clinical and research laboratory accredited by the College of American Pathologists with concentration in infectious disease molecular genomics and Scienetix, a bioscientific company centered around products to optimize molecular genomic
workflows.
- In the podcast, Dr. Sharma and Dr. Carpenter talk about the healthcare industry's need to optimize workflow and reduce costs in laboratory testing.
- Their company, Scienetix, is working on developing extraction-free tests that will eliminate the need for sample pre-processing and make testing more accessible and cheaper for labs.
- They are also focused on increasing the multiplex capability of PCR reactions, which will allow labs to test for more targets in a single reaction.
- Dr. Sharma and Dr. Carpenter also discuss their leadership styles and offer advice on being reliable, thinking about the application of science, and staying creative.
- They express concern about the growing distrust of science and the spread of misinformation, particularly in the age of social media.
- What excites them most is the opportunity to solve scientific challenges and create products that have a societal impact.
In this episode of Life Sciences Success, my guest is Sharon Rogers the CEO of AmyriAD. Sharon brings the strength of her 35 years of pharmaceutical experience to AmyriAD. She is best known as the worldwide leader and development strategist for the highly successful AD treatment, Aricept. Aricept has been the standard of care for more than 20 years, and no other AD program has produced more compelling results.
- Sharon L. Rogers, a research scientist, talks about a new drug for Alzheimer's disease
- The drug, AD101, is designed to improve cognition and global function in Alzheimer's patients
- It is a cholinergic drug, but its action is limited to the brain, making it more effective than other cholinergic drugs
- The drug has gone through phase two trials and is now moving into phase three
- Rogers also discusses her experience as an expat in Japan and the importance of resilience and leadership
- She expresses concern about complacency and outrage fatigue
- Rogers is excited about the potential of Gen Z to effect change
Today on the Life Science Success podcast my guest is Sal Buscemi. Sal is a notable figure in the world of finance and real estate, has made a name for himself through his impressive portfolio of investments and his leadership roles in various investment offices. Currently serving as the CEO and Co-Founding Partner of HRN, a private multi-family investment office, as well as the CEO for Dandrew Partners Capital Management.
- Sal Buscemi discusses the importance of understanding the science and evaluating user feedback effectively
- He advises making investment opportunities attractive to investors, as they are unlikely to focus on the math
- Sal emphasizes the significance of building relationships and networking, as it is important for building a brand and reputation
- He expresses concerns about the potential destabilization of the petro dollar and the impact it might have on the strength of the country
- Sal mentions that he enjoys building things, meeting new people, and making an impact in the life sciences industry
his week on the Life Science Success Podcast, my guest is Surekha Karudapuram, VP Commercial Operations - Isolation Bio Inc. Surekha is an innovative, technically-savvy and accomplished product & marketing executive with 15+ years of experience, including leading the development and execution of corporate product management and marketing programs to support long term strategic, commercial, and financial goals.
- Surekha Karudapuram is a product manager who leads marketing, product management, and commercial operations teams.
- Isolation Bio provides a high throughput microbial cultivation platform and services to accelerate the time to discovery for microbiome R&D and product development.
- Isolation Bio's platform is automated, scalable, and helps to generate microbes that could be used in therapeutics or bio fertilizers.
- Surekha is concerned about the ethical and regulatory guardrails in the fast-moving life sciences space and the communication of scientific discoveries to the general public.
- Surekha is excited about the possibilities in the microbiome space and believes that microbiome scientists in both academia and industry are going to make exciting discoveries that will translate into great benefits for humanity.
In this episode of the Life Science Success podcast my guest is Jeremy Stackawitz. Jeremy has over 25 years of healthcare industry experience and 15 years of diagnostics experience. Before joining Senzo as CEO, from 2009-2021 Mr. Stackawitz held roles of CCO, President, and CEO at Quotient (QTNT), helping lead the company from start-up to IPO.
Jeremy Stackawitz, CEO of Senzo Biosciences, recently discussed the current state of the diagnostic industry. The industry faces several challenges and opportunities, including the need for accessibility and cost reduction. Stackawitz notes that the COVID-19 pandemic has had a significant impact on the industry, with many companies struggling to stay afloat.
One of the key topics Stackawitz discussed was the advantages and disadvantages of small versus large companies in the industry. While smaller companies may have more agility and flexibility, larger companies may have more resources and established relationships with key players in the industry.
When asked to share his favorite leadership advice, Stackawitz emphasized the importance of building a strong team and fostering a culture of collaboration and innovation. He also shared what inspires and concerns him in his work, including the potential to make a positive impact on people's lives through improved diagnostics, as well as the challenges of navigating a complex and constantly evolving industry.
Overall, Stackawitz's insights provide a valuable perspective on the diagnostic industry and the opportunities and challenges it faces. By addressing issues such as accessibility, cost reduction, and the advantages and disadvantages of different types of companies, the industry can continue to innovate and improve the lives of people around the world.
In this episode of Life Science Success I interviewed Samantha Dale Strasser - CSO & Cofounder at Pepper Bio at #bio2023.
- Samantha Dale Strasser is the Chief Science Officer and co-founder of PEPPER Bio.
- PEPPER Bio is the world's first trans omics analysis company.
- Trans omics involves analyzing a wealth of biological information from genomics all the way up to more functional data of phospho proteomics.
- PEPPER Bio is able to see more relevant disease insights about how to best treat disease and how to characterize potential drugs that can be used as therapeutics.
- PEPPER Bio has four contracts and is actively seeking partnerships with pharma.
- The Compass platform is PEPPER Bio's computational technology that provides the computational ability to analyze genomic, transcriptomic, proteomic, and phos proteomic data in a novel way through trans omics to best support partners' drug discovery questions as well as our own pipeline.
- PEPPER Bio can work with partners early on from characterizing the disease to answer what targets are best to go after for it to staying with them through the drug discovery process to bring the power of Ranomics all the way through to the clinic.
- PEPPER Bio sees potential for shortening the timelines for drug discovery, notably around the ability to very early on select drug candidates that are most likely to be successful in the clinic.
- Trans omics can have an impact on the massive failure rate at the very end of the drug discovery process by allowing for early identification of potential concerns of toxicity.
Today on the Life Science Success podcast my guest is Oksana Bovt. Oksana is the founder of Theoria Creative, an agency that develops unique fundraising materials enabling biotech and life sciences clients to clearly and succinctly articulate their unique message and value when raising funds, soliciting partnerships, pitching at roadshows, or presenting to prospective buyers.
- Oksana Bovt helps biotech companies communicate their scientific innovations to investors and potential partners.
- She emphasizes the importance of crafting an interesting story to grab investors' attention.
- Her company, Theoria Creative, is known for translating complex science and creating visual and illustrative materials, such as investor decks, scientific illustrations, and scientific animations.
- Theoria Creative works mostly on referral and helps companies that are ready to communicate effectively and have a clear direction.
- Oksana Bovt's background in science and advertising helps her to understand and communicate complex scientific concepts effectively.
- Theoria Creative helped a company with a broad oncology pipeline clarify their story and focus on approaching oncology and cancer holistically, resulting in a successful oversubscribed round and public offering.
- Oksana Bovt's best career advice is to understand oneself first and pursue what one is good at and passionate about.
- She is inspired by her clients and concerned about the global economy and the safety of her team in Ukraine.
- Her dog excites her and reminds her to take breaks and enjoy the outdoors.
In this episode of Life Science Success my guest is Mason Ailstock the CEO of Rowen Foundation. The mission of Rowen is to be a catalyst for education, research, innovation and transformation through the creation of a global destination which recognizes stewardship of the land as the cornerstone of an inspired community.
- Mason Ailstock is part of a foundation that oversees the covenants, the programming, the partnerships, attracting investors, and more.
- They want to create a place for companies and people to grow, and for startups to have access to opportunities.
- Rowan is a 50+ year project that aims to create a platform for other people to step up and have greater access to opportunities and the vision that they have.
- They are working on infrastructure and doing things that are very different from what the Department of Transportation typically does.
- They are hoping to create a place where implementation is a primary objective of doing as part of the culture, and where implementation is a primary objective of doing.
- The initial infrastructure will be finished in the second quarter of 2024, which will include the first two miles of complete streets designed in construction, ribbon cutting, opening of the roadway.
- They are working towards a sustainable and environmentally friendly development.
- They have been meeting with companies that have existing relationships or an interest in Georgia, and most of the companies they're talking to are internationally based.
- They have sites that could be 2 acres to 50+ acres, and most of the companies they're talking to are looking for a North America, either headquarters or R&D innovation, foothold.
- They are looking to connect startups to Georgia, locate, grow, attract investments, scale up.
- They are hoping to have multi-tenant buildings, multi-tenant lab space, and mixed-use components in the future.
In this episode of Life Science Success my guest is Kent Wakeford. Kent is the co-founder and Co-CEO of Form Bio an organization that focuses on providing computational life sciences and AI solutions to biotech and biopharma companies.
- Form Bio was spun out of Colossal Bioscience, and focuses on providing computational life sciences and AI solutions to biotech and biopharma companies
- Form Bio announced a partnership with Google as part of the Google multi omic suite of products
- Form Bio's computational platform focuses specifically on cell and gene therapy, and is designed to optimize the manufacturability of these therapies
- Kent Wakeford is inspired by the potential of AI to transform the industry, and is concerned about the need to change the infrastructure to make drug development more efficient
- Kent Wakeford believes that collaboration is key to solving industry-wide problems, and that the speed of innovation is transformative
In this episode of Life Science Success my Guest is Alex Zhavoronkov. Alex is the CEO Insilico Medicine an AI-powered drug discovery company.
-
Insilico Medicine has progressed three internally-derived assets into human clinical trials.
-
Insilico Medicine has discovered over 30 other programs in different stages.
- Insilico Medicine incorporates three engines in their platform: biology, chemistry, and clinical.
- They generate normal molecules with desired properties using 42 generative engines.
- They have a system that predicts clinical trials outcomes.
- Insilico Medicine’s main strategy is partnering with pharma companies at the preclinical candidate stage.
- They value patient first, relentless innovation, and transparency and integrity.
- Alex's biggest concern is human tendency to prioritize unimportant things over important ones.
- Alex is excited about large language models, multimodal generative AI, robotics, and quantum computing.
In this episode of Life Science Success my guest is Alex Chen. Alex is the President of Overseas Operations at uBriGene Biosciences Inc.
- He has diversified experience, having worked in various industries such as mining, real estate, and investment banking before joining uBriGene Biosciences Inc.
- uBriGene Biosciences Inc. is a biotech company that provides services ranging from upstream to downstream, including QC testing
- The company is focused on innovation and utilizes the most up-to-date technologies to provide cost-effective and quality products
- uBriGene Biosciences Inc. has sites in the US and China, and its core competency is research and development
- The company aims to be a partner with its clients and grow with them
- uBriGene Biosciences Inc. has over 500 employees globally and has raised $100 million to date
In this episode my guest is Jason Bock PhD. Jason is the CEO of CTMC / A joint venture between Resilience and MD Anderson Cancer Center.
- Jason Bock has been in biotech and biopharma for over 20 years, mostly in Biologics development.
- He founded Ctmc, a technology platform to industrialize cell therapies and bring them into the MD Anderson Clinic.
- Ctmc is a joint venture between MD Anderson and National Resilience.
- Ctmc partners with preclinical biotech, MD Anderson faculty, and Factus to provide a capital-efficient model to bring impactful single dose curative treatments to patients.
- Ctmc has filed three INDs in the first six months since it spun off on novel cell therapies brought into the clinic.
- Ctmc has progressed on the seven clinical studies that it supports.
- Ctmc recently announced that it was the recipient of a $9.1 million grant to help develop cell therapy platforms and improved ways of making these cell therapies.
- Jason is inspired by the patients and patient-centricity. He is concerned about the challenges, logistical and manufacturing challenges with autologous cell therapy. What excites him is the potential to transform healthcare and be single-dose curative treatments.
In this episode of Life Science Success my guest is Benedicta Durcan, CEO of Afrobodies. Her work experience has been in complex industries and environments spanning 12 years in Private Sector globally and 8 years in Public Sector in South Africa. I am an Upstream Oil & Gas and Maritime industry Specialist. I am an innovator and contributor in the field of STEM.
- Benedicta Durcan is the co-founder and CEO of Afro Body, a biotechnology company in South Africa that produces biological products for global consumption, including novel antibodies.
- Benedicta's background is in chemical engineering, and she has worked in the oil and gas and energy sectors before starting Afro Body with co-founder Dr. Peter Durkin.
- Afro Body's antibodies are recombinant alpaca antibodies used in life science research, diagnostics, and therapeutics for various diseases.
- Benedicta's role involves stakeholder management and engagement, raising initial grant funding, building a team, finding collaborators and partnerships, and expanding the company's global reach.
- Companies and researchers come to Afro Body for custom antibodies to study specific proteins, detect or test for the presence of molecules or bacteria, or develop treatments for diseases.
- Benedicta is inspired by the passing it on philosophy and believes in leaving a legacy for her children.
- Benedicta is concerned about the geo policies, global economics, and competing priorities that exacerbate inequalities, particularly in access to lifesaving medicine.
- Benedicta is excited about traveling and continually expanding her world and perspective.
In this episode of Life Science Success my guest is Jason Mundin, MBA who is the CEO of Ubiquigent. Jason has over 30 years’ experience in the pharmaceutical and biotechnology industries. He joined Ubiquigent in 2015 as Commercial Director, becoming Managing Director in 2018 and CEO in 2021.
- Jason Mundin is the CEO of Ubiquigent, a biotech company that focuses on drug discovery
- They have taken the company from a loss-making biotech to a profitable one.
- They are now focused on becoming a drug discovery-focused therapeutics company.
- They are actively engaged in securing inward investment.
- They are concerned about the state of funding for the life sciences industry.
- They are excited about the potential of their programs and the value they can bring to the industry.
- They believe that innovation is necessary due to limited resources and are constantly looking for ways to be innovative.
- They are excited to attend conferences and connect with people who are interested in their work.
In this episode of the Life Science Success Podcast my guest is Pavel Printsev. Pavel is the Director of Business Development at Bridge Biotherapeutics. Prior to joining Bridge in early 2021 he was working at a South Korean VC firm. Pavel’s academic background is in Organic Chemistry and worked as a Research Scientist for several years. Since then, he has been active in advancing scientific development through global partnership, collaboration and investment between South Korea and the rest of the world.
- Bridge Biotherapeutics is a small to mid-size Biotherapeutics company founded in 2015.
- They have clinical-stage assets in nonsmall cell lung cancer, ulcerative colitis, and idiopathic pulmonary fibrosis.
- They also acquired a next-generation biosensor detection company, which is a thousand times more sensitive than the current commercial ECL biosensor device.
- Bridge Biotherapeutics is focused on maximizing resources and following the path where they see the most opportunity.
- Pavel Printsev is inspired by people who have become masters in their respective fields and are dedicated, motivated, ambitious, and do not give up.
- Concerns include the gap in research and unmet medical needs for indications that may not be profitable.
- Pavel is excited about the advancements in AI and deep learning, gene editing, and precision medicine.
In this episode of Life Science Success, my guest is David Baram. David Baram is the co-founder and CEO of Emendo Biotherapeutics. David has taken Emendo from the pre-seed stage through multiple financing rounds and a successful acquisition in 2020.
- Don Davis, PhD, MBA interviews David Baram, PhD, CEO of Emendo Biotherapeautics
- Mendo is focused on developing gene editing therapies for rare and prevalent diseases, including cardiovascular diseases.
- They discuss the challenges of managing a company with different interests at play, including investors and patients.
- They touch on the potential of AI and the need for regulation and control.
- David shares his motivation and excitement in achieving his goals and seeing his inventions materialize.
In this episode of the Life Science Success podcast my guest is Robert Bruchet. Robert is a General Manager - Middle East & Africa at Ethypharm. He applies a deep understanding of commercial levers to maximize the P&L and drive growth. Demonstrated leadership across multiple functions (marketing, sales, market access, and public affairs) and general management.
- Rob Bruchet discusses his work in the pharmaceutical industry in Africa and the Middle East
- He talks about the challenges of expanding a business in that region, particularly with established brands and price pressure
- Bruchet emphasizes the importance of diversity in those markets, noting the wide range of languages and cultures
- He also shares his experience working in Dubai and the sense of adventure that drove him to move there
- Bruchet enjoys the opportunity to create something new and make changes in his work, and he is motivated by the drive and ambition of younger people in the industry
The interview discusses challenges faced by at-home diagnostic companies, including differentiation from competitors, market education, and lack of direct billing code. Opportunities for growth in the at-home healthcare market are highlighted, while concerns include the blurring of personal and work life and potential for overcommitment. Exciting developments in technology, particularly in digital health and medtech, are noted as improving quality of life for individuals.
- Challenges faced include differentiating from competitors, educating the market, and lack of direct billing code for at-home diagnostics
- Opportunities include growth as at-home healthcare becomes more mainstream
- Concerns include the blurring of the line between personal and work life and the potential for overcommitment
- Exciting developments in technology, particularly in the digital health and medtech fields, improving quality of life for individuals
In this episode of the Life Science Success Podcast my guest is Chris Anderson. Chris is a seasoned Pharmaceutical Professional with more than 20 years of experience in multiple fields within the Industry.
- Don Davis and Chris Anderson discuss the regenerative medicine industry
- Chris highlights the need for partnerships between companies and government entities
- The challenges of ensuring compliance and patient safety in a new and evolving industry are discussed
- Chris talks about being inspired by the people and ideas in the industry
- They both express excitement about the potential for future advancements in regenerative medicine and other areas like AI.
In this episode of the Life Science Success podcast, my guest is Dr. Scott Wagers. Scott is the CEO of BioSci Consulting, the author of Assembled Chaos, and the host of Beyond Publications podcast. (Consortium Whisperer)
- Dr. Scott Wagers helps people develop consortium projects to speed up the realization of the future of medicine.
- The translational gap is the delay between research findings and clinical implementation, and it takes about 17 years to cross.
- The bottleneck in the translational gap is the resistance to change and the lack of adoption.
- AI has the potential to free humans to focus on what they're really optimized for, which is creativity, pattern recognition, and working together.
- The human mind is optimized for certain things that AI can free us to focus on.
- Collective thinking of a bunch of different people is a very powerful computer in its own right.
- Leadership isn't just at the very top level; it's at every level, down to the PhD student who writes an outline or an SOP.
- Beyond Publications is a podcast about going beyond publications and pushing through the translational gap.
- Patients inspire Dr. Scott Wagers, and the translational gap concerns him.
- The dynamic of collective thinking and working together excites Dr. Scott Wagers.
This week on the Life Science Success Podcast my guest is Nathan Clark. Nathan is the co-founder of Ganymede and is passionate about biotechnology. He is at the frontier of biology and engineering, and has merged his profound knowledge in this field with business development to reimagine data infrastructure in the life sciences.
- Nathan Clark discusses his company's goal to become the infrastructure for the life sciences industry
- The industry is moving slowly in terms of digital transformation and data integration
- The complexity of data in the life sciences industry is a unique problem that requires a science of managing that complexity
- Instrument manufacturers are inhibiting connectivity by putting all their data into different formats
- The goal is to create a centralized data lake that can be mapped together and linked
- The complexity of the industry and the slow pace of digital transformation concerns Nathan Clark
- Nathan Clark is excited about the potential for scientific advancements in the life sciences industry, including understanding epigenetics and how biological systems interact with each other
The Happy Engineer 🎧 Top Podcast Host || Helping Thousands of Engineering Leaders Reach the Next Level (without Suffering Burnout) || World's Best Lifestyle Engineer || CEO & Career Coach In this episode of Life Science Success, my guest is Zach White. Zach is the host of the Happy Engineer Podcast, and he is also a career coach who is helping thousands of engineering leaders reach the next level without suffering burnout.
- Zach White discusses the challenges that engineers face in their careers, including continually increasing demands and the need to balance leadership development with technical knowledge.
- He also discusses the importance of mindset and coaching to help engineers achieve their goals and find fulfillment in their work.
- Zach is inspired by seeing clients take courageous steps and achieve what they previously thought was impossible.
- He is concerned about the impact of financial systems and policies on the economy and the need for continual learning in the face of rapidly advancing technology.
- Zach is excited about travel and the opportunity to experience new places and cultures.
- The Happy Engineer Podcast, hosted by Zach, focuses on helping engineers build their careers, balance their lives, and find happiness along the way.
In this episode of Life Science Success, my guest is Gino Martini. Gino is the CEO of the Precision Health Technologies Accelerator (PHTA Ltd). Previously, he was the Chief Scientist of the Royal Pharmaceutical Society.
Key Topics Covered:
- Description of an accelerator program for health tech companies
- The importance of social interaction for innovation in a hybrid work environment
- Excitement for precision medicine and personalized treatment plans
- Interest in bedside manufacturing and its potential for patient care
- Challenges in the life sciences industry, such as the lack of lab space and access to skills
- Opportunities in precision medicine, bedside manufacturing, and the microbiome
- AJ Melet is the CEO of a startup biotechnology company Ronawk Inc.
- Ronawk Inc’s technology involves growing cells in a tissue mimetic substrate called bio blocks.
- The cells grow in 3D and form their own micro tissues, which can be used to manufacture new therapies.
- Roanoke's technology has potential applications in tissue engineering and scaling the production of biological factors.
- The biggest challenges Roanoke is currently facing are building a new lab and getting people to understand the new technology.
- AJ Melet is inspired by people who serve others, concerned about our ability to connect in a digital world, and excited by people tackling big challenges.
In this episode of Life Science Success, my guest is Katherine Vega Stultz. Katherine is the President and CEO of Ocelot Bio, a clinical stage company focused on developing innovative therapeutics to significantly improve outcomes for patients with end-stage liver disease.
In this episode of Life Science Success my guest is Katherine Vega Stultz and we touch upon a number of topics, including the non-linear path of career growth, the importance of being a generalist in a specialized industry, and the challenges and opportunities facing Ocelot Bio, a private venture-backed company that is focused on liver disease. Stultz talks about the importance of team collaboration, transparency, and communication, and how her experiences have helped her develop a continuous improvement mindset. She also discusses her passion for tackling complex problems that impact people's lives and how she is excited to be in a position of leadership that advocates for diversity and talent.
- Non-linear path of career growth
- Importance of being a generalist in a specialized industry
- Challenges and opportunities facing Ocelot Bio
- Importance of team collaboration, transparency, and communication
- Continuous improvement mindset
- Passion for tackling complex problems that impact people's lives
- Advocacy for diversity and talent in leadership
In this episode of the Life Science Success podcast, my guest is Martin-Immanuel Bittner 𝘔𝘋 𝘋𝘗𝘩𝘪𝘭 𝘍𝘙𝘚𝘈. Martin-Immanuel is the CEO & Co-Founder of Arctoris, a biotech platform company powered by robotics and machine learning based in Oxford and Boston.
Martin-Immanuel Bittner is the CEO and founder of Arctoris, a biotech platform company focused on drug discovery with partnerships worldwide.
- Martin-Immanuel Bittner is the CEO and founder of Arctoris, a biotech platform company powered by robotics and machine learning based in Oxford and Boston
- The company's focus is on drug discovery, and it has partnerships with dozens of biotech and pharma companies worldwide
- The company is actively hiring and anticipates continued revenue growth and team growth in the coming years
- Bittner is excited about the continued drive towards having physiologically more relevant model systems
- Bittner sees AI and machine learning as powerful tools that will be increasingly adopted in a drug discovery context and predicts that all drugs reaching the market will have had some form of AI involvement in the future
- Bittner is concerned about human health being jeopardized by conflicts between different geopolitical blocks and the risk management that companies need to consider
- Bittner is excited about the transformation of the industry and the opportunities that lie ahead with new technologies and techniques that can bring more and better drugs to patients faster
In this episode of the Life Science Success podcast, my guest is Bremer Louw. Bremer is the vice president of operations at Bioforum, a data focused CRO. He has been in the clinical research industry for over 15 years and has extensive experience in data management and biostatistics programming.
Bremer Louw, VP of Operations at Bioform, discusses the company's focus on meeting customer needs and building solutions for complex problems. He also expresses concerns about the pace of innovation and the ethical and regulatory implications of machine learning and artificial intelligence in the life sciences industry. Louw emphasizes the importance of small successes and momentum in achieving larger goals.
- Bioform is a smaller, more nimble organization with a different culture than larger companies like IQVIA.
- Bioform is attentive to customers' needs and works to meet them on an individual basis.
- Bremer Louw, the VP of Operations at Bioform, is responsible for overseeing operational metrics, professional services, quality, business development, and innovation.
- Bioform works with both drug and diagnostic companies.
- Louw is concerned about the pace of innovation in the industry and the ethical and regulatory implications of machine learning and artificial intelligence.
- Louw emphasizes the importance of small successes and momentum in achieving larger goals.
In this episode of Life Science Success my guest is Siddhartha Shrivastava, Ph.D. Sidd is the Vice President, Head of CMC and Global Technical Operations at Cue Biopharma. He is a proven leader and well-published scientific-technical operations professional with experience in leading research, early to late-stage process development, commercial launch, cGMP commercial manufacturing (DS/DP), due diligence of new targets and facility acquisition, end to end supply chain management, and CMO management for bio-therapeutic drugs.
In this episode of the Life Science Success Podcast my guest is Vadim Klyushnichenko, Ph.D, Vadim is the VP Pharmaceutical Development at Scripps Research. He has over 25 years of progressive experience in Global Bio/Pharmaceutical Development from Discovery to Clinical and Commercial Manufacturing.
In this episode of Life Science Success, my guest is Dr. Steven Fox. Dr Fox is an experienced entrepreneur, doctor, educator and author. He is also the founder and chairman of Akelos Inc. a biotechnology company developing non-addictive, non-opioid drugs for the treatment of neuropathic chronic pain.
This week on the Life Science Success Podcast my guest is Jae Yoo. Jae is the Executive Director at EPM Scientific. EPM Scientific exists to enable exceptional careers around the world. They connect exceptional talent, with exceptional opportunities.
This week on the Life Science Success Podcast my guest is Cristina Varner. Cristina is the National Life Science and Digital Health & Telemedicine Practice Leader for Newfront. She supports the risk management needs of biotech, medical device, pharmaceutical, diagnostic, digital health and telemedicine companies from early stage on up.
This week on the Life Science Success Podcast, my guest is Stefan Lukianov. Stefan is the Founder/CEO of Salve Therapeutics, a biotech company in LA building viral biologics with computational tools.
In this interview for Life Science Success, my guest is Elizabeth Smalley. Elizabeth is the Sr. Product Manager at ArisGlobal. With over 15 years of experience across data analytics, Elizabeth has a passion for exploring the intersection of data science and human reasoning, and has experience bringing AI-powered software to market, to drive safety and clinical outcomes for patients and clinicians.
In this interview of Life Science Success my guest is Andrew Norris. Andrew is the co-founder of BCN Biosciences, a recent startup that has projects ongoing in the oncology drug space.
In this episode of Life Science Success, my guest is Amy Brown. Amy is an executive with 20 years of public and private sector experience in health care public relations, startup management, policy development, quality improvement, and insurance operations. She is also the founder and CEO of AuthentiCx.
Today on the Life Science Success podcast, my guest is Isaac Houston. Isaac is the Director Of Business Development of Clinical Diagnostics at Thomas Scientific. He has experience that encompasses a range of disciplines, including business development, contract negotiations with Fortune 500 companies, complex sales, personnel management, project management, strategic marketing, and molecular diagnostics.
This week on the Life Science Success podcast, my guest is Dean McAlister. Dean is the Executive Vice President, Inizio Biotech. He has over 25 years of executive leadership experience in pharma in both growth stage and startup organizations.
In this episode of Life Science success my guest is Keren Leshem. Keren is currently the CEO and a Director/Board Member at OCON healthcare. An innovative women’s health company with a mission to introduce safer intrauterine drug-delivery technology to improve and impact women’s health and quality of life.
In this episode of Life Science Success, my guest is Ralph Hess. Ralph is the Executive Vice President Sales and Marketing at Navigator Business Solutions. Navigator Business Solutions is a global leader in Cloud Based ERP Solutions from SAP AG and they focus in on the life sciences industry.
In this episode of Life Science Success, my guest is James Hamet. James is the founder and CEO of Vistim Labs. Vistim Labs is a medtech diagnostic company helping to detect, treat, and track neurological disorders.
In this episode of Life Science Success, my guest is Tom DeStefano. Tom is currently the executive vice president of the specialty division at Camber Specialty. He is a pharmaceutical executive with vast experience in generics, brands, and specialty products. Related experience includes sales and marketing, business development, trade relations, and national accounts management.
In this episode of the Life Science Success podcast, my guest is Mike Landau. Mike is the COO of KBI Biopharma. An accomplished professional with 17 years of operational experience and has demonstrated expertise in the areas of lean leadership, quality compliance, and people management.
In this episode of Life Science Success, my guest is Dr. Lisa Faast. Dr. Faast is the CEO of DiversifyRx. Her passion is finding exciting new ways to generate revenue and profit for independent pharmacies. She helps pharmacy owners navigate the 6 Pillars of Pharmacy Profitability to build the pharmacy of their dreams.
In this episode of Life Science Success, my guest is JoJo Platt. JoJo is a neurotech strategist with extensive expertise in the medtech industry, including neurotech research and biomedical devices.
02:16 Tell listeners just a little bit about yourself
06:03 Why did you start your own consulting business?
10:11 In your 15 years in consulting are there any sort of, guiding tips or advice that you might offer to new?
13:10 What do you find that's the most challenging part of being, a neurotech strategy consultant?
16:56 I saw in your bio that you also are with Joy Ventures. What do you do with them?
18:07 How long have you been working with them?
21:19 And then you have a podcast of your own. Can you tell listeners just a little bit about what that podcast
22:56 Why do you make people cry on your podcast?
25:54 How often do you put out podcast? how many episodes have you done? And how often do you put out episodes?
28:24 There are three questions that I like to ask every guest.
-What Inspires you?
29:53 -What concerns you?
31:01 -What excites you?
Today on the Life Science Success Podcast my guest is Jeffrey Whitford. Today, Jeffrey serves as head of sustainability & social business innovation at the Life Science business of Merck KGaA, Darmstadt, Germany, an almost 10 billion euro global supplier of tools, chemicals and equipment, employing more than 28,000 employees.
In this episode of Life Science Success My Guest Is Dr. Gil Blander. Dr. Blander is internationally recognized for his research in the basic biology of aging and translating research discoveries into new ways of detecting and preventing age-related conditions.
In this episode of Life Science Success my guest is Liang Schweizer. Liang is the founder, chairperson and CEO of HiFiBio Therapeutics.
In this episode of the Life Science Success podcast my guest is Raj Indupuri. Raj is the CEO of eClinical Solutions. He is also a technologist with significant industry experience, passionate about fostering innovation to revolutionize the Life Sciences industry with ground-breaking technologies that will modernize clinical trials and bring treatments to patients faster.
In this episode of Life Science Success, Chris Conner from Life Science Marketing Radio and I recapped the top episodes for 2022 from each of our podcasts. We have both had a great year in interviewing different individuals and made selections based both on data and our personal favorites.
In this episode of Life Science Success my guest is Shane Needham PhD. Dr. Needham is a serial entrepreneur and founder of many scientific business including several bioanalytical CROs. Dr. Needham has more than 20 years experience leading and growing four different companies.
In this episode of Life Science Success my guest is Ross Youngs. Ross is the CEO and Founder of Biosortia Pharmaceutical. They are working to Provide previously unobtainable drug-like small molecules directly from microbiomes.
In this episode of the Life Science Success Podcast my guest is Robin Mansukhani. Robin is the CEO of Deciduous Therapeutics, a venture backed startup developing novel immunotherapies to treat age-related diseases. Additionally, he co-founded BlueStamp Engineering, an intensive, project-based engineering program for high school students in NYC, San Francisco, and Palo Alto.
In this episode of the Life Science Success Podcast my guest is Chris Leidli. He is the founder and managing partner of Boulder Biotech Launch Specialists. His organization helps Companies Enhance Product Positioning and Communications While Improving Operational Launch Readiness. Chris is also a Podcaster & TEDx Speaker.
In this episode of life science success my guest is Barb Pearlman. Barb is the President Cambridge Scientific Products / CEO of Cambridge Scientific Labs, Watertown's First Biotech Incubator.
In this episode of the Life Science Success podcast my guest is Lisa Tamati. Lisa is a keynote speaker and MC, facilitator and corporate wellness coach. She works with organizations to inspire and motivate their teams to take on incredible challenges, help them build mental resilience and a mindset for growth, leadership.
In this episode of Life Science Success my guest is Roger Frechette. Roger is the co-founder and principal of New England PharmAssociates, LLC. He leverages a global network and insights derived from his greater than 20 years experience in the Business of Biotech and R&D Operations, calibrated with a background as a scientist and scientific leader.
In this episode of the Life Science Success Podcast my guest is Amita Goel. Amita is the CEO of Celltheon a Global leader in Cell Line Development for Next Generation Bio-therapeutics.
In this episode of the Life Science Success Podcast, my guest is Farah Ahmad. Farah is the President of Life Sciences at Press Ganey. We discuss her career journey and how Press Ganey is putting the human experience at the heart of healthcare.
This week on the Life Science Success Podcast my guest is Jaswinder Chadha. Jassi founded Axtria - Ingenious Insights with the vision of building cutting-edge analytics and software solutions that will help global Life Science companies to manage and get insights from data and engage their customers effectively.
In this episode of the Life Science Success Podcast I am back with Gary McAuslan the CEO of aCGT Vector and we are discussing the growth of the company.
Today on the Life Science Success Podcast my guest is Liesbeth Ceelen. She is the CEO of BioLizard an agile bioinformatics and data management consulting company providing tailored solutions to the life sciences industry. They specialize in the handling of complex scientific data and the application of state-of-the art technologies for data-driven R&D, drug development, clinical trials, healthcare and other applications.
This week on the Life Science Success Podcast my guest is Laurie Schloff. Laurie is a lifelong corporate communication coach to professionals who use speaking as a tool for success and results. She specializes in developing valuable programs for the financial and biotech fields.
Today on the Life Science Success Podcast my guest is Katherine Lynch. Katherine serves as a Senior Vice President within (TCC) Trammell Crow Company’s Atlanta Business Unit. She is responsible for sourcing, shaping and executing TCC’s office and life sciences development and investment in Atlanta, and the Southeast.
This week on Life Science Success my guest is Donna Lavoie. Donna is the Founder of LaVoieHealthScience, a leading health and science integrated communications firm. Leader of specialized thinkers in health and science marketing. Proven strategic communications executive in biotechnology, healthcare, medical device and pharmaceutical fields. Additionally, she is a CXO counselor on strategic communications issues.
Her firm focuses on:
- Media Relations
- Value Creation
- Pre-IPO
- Strategic Communications
01:29 Tell to listeners about yourself
05:02 Talking about more sort of translation from selling to, going to start up
06:26 What led you to focus more on reagents and chemicals in scientist.com
08:05 Talking about more on Scientist.com
12:26 What are some key problems customers want to deal with, when they come to Scientist.com
14:14 Example of initiatives that they might look into use of your system
16:05 Are you working also with the suppliers or some of the clients
17:56 How does Scientist.com start to work with the customer
19:08 If have any idea how to start up your system
19:57 There are three questions that I like to ask every guest.
-What Inspires you?
21:07 -What concerns you?
22:37 -What excites you?
In this episode of the Life Science Success Podcast from Bio in the Bayou 2022, I sit down with Paul Romness the founder of OS Therapies. During our interview Paul shares his absolute passion for Osteosarcoma. He shares that roughly 1000 children will get osteosarcoma each year and roughly 50% will die. (Paul agreed to let me share the emotion expressed during the interview)
I greatly appreciate companies that are attacking problems like this and look forward to seeing OS Therapies in the news as they go public.
At Bio in the Bayou for the Life Science Success Podcast I sat down with Naheed Kurji and we talked about how Cyclica works with Universities and Startups using their AI platform.
#biotech, #medicines, #innovation, #drugdiscovery, and #artificialintelligence
This is my first time having a returning guest on the Life Science Success Podcast. Trivia Frazier, PhD, MBA sat down with me to give me an update on Obatala Sciences. They are currently expanding their commercial team and overall footprint. It was such a blast to sit down with someone who has been on the show previously.
In this episode of Life Science Success Podcast my guest is Heidjer Staecker a Partner at TreMonti Consulting. We discuss how TreMonti helps Universities evaluate their technologies and commercialization opportunities.
At Bio in the Bayou I had the opportunity to sit down with Shobha Parthasarathi an Advisor Xontogeny. We talked about her engagement across life sciences and the approach she has with companies.
I sat down with Chris Garabedian the CEO of Xontogeny a virtual incubator in Life Sciences and we discussed how Xontogeny helps companies grow and leverage their experience in Life Sciences.
🧬 Kris Khalil 🧬is the Executive Director at the New Orleans BioInnovation Center and we sat down during Bio in the Bayou and talked about how he works with companies.
This is a part of the group of podcast interviews recorded at Bio in the Bayou. Check out Lowry Curley and AxoSim 3D Tissue Models.
This week on the Life Science Success podcast my guest is Ariel Auwrier. Ariel has been involved in startups from the beginning including research and patents through operations and sales & marketing. His company Stressmarq provides tools to researchers in Life Sciences.
Today on the Life Science Success podcast my guest is Reginald Swift. He is the Founder and CEO of Rubix LS. They are using innovation at a greater scale to change how health outcomes can be realized through patient product and service innovation.
This week on the Life Science Podcast I am interviewing Fungai Ndemera. Fungai is the CEO of Checkup Health. Fungai and I are going to talk about her journey to becoming the CEO, Diversity and we are going to cover her focus as a Keynote speaker.
00:58 Introduction for Fungai and greeting
01:18 Telling to listeners a bit about yourself
02:07 Lead you to Create Check Up Health company
04:52 More about Check Up Health company function and how it helps
08:04 How it works with populations get involved and limiting biases
10:26 How targeted populations shift and leverage technology, considering diversity
12:37 About being panelist and discussion with the Melan and medic panel
15:55 One of the Social Media posts thought provoking question
- What are the best ways that a business could reduce health inequalities?
20:23 What oftentimes do you speak about as a Keynote speaker, whenever on stage?
22:02 Three Question
-What Inspires you?
-What concerns you?
-What excites you?
This week on the Life Science Success podcast my guest is Owen Swift. His organization was founded to represent manufacturers and CROs who are selling into the life science market across the US. Additionally, he uses the balance of his time to work directly with customers in solving their research challenges.
Today on the Life Science Success Podcast my guest is Patrick McCarthy. He is an accomplished executive and licensed attorney with over 30 years of healthcare specific experience. He has demonstrated a strong track record of leadership and consistent overachievement of aggressive goals whether in “start-up” mode or with Fortune 500 companies. McCarthy is an entrepreneur at heart and has an outstanding track record of building successful SaaS based companies and clinical product franchises.
My guest on the Life Science Success Podcast is Jeff Wessinger. Jeff is the VP of Life Sciences for PointClickCare (PCC). We are going to discuss how PCC is providing the de-identified data companies need to improve care outcomes and expand drug discovery and development.
My guest on the Life Science Success Podcast is Jeff Wessinger. Jeff is the VP of Life Sciences for PointClickCare (PCC). We are going to discuss how PCC is providing the de-identified data companies need to improve care outcomes and expand drug discovery and development.
This week on the Life Science Success Podcast my guest is Jitendra Pant. He is an experienced Researcher with 13+ years of expertise in Clinical and Translational Research, Biocompatible Invasive Biomedical Devices, In vitro Biology, FDA approved Immunotherapeutic (Cancer and Autoimmune disorders), Bioprocess Development, Antibacterial, and Antithrombotic Biomaterials, Tissue Engineering applications, Macro and Microencapsulation technology for making artificial pancreas for Type 1 Diabetes (T1D) treatment. He is also an entrepreneur and 2x TEDx Speaker.
This week on the Life Science Success Podcast my guest is Jitendra Pant. He is an experienced Researcher with 13+ years of expertise in Clinical and Translational Research, Biocompatible Invasive Biomedical Devices, In vitro Biology, FDA approved Immunotherapeutic (Cancer and Autoimmune disorders), Bioprocess Development, Antibacterial, and Antithrombotic Biomaterials, Tissue Engineering applications, Macro and Microencapsulation technology for making artificial pancreas for Type 1 Diabetes (T1D) treatment. He is also an entrepreneur and 2x TEDx Speaker.
On the Life Science Success podcast this week my guest is Dr. William B. Miller he is an internationally known evolutionary biologist, medical doctor, and author and co-author of seven science books, including the acclaimed The Microcosm Within. He has also contributed over three dozen peer-reviewed, highly influential academic articles on evolutionary biology. After a career practicing medicine, Dr. Miller became fascinated by evolution through a chance encounter with Sue, the startling T-Rex skeleton housed in the magnificent rotunda of the Chicago Field Museum.
On the Life Science Success podcast this week my guest is Dr. William B. Miller he is an internationally known evolutionary biologist, medical doctor, and author and co-author of seven science books, including the acclaimed The Microcosm Within. He has also contributed over three dozen peer-reviewed, highly influential academic articles on evolutionary biology. After a career practicing medicine, Dr. Miller became fascinated by evolution through a chance encounter with Sue, the startling T-Rex skeleton housed in the magnificent rotunda of the Chicago Field Museum.
This week on the Life Science Success podcast my guest is Kyle Giffin COO at LatchBio. These three founders launched the San Francisco-based startup in 2021 to build and disseminate the data infrastructure for the biocomputing revolution.
Brad Feld is an American entrepreneur, author, blogger, and venture capitalist at Foundry Group in Boulder, Colorado. He began financing technology startups in the early 1990s, first as an angel and later as an institutional investor. He has written several books on entrepreneurship and in his latest book he focuses on the construction of effective startup boards.
In this episode of the Life Science Success podcast I interviewed Stephanie Wisner. We discussed Co-Founding Centivax and her new book Building Backwards to Biotech: the Power of Entrepreneurship to Drive Cutting-Edge Science to Market.
Chris Conner is the host of the Life Science Marketing Podcast. He is a Scientist turned storyteller, he turns conversations into content to be used for thought leadership and demand generation. Chris has led global Marketing Communications programs at Varian, Inc., Agilent Technologies, and Thermo Fisher Scientific. He has been producing his own podcast for 7+ years and has been recognized by C&E News Media Group as an influencer alongside Gary Vaynerchuck and Seth Godin.
This week on the Life Science Success Podcast I interviewed Alex Koglin, PhD. Alex is the co-founder and president of NTx (Natures Toolbox) a bioinformatics and bio manufacturing company that is advancing medical products and material sciences with cell-free, innovative biomanufacturing solutions.
This week I am joined by Raymond Peterson the CEO of DNA Analytics and we will be discussing the use of AI in establishing DNA targets. Therapy for viruses with honey bees.
This week on the Life Science Success podcast I interviewed David Sanders. David is an experienced Business and Advocacy Professional with a demonstrated history of success creating business and policy changes and improving outcomes in the technology, IP, pharmacy, pharmaceutical, & healthcare services industries. We are going to be talking about David’s Government Affairs and Public Policy work & Securing America's drug supply in the US.
In this episode of the Life Science Success podcast I interviewed Ramani Varanasi. Ramani is a Biopharma Executive, Board Member, CEO, Founder/Entrepreneur, Advocate & Optimist. In this episode, we discussed her career, where she serves as a trusted partner to CEOs and Executive Management and advises on corporate strategy, fundraising, corporate development, and operations.
In this episode of Life Science Success, I interviewed Dirk Abeel. He is a consultant in Life Sciences who focuses on implementing a new commercial model called Omnichannel. If your commercialization efforts need a shift in focus this episode is for you.
Notes:
1:02 Dirk's career in marketing, sales and sales enablement.
5:57 Dirk's work in Africa
7:17 What is Omnichannel
9:55 How Omnichannel is deployed
12:00 The power of data
15:25 The importance of mindset
19:37 The transition to the future may not be fully face-to-face selling
23:50 Engraining the behavior in the sales team
33:00 The importance of having the right data
36:24 Three questions:
- What excites you
- What concerns you
- What inspires you
In this episode, I recap all of the podcasts that we have recorded thus far. We have had some great guests on with phenomenal things to share.
In this episode, I interviewed Anthony Marotta, PhD. We will talk about Anthony’s career in Rheumatology and his work in diagnostics. Additionally, Anthony has a company Peqish that makes it easier for you to Eat Healthy On-The-Go. Food is created by doctors and chefs.
In this episode I interviewed Akunna Iheanacho, PhD. Akunna is the CSO at Texcell North America. Texcell is a Global CRO specializing in custom cell culture, virus propagation, virus concentration, viral clearance services, and viral safety testing in support of biopharmaceutical applications submitted to the FDA and other regulatory authorities.
0:56 Introduction
3:26 How STEM impacted Akunna's journey into Life Sciences
9:17 Who is Texcell and what do they do?
11:24 What is one lesson that has shaped what you do?
14:47 What advice would you give to someone that is thinking about starting in life science?
21:14 What are the big challenges you have faced this year?
28:00 Three questions
- What inspires you?
- What concerns you?
- What excites you?
This week on the Life Science Success podcast I am interviewed Mike Klein the CEO of Genomenon. Mike is an accomplished CEO with over 25 years of experience developing, building and growing high tech, software and IT companies.
As a seasoned CEO, he draws upon a unique blend of vision, strategic thinking, communication and execution skills to help turn around and put companies on the high growth track. He has the technical and financial background to guide businesses to meet their objectives and extensive experience in raising capital, acquisitions and delivering successful investor exits.
Notes:
3:00 What does Genomenon Do?
4:00 What made Mike want to be in Life Sciences?
7:30 What are some of the lessons learned in his previous startups that he brought to Genomenon?
11:00 The importance of culture & core values
12:55 The impact Genomenon will have on the world
18:30 Advice Mike would give a new entrepreneur
20:00 Advice to someone outside of life sciences
22:50 Proudest Moment
26:32 Biggest Challenges
28:00 Three Questions
What inspires you?
What concerns you?
What excites you?
This week we are taking a brief break from interviewing guests and I am talking about recent changes in the Life Science Success website (www.lifesciencesuccess.com) and an upcoming event with Music Beats Cancer.
2022 has turned out to be an extremely pivotal year for computational pathology with major announcements coming out of USCAP and AACR2022. With AI-powered algorithms fueling the excitement in the space across the continuum of clinical trials and diagnostics, there is an increasing interest in unraveling the spatial relationships in the tumor microenvironment. However, the use of 'black-box' algorithms and lack of insights into cell-cell communication, understanding of intermediate cell types, and unambiguous microdomain characterization have hindered the progress in this field. The new SpIntellx platform differentiates itself from other general computational pathology platforms with its focus on spatial intelligence and explainable-AI to reveal insights that help in accelerating discovery, optimizing clinical trials, advancing companion diagnostics, and personalizing therapeutic options. The secret sauce here is the deep understanding of tumor biology from the standpoint of the existence of intermediate cell types and their functional states as well as communication between cells in the tumor environment, thus establishing the new space of Precision Pathology!
In this episode of the Life Science Success Podcast I interviewed Raphael Ognar, CEO and Co-Founder of NKILT Therapeutics. We discussed his career from product marketing to co-founding a cancer therapy organization.
In this episode of Life Science Success I talked to Dorie Clark for the second time on the show.
Dorie is a marketing strategist and keynote speaker who teaches at Duke University’s Fuqua School of Business and has been named one of the Top 50 business thinkers in the world by Thinkers50. Her latest book is The Long Game: How to Be a Long-Term Thinker in a Short-Term World (HBR Press, 2021)
For more information visit: www.lifesciencessuccess.com
This week on Life Science Success, I interviewed Chris Yeh. Chris is the Co-Author of Blitzscaling. We will be talking about blitzscaling, key factors to blitzscale, and key things Chris looks for when working with companies.
This week on the Life Science Success podcast I interviewed Jason Winder CEO of Sonogen Medical. Sonogen Medical is a company that has developed a novel technology for ultrasonic bone fracture healing.
In this episode I interviewed Beth Bauer the Founder and CEO of PosiROI, LLC. Her company focuses on bridging the gaps between business, data, analytics, and technology to maximize shared value creation.
https://5280lsc.com/podcast/beth-bauer/
In this episode of the Life Science Success podcast I interviewed Ross Jackson - Literally, The Man Who Wrote the Book on Patient Recruitment for Clinical Trials using Facebook Ads. We discuss everything from SEO to current and future challenges in patient recruitment.
Drs. Todd & Kim Saxton are award-winning professors at Indiana University’s Kelley School of Business, as well as co-authors of The Titanic Effect, The book is a practical guide to help startup founders, as well as their investors and supporters, successfully navigate the icebergs that so often sink startups in the ideation and early stages of development. They’ll tap into decades of academic and professional experience in business strategy, entrepreneurship, marketing, market research, and venture-funded startups to help you navigate the “debtbergs” that so often sink early-stage startups.
In this episode of Life Science Success, I interviewed Mark Gordon. Mark is the CEO of Diviner, a company that has developed a novel collective intelligence technique to help investors and biopharma make better drug development decisions. This company is at the intersection of data/analytics and biopharma.
In this episode of Life Science success I interviewed April Zambelli-Weiner PhD. April is the CEO of TTi Health Research & Economics. At TTi they provide life cycle clinical and economic research and consulting services to guide strategic decisions from pre-market development through commercialization and growth, enabling companies to demonstrate and evolve their product’s true differentiated value story.
In this episode of the Life Sciences Success podcast, we discussed Liquid Biopsies for the early detection of cancers. I am joined by Samir Hanash MD, PhD from MD Anderson Cancer Center, and Dusty Majumdar PhD. We will cover Liquid Biopsies, its importance in the field of detection of cancer in early stages when it is most curable, and where we stand today with the technology. Additionally, Dr. Hanash has very recently published a seminal article in the Journal of Clinical Oncology where the largest blinded study of its kind reviewed a four-protein marker panel that informs about the risk of harboring lung cancer and the need for CT screening.
In this episode of Life Science Success, I spoke with Bella Englebach. Bella focuses on Lean, Operational Excellence, and Continuous Improvement. She also coaches people who are in various stages of their careers.
In this first episode of 2022 of the Life Science Success Podcast, I am honored to be joined by Ron Kaufman. Ron is one of the world’s most sought-after educators, thought-leaders, and keynote speakers on customer experience and service culture development. Ron has been quoted in the New York Times, Wall Street Journal, and Harvard Business Review, and for years Global Gurus has ranked him as the #1 customer service guru in the world.
In this Episode of the Life Science Success Podcast I am joined by Mark Collins PhD, Dusty Majumdar PhD and Janik Jaskkolski in a panel discussion about Artificial Intelligence. We cover the current state, eliminating mundane tasks in healthcare, what will happen before we see further adoption of AI and the future state of the field.
In this episode of Life Science Success, I spoke with Rajasankar Viswanathan the founder of Naturaltext. NaturalText A.I. understands the content and context of text data. Its powerful natural language processing technology can integrate various data formats from internal and public sources, revealing hidden relationships and insights that aid Life Sciences clients.
In this episode of Life Science Success, we are speaking with Harsha Rajasimha. Harsha is a Social Entrepreneur committed to applying his 15+ years of distinguished experience in healthcare and life sciences consulting, precision medicine, genomics of rare diseases and cancer to help accelerate drugs R&D and digital therapeutics.
In this episode, my guest is Jon Picoult. Jon is a customer experience expert who has been helping guide companies through the customer experience journey to creating "raving fans" that drive business growth. Jon has a new book "From Impressed to Obsessed" and we spend time discussing the book along with an in-depth discussion of his body of work in customer experience.
A sought-after business advisor and speaker, Jon has worked with some of the world’s foremost brands, personally advising CEOs and other members of the C-Suite. He helps organizations capitalize on the power of loyalty, both in the marketplace and in the workplace.
In this episode of the Life Science Success Podcast I interview Reed Mclaughlin and Kelly Malloy from Anju Software. Our discussion centers around Reed and Kelly’s perspectives on the evolution of the Medical Affairs function, how it continues to emerge as a strategic pillar within life sciences organizations, and its critical importance to driving patient outcomes. They will further discuss how Anju Software medical affairs solutions like IRMSmax and PUBSTRATmax are being leveraged to optimize work across medical affairs to increase effectiveness and leverage insights to ensure the right information is delivered to the right person at the right time.
Michael Patterson is a Health Care Executive with over 27 years of experience in the following areas (Cannabis/CBD/Hemp Investing, Operations, Laws, Regulation, Compliance, Banking, Digital Assets/ Cryptocurrency, Management, and International trade, Skilled Nursing, Assisted Living, Home Healthcare, Therapy Management, Laboratory, Pharmacy Management, and Health Care Analytics).
In this episode of the Life Science Success podcast, Tom Heck is our guest. He will be covering his career journey from Pharma to SVP at TrialCard - providing commercial support in remote areas and vacant territory coverage as well as a series of additional services for companies looking to launch their next patient focused campaign.
Dusty Majumdar, PhD is a senior executive leader in healthcare and life sciences for the last couple of decades and has been in leading positions in companies like GE Healthcare, IBM Watson Health, Exact Sciences and a range of start-ups. Dusty has provided inspirational leadership across various initiatives in healthcare and life sciences including diagnostic imaging, AI, liquid biopsies and more recently RWD/RWE leveraging clinico-genomic data across organizations like CancerLinQ with ASCO and a number of start-ups in the Boston/Cambridge/NYC area, both as the Chief Marketing and Strategy Officer and Chief Commercial Officer. He has led the commercialization of more than 20 AI based products across Oncology, Genomics, Population Health and Imaging over the last 6 years. More recently he has been involved with organ-on-chip and organoid-on-chip systems focused on accelerating drug discovery and development through simulating the micro-environment that emulates the natural physiology and mechanical forces that cells experience within the human body. AI is an integral part of gleaning insights from such systems.
In this episode I interview Leslie Loveless. Leslie is the CEO of Sloane Partners. Her career journey has led her from Takeda Pharmaceuticals to Quest and now as CEO of Sloane Partners.
Today on the Life Science Success my guest is Yash Sabharwal. Yash is the CEO of CherryCircle Software. He is passionate about bringing novel software solutions to the life science industry to accelerate novel therapies to patients with lower development costs. At CherryCircle Software, the team has defined a new category of software for product quality and lifecycle management to facilitate digital maturity in pharma/biotech manufacturing.
In this episode of Life Science Succes, I interview Christopher Pirie CoFounder and COO of HDT Bio. His technical experience is centered primarily on protein/enzyme engineering with forays into synthetic biology, metabolic engineering, polymers, drug delivery, and biopharmaceuticals.
In entrepreneurship Christopher is motivated by alternative financing/business models for commercialization of cutting-edge technologies, creative strategies for protection of intellectual property, and a laser-focus on customer engagement and end-user value creation.
This week on the Life Science Success podcast I interview Josh Seidenfeld. Josh is a partner with Cooley LLP in the Palo Alto office. His practice consists of representing clients on general corporate matters, with a focus on emerging companies, private financing, initial public offerings, and mergers & acquisitions. Prior to joining Cooley, he was the Director of Business Development and Corporate Counsel for Practice Fusion, an electronic health record company located in the San Francisco Bay Area.
In this episode, I interviewed Mark Charbonneau. Mark is a biotechnology R&D leader with cross-functional expertise in live biotherapeutic drug development, mechanistic modeling, computational biology, and biomarker assay development. He integrates technical acumen and emotional intelligence to build high-functioning teams and foster innovation.
This week on the Life Science Success podcast my guest is Jenifer Wheat. Jenifer has a unique combination of skills in scientific, regulatory, legal, and business development expertise. She has extensive knowledge of biopharmaceutical manufacturing and business life cycles. Given her background and career, she has negotiated agreements internationally in the US, EU, Korea, Japan, Canada, Australia and the Middle East.
This week on Life Science Success Podcast my guest is Yan Leyfman, MD is a unique individual in life sciences and is someone we all need to be paying attention to. Yan was raised in the medically deprived community that was ravaged by the Chernobyl nuclear disaster. Today, we are going to talk about his experience with Chernobyl, how that led to his career in medicine and what he has done to turn struggles into triumphs.
Lee is a results-focused operations executive in biotech and medical devices with deep experience in leveraging lean six sigma methodologies to drive cost-saving initiatives and improve operational efficiency in an organization. He has a great ability to motivate, encourage, and develop high-performing teams helping individuals take their performance to the next level.
This week on the Life Science Success podcast my guest is Tom Denison. His passion is mentoring, advising, and funding biotech startups. He has engaged with over 200+ startups, at all stages, from concept to exit.
Tom is the Founder and Chief Relationship Officer of SmartHealth Catalyzer, the hub for Midwest Biotech Venture Creation.
We discuss her journey from passionate Scientist to an inventor to entrepreneur. In her newest venture, she is helping new science become transformative therapeutics. Elaine is a cutting-edge Life Science leader helping companies become a reality from Oaklahoma.
In this interview, I speak with Laura Prisc the Most Trusted Authority on Conscious Leadership for High-Performance Organizations. For more than 20 years, she's worked side-by-side with leaders at all levels in organizations of every size imaginable, from one-location operations through the full continuum of multi-site global organizations.
This week on the podcast I interview Jacob Glanville, PhD we discuss Jacob's journey that led him to Distributed Bio then to Centivax and his work on the Netflix show Pandemic. Jacob Glanville is a serial entrepreneur and computational immuno-engineer. He built and sold his first company Distributed Bio from founding in March of 2012 to a 104M dollar sale to Charles River Laboratories in December of 2020. During that period, he developed the core business model, the research teams, and the technologies that enabled Distributed Bio to become profitable without investment. As part of the acquisition agreement, he founded Centivax Inc and spun out his assets in COVID-19 therapeutics, broad-spectrum vaccines, antivenom antibodies, anti-wound pathogen antibodies, anti-CXCR5 autoimmunity therapeutics, and blood-brain barrier translation technologies into Centivax, where he is now CEO.
This week's guest is Dave Bjork the Research Evangelist. He is a Patient Advocate, Lung Cancer Survivor, Speaker and Advisor. His career spans more than 20 years of progressive experience in nonprofit marketing, patient advocacy and fundraising leadership roles including Vice President of Development, National Foundation for Cancer Research, Bethesda, MD. In this role, He launched several fundraising and advocacy programs and became known as the “Cancer Research Evangelist” because of his dedication and commitment to basic scientific research. He also hosts the Research Evangelist Podcast.
In this interview, I have the tremendous opportunity to speak with Preveen Ramamoorthy PhD of Regenerative Medical Solutions. We talk about his journey from India to Clemson and the work that he is currently doing with Regenerative Medical Solutions. His current work on Type I and Type II diabetes and his work at the University of Colorado Denver.
In this episode, I interview Debora Barton, MD, and we discuss Carisma Therapeutics (CAR-T, CAR-M, Macrophage, and Cancer Therapies) as well as her new board role at Tigerlily Foundation.
In this week's podcast, I interview Neil Sankar and we talk about his work in helping teams bring cancer therapies to market. He has worked at the National Cancer Institute and for the past 20 years has been working with large and small pharmaceutical companies that are trying to bring drugs to market. His experience spans small molecules, biologics, and antibody-drug conjugates used in the treatment of advanced tumors. Our conversation covers elements of his 20-year career, leaders he would most like to have a conversation with, and what led him to his career in oncology.
This week on the podcast my guest is Chris Conley. Chris is the founder of DNA consulting. In her interactions with Life Sciences companies, she leverages her network to help her clients get things done from bench science to launched product.
In this episode, I interview Francesco Salituro Independent Consultant at Salituro MedChem Solutions. Francesco has a tremendous background in drug development and he is helping a lot of early-stage companies. Additionally, Frank has supported the Epilepsy Foundation of New England for years because of his son Joseph. Joseph passed away from SUDEP (Sudden Unexplained Death in Epilepsy) which initiated the creation of Joseph's HOPE (Helping Other People with Epilepsy) Scholarship Fund. We discuss Francesco's career, drug discovery and his active life in the Epilepsy Foundation of New England after the loss of his son, in this episode.
Michael Papadimitrious is the Medical Affairs Manager for Miltenyi Biomedicine. In this episode, Michael and I have a fantastic conversation about CAR-T therapy, delivering personalized cancer therapy and what the future may hold as science continues to evolve.
Michael Papadimitrious is the Medical Affairs Manager for Miltenyi Biomedicine. In this episode, Michael and I have a fantastic conversation about CAR-T therapy, delivering personalized cancer therapy and what the future may hold as science continues to evolve.
In this podcast, I interview Gary McAuslan who has a consulting company GMAC Pharma that has been helping companies with their drug pipelines and commercialization activities. Additionally, Gary has now started ATGC Ventures a CDMO in Ireland. We cover Gary's history in pharma, how lean and an agile approach can help pharma companies and the key role that CDMO's will play in speeding drugs to market.
In this podcast, I interview Norris Turner the Principal for Turner Healthcare Quality Consulting. We have a great discussion about his career, healthcare economic disparities, and his work with organizations around building a market access strategy and a healthcare quality strategy for their organizations and products. Norris has also published some great blog posts that challenge existing thinking and provide some key insights on future improvements in healthcare systems.
Today I interview Michael Fero the Founder and President of TeselaGen. Michael and the team at TeselaGen have created an AI enabled operating system that can help biopharma companies design their next drug. TeselaGen uses methods from machine learning and synthetic biology to help Pharmaceutical companies build and optimize cancer fighting drugs and vaccines by letting experimental data drive the discovery process.
In this episode, we discuss Ray's background in business development for three different companies. Ray has spent time in Japan and in France working for a couple of different organizations. Additionally, he completed his MBA in France. Ray's employer, Phenovista is doing some interesting imaging work for their clients who are working on Phenotyping samples for assay development.
In this episode, I interview Janik Jaskolski CEO and product architect of Semalytix a company with an AI-driven way to gather patient insights about the treatments they are receiving. Semalytix is working with pharma companies to gather real-world evidence about patient experiences, outcomes, burdens, and needs.
In this episode, I interview Ken Banta Founder and Principal of the Vanguard Group. Ken has distinctly worked in the Life Sciences Industry with Pharmacia & Upjohn and Schering-Plough. He continues to work with CEO's and teams growing capabilities and changing the landscape for leadership in healthcare and life sciences. We dive into the shifts he has seen over the past year in delivery methods for his content as well as some key topics from his Harvard Business Review articles.
In this episode, I discuss with Patrina her career journey from Microscopy to Medical Affairs. She describes the contemplation of her early career choices leading to something that she loves with the Medical Affairs team at MedEvoke. At MedEvoke Patrina is working with companies on everything from conference posters through ensuring that critical communication methods are used in translating ideas within an organization. Additionally, in this podcast, we discuss a bit about where our paths crossed at GE and the hiking group at GE's API business in Issaquah WA had a hiking group that continued to flourish even after my time with the organization.
Julio is the CEO of Bioaccesss (https://www.bioaccessla.com/) a CRO that focuses on transferring Life Science and Medical Device technologies into Latin America. Julio also hosts the LATAM Med Tech Leaders podcast and has written for Med Device Online. In this interview, we discuss trends in Latin America, the impact of COVID on his business and how his organization has had to think differently in our “new normal” to overcome the challenges.
Carlos is the Founder of Lacerta Bio, Lacerta Bio is a pharmaceutical business development consultancy. We work with pharmaceutical, biotechnology, medical device, diagnostic, and other life science companies. We also work with venture capital and private equity firms that invest in these companies.
He is also the CEO of Connexin Therapeutics, Inc. an early-stage glaucoma drug developer. Who has the goal of developing and partner novel connexin inhibitors for retinal neuroprotection secondary to glaucoma and other ophthalmic disease conditions.
In this episode, we discuss his startup Connexin Therapeutics and how things are progressing for a startup that is focused on bringing a Glaucoma drug to market.
In this episode, I interview Caroline Ceniza-Levine. Caroline works with individuals and organizations as a career coach, including professionals from Amazon, Conde Nast, Goldman Sachs, Google, JPMorgan Chase, McKinsey, Tesla and other start-ups thru global companies. Her specialty is career change -- She is the author of “Jump Ship: 10 Steps To Starting A New Career“.
Additionally, she appears as a guest expert on CNN, CNBC, CBS, FOX Business and other outlets; as a Senior Contributor to Forbes and former career columnist in Money, CNBC and Portfolio.
She shares with us her experience about looking for the right talent in Life Sciences and how to best leverage recruiters. This episode will hopefully help anyone currently searching for the next opportunity.
Rebecca D. Costa is an American sociobiologist and futurist. She is the preeminent global expert on the subject of "fast adaptation" and recipient of the prestigious Edward O. Wilson Biodiversity Technology Award. Her career spans four decades of working with founders, executives and leading venture capitalists in Silicon Valley. Costa's work has been featured in the New York Times, Washington Post, USA Today, The Guardian, and other leading publications.
We have a fantastic conversation about her books "The Watchman's Rattle" and "On the Verge"
At the end of the podcast, Rebecca shares with me her thoughts on new technologies that will be coming in the future.
Christina DiArcangelo - Is the CEO and Founder of Affinity Bio Partners. She also has created a technology company and a charity. In this episode, Christina and I talk about her career, the current research that Affinity Bio Partners is doing in COVID, a tie to the CBD/cannabis industry, and the capabilities her company has developed in AI.
Don Hawthorne is the CEO of GTM a consulting firm focused on helping customers Go To Market.
In this conversation, Don and I talk about his career, product development and how Go To Market really empowers organizations to have a stronger position in placing their products in front of customers that really want to have your products in their hands.
Matt Hicks CEO of Federal Equipment Company
In this episode, we discuss Matt's career and how his equipment company acquires and sells pharma equipment. Matt recently published an article titled "Reshoring a Nation’s API and Pharmaceutical Production"
In this podcast, Tim Sangster discusses his career, Bioanalysis, and what he would tell his younger self. Tim is the Executive Director of Bioanalysis at Celerion and we talk about what Celerion does as a CMO and where Bioanalysis supports the goals of their customers.
In this episode, Dr. Frazier shares with us her background starting with both Physics and Biomedical Sciences translating into becoming CEO of Obatala Sciences. We discuss the tissue on a chip industry, what "Fat on a Chip" is used for and how Obatala is also working on wound solutions.
For more information, detailed show notes and links to Dr. Frazier please visit: www.lifesciencesuccess.com
Joe is the CEO of STAQ Pharma and has previously been the leader, CEO and entrepreneur for three other startups in Life Sciences:
- Sharklet
- RevGen
- BIOamps
For more detailed information about the show, show notes and links to Joe please visit www.lifesciencesuccess.com
This week Dr. Segurado discusses CRISPR and how gene therapies are being developed to help Hemophilia patients.
For more details and complete show notes please visit: www.lifesciencesuccess.com.
To connect with the guest, links and show notes please visit: www.lifesciencesuccess.com
In this episode we talk to Dr. Andrews from BD about the team's work on the COVID task force, the test that has been developed for SARS COV-2 to provide rapid results to patients on the Veritor platform and lastly Dr. Andrews work in Womens Health and Cancer at Becton Dickinson.
To connect with the speaker, links and detailed show notes please visit: www.lifesciencesuccess.com
In this episode we talk about Dorie’s expertise as a communicator and how it can help Life Science leaders focus on their audience and their message to get their ideas translated. If you are working on a breakthrough idea or are in the midst of having to communicate your idea to the masses you will not want to miss this episode.
To connect with the guest, links and show notes please visit: www.lifesciencesuccess.com
In this episode we switch gears and talk about two topics that have not yet been covered on the podcast, bioprocess and construction. Erich has an interesting background and is helping bioprocessing facilities grow to meet the demands of both new drugs that are being developed and at the moment facilities that are preparing for both COVID-19 drugs and possibly vaccines.
To connect with the guest, links and show notes please visit: www.lifesciencesuccess.com
In this episode, we delve into Mona’s background and how her organization Sound Affects is helping cancer research companies make it through the valley of death. Creating crowd-funded supported cancer therapy is at the heart of the overall discussion.
To connect with the speaker, links and detailed show notes please visit: www.lifesciencesuccess.com
Ben Locwin recently published an article titled “Use These 7 Tools For Breakthrough Quality And Performance In 30 Days”. We walk through each of the seven tools and discuss its use, history of the tool, and actual implementation. This interview is filled with interesting facts about each one of the tools discussed along with areas that Ben has seen them applied. I would highly recommend downloading the article in the links section to have for reference as you listen to this episode.
For more information, links and show notes please visit:www.lifesciencesuccess.com
Dr. Mark Collins talks about how Helomics uses AI (Artificial Intelligence) to find patterns in Ovarian Cancer treatments that have been applied to 35,000 patient’s responses to certain drugs. This data has been used on both the drug discovery and clinical side of developing a functional tumor profile and possible mutation information for ovarian cancer patients.
For more information and detailed show notes please visit: http://www.lifesciencesuccess.com
In this first episode, I wanted to give you a little preview about why I am creating the podcast, what the podcast focus is, to walk you through some of the upcoming themes and I also have a request for help from you.
First of all, where did the idea come from to create another podcast?
I have worked in Healthcare and Life Sciences for the past 30 years. Amid the pandemic, I started a boutique consulting company because I believe that personal connection is our most significant advantage in understanding the challenges my clients face in meeting their goals.
This focus on clients works well for me because I am naturally inquisitive, and I am a lifelong learner who wanted to create a connection with my community. To create this connection with my community, I started having conversations with Life Science executives and in these conversations, I found myself immersed in their interesting backgrounds, successes and challenges. I thought that it would be great to be able to share them with everyone in our Life Science community.
Over the past couple of months in my “free time” I started building all of the components that you need for a good show with the most important element, great guests.
Some of the themes that are coming out are:
- Building a company during the pandemic
- Venture Capital in Life Sciences
- Project Management in Life Sciences
- Building Scalable organizations
- New Technologies or Treatments
- New approaches to solving key issues
I am currently actively recruiting leaders Director and Above that have backgrounds and topics that fit the themes that I outlined and pre-recording episodes so that we can have a bit of a backlog. Additionally, with the plan being to release an episode a week so we will need a great lineup of people to be able to keep the momentum.
In finding and recruiting great guests I would love to hear from you if you have an idea for a leader that should be on the show. Who do you most want me to have on the show? Are there specific themes or topics that you most would like to hear about within Life Sciences? Are there key questions you would like me to ask?
It has been a fun journey so far and I am really looking forward to seeing the show take off.